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Abstract 
 Eukaryotic DNA is packaged into a highly condensed chromatin state, 
which inherently serves as a barrier to critical cellular processes such as DNA replication, 
repair and transcription.  The modulation of chromatin structure to allow access to the 
underlying DNA is vital for the appropriate regulation of these processes.  One class of 
enzymes responsible for modulation of chromatin structure is the SNF2 superfamily of 
ATP-dependent chromatin remodeling enzymes.  These enzymes use the energy from 
hydrolysis of ATP to mobilize, disrupt and modulate nucleosomes.  These enzymes are 
classified into several different families based on their domain architecture, the largest of 
which is the CHD (Chromodomain Helicase DNA-binding) family.  This family is 
comprised of nine enzymes, CHD1 through CHD9, which are further divided into three 
subfamilies, CHD1-2, CHD3-5, and CHD6-9.  Relatively little is known about the third 
subfamily, and the research described here is directed towards one particular member of 
this subfamily, CHD8. 
Previous studies have established a functional association between the CHD6-9 
subfamily and nuclear receptor-mediated transcriptional regulation.  One such nuclear 
receptor, the androgen receptor (AR), mediates the effect of androgens through its 
transcriptional function during both normal prostate development and in the emergence 
and progression of prostate cancer.  AR is known to assemble coactivator complexes at 
target promoters to facilitate transcriptional activation in response to androgens.  Here we 
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identify CHD8 as a novel coregulator of androgen-responsive transcription.  We show 
that CHD8 directly associates with AR and that CHD8 and AR simultaneously localize to 
the enhancers of androgen-responsive genes following androgen treatment.  In the 
LNCaP prostate cancer cell line, reduction of CHD8 levels by siRNA treatment severely 
diminishes androgen-dependent activation of these genes.  We demonstrate that the 
recruitment of AR to target promoters in response to androgen treatment requires CHD8.  
CHD8 also facilitates the androgen-stimulated proliferation of LNCaP cells, emphasizing 
the physiological importance of CHD8 in prostate cancer.   
Further studies were conducted to examine the mechanism by which chromatin 
remodeling by CHD8 is involved in androgen-responsive transcription.    We found that 
CHD8 can remodel nucleosomes without histone tails and prefers substrates that are 
methylated at H3K4.  The association of CHD8 with H3K4 methylation was supported 
by our findings that CHD8 interacts with the MLL1-WAR histone methyltransferase 
complex.  The interactions of CHD8 with this complex and their effect on its remodeling 
activity were further characterized. 
These studies collectively implicate CHD8 in the regulation of androgen-
responsive gene expression and as a novel coregulator of AR-mediated transcription.  We 
also establish potential mechanistic details of transcriptional regulation by CHD8.  Our 
results present CHD8 as a novel diagnostic, preventative, or therapeutic target in prostate 
cancer.  
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CHAPTER I 
General Introduction 
Chromatin Structure 
The hereditary information that specifies the structural composition and 
functional characteristics of all living organisms is contained within discrete sub-cellular 
elements called genes.  These genes are encoded within the DNA, which is a 
macromolecule comprised of four different polymerized bases.  The specific sequence of 
these different bases is where all the genetic information required for the development 
and survival of the organism is stored.  This information is so complex and vast for even 
the simplest organisms that a huge number of genes, and consequently an immense 
amount of DNA, is required to store all of it.  The human genome contains an estimated 
30,000 genes carried on over 3 billion base pairs of DNA (1).  The DNA from one single 
human cell would stretch up to 2 meters in length and all of the DNA in the human body 
would be enough to reach from the earth to the sun and back 610 times (2).  This 
enormous amount of DNA needs to be packed into the nucleus of a eukaryotic cell, which 
is only about 6 m in diameter.  This poses a daunting challenge to the cell and requires 
extremely efficient packaging of the DNA into the nucleus. 
In eukaryotic cells, the DNA is packaged into a highly condensed structure called 
chromatin.  Chromatin is made up of a fundamental repeating unit called the nucleosome 
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(3).  Each nucleosome consists of ~146 bp of DNA wrapped around a histone octamer, 
which is comprised of two units each of the four histone proteins H2A, H2B, H3 and H4 
(4).  The H3 and H4 histones associate as a tetramer consisting of two units of each, and 
this in turn interacts with two dimers of H2A-H2B to form the histone octamer.  The 146 
bp of DNA then wraps 1.65 turns around this histone octamer, with 14 points of contact 
between the DNA and the histone core (5).  This makes the nucleosome structure a 
uniquely stable DNA-protein complex, which is suitable for its packaging function.  
Several of these nucleosomes are strung together into linear arrays so that they give a 
“beads on a string” appearance under the microscope (6).  These linear arrays of 
nucleosomes can be tightly packed together by twisting into three-dimensional coils and 
irregular, interdigitating structures, resulting in the formation of condensed chromatin 
fibers.  These chromatin fibers then fold into looped domains by attachment of the DNA 
to a network of non-histone proteins in the nuclear matrix which form a chromosomal 
scaffold.  The more loosely packed, diffuse regions of chromatin, known as the 
euchromatin, represent the part of the genome that is being actively transcribed.  
Transcriptionally inactive regions of the chromatin exist in a more condensed form called 
heterochromatin, which appears as dark spots under a microscope upon staining the 
DNA.  Most of the chromatin in metabolically active cells exists as diffuse euchromatin 
as the genome is constantly being transcribed.  However, during cell division all the 
chromatin in the cell condenses into heterochromatin and this helps to compact the DNA 
into larger subcellular structures which comprise the visible form of the chromosomes.  
The metaphase chromosomes, which are microscopically distinguishable as distinct, 
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highly condensed structures, are thus a result of several degrees of compaction of the 
chromatin (7). 
Chromatin and Transcription 
The function of chromatin extends beyond merely that of DNA compaction.  Due 
to the extensive packaging of DNA, the chromatin structure inherently prevents access to 
the underlying DNA due to steric hindrance and thus interferes with critical cellular 
processes like transcription, replication and DNA repair.  Indeed, it has been well 
established that incorporation of nucleosomes impedes the transcription of DNA 
templates in vitro (8).  It has been shown that the elimination of histones at promoter 
regions results in changes in expression of downstream genes in vivo further indicating 
the importance of chromatin in the transcriptional process (9). 
The stereotypical RNA polymerase II (Pol II) transcription cycle begins with the 
binding of transcriptional activators, which are sequence-specific DNA-binding proteins, 
to the promoter region upstream of the transcription start site of the gene being 
transcribed (10).  This results in the recruitment of adaptor complexes like SAGA (Spt-
Ada-Gcn5 acetyltransferase) and mediator, which in turn recruit the general transcription 
factors (GTFs) (11, 12).  A combination of these GTFs (TFIID, TFIIA and TFIIB) then 
positions Pol II and TFIIF at the core promoter, forming the closed preinitiation complex 
(PIC).  TFIIH then assists in the opening of double-stranded DNA so that the single-
stranded DNA template can be positioned at the active site of the open Pol II complex to 
initiate RNA synthesis (13).  The carboxy-terminal domain (CTD) of Pol II is 
phosphorylated by TFIIH and dissociates from the GTFs before progressing into the 
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elongation stage of the transcription cycle.  The phosphorylated CTD then recruits factors 
involved in transcriptional elongation and mRNA processing (14). 
All of these processes require the factors involved to be able to access the DNA 
being transcribed, but the highly condensed packaging of this DNA into chromatin serves 
as a physical barrier to many of these steps in the transcriptional cycle.  It prevents the 
binding of activators to their specific target DNA sequences.  It also prevents the 
recruitment of the massive general transcriptional machinery to target promoters and their 
subsequent assembly into the PIC.  It presents further impediment to the melting of the 
DNA and establishment of the DNA-Pol II holoenzyme-RNA complex.  Chromatin is 
also a physical barrier to transcriptional elongation by Pol II, as well as to the recruitment 
of elongation, mRNA processing and splicing factors. 
Transcriptional Regulation by Chromatin Remodeling Enzymes 
The regulation of chromatin structure is essential for allowing the factors involved 
in the transcriptional process adequate access to the nucleosomal DNA, and thus serves 
as an important regulatory point in transcriptional control.  This regulation of chromatin 
structure is achieved by two classes of chromatin remodeling enzymes: one that is 
involved in the covalent modifications of histones, and the other that uses energy derived 
from ATP-hydrolysis to modulate the contacts between histones and DNA within 
nucleosomes.  Covalent modifications of histones include acetylation, methylation, 
phosphorylation and ubiquitination besides others of specific histone residues.  Each of 
these modifications is catalyzed by a distinct category of enzymes and can serve as 
molecular signals which are recognized and bound by various factors that influence 
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chromatin structure and general transcription.  The ATP-dependent remodeling enzymes 
usually occur in large complexes that alter chromatin structure by disrupting or 
mobilizing histones to regulate access to the nucleosomal DNA. 
Transcription factors (TFs) or activators recognize specific DNA sequences in 
their target promoters and can bind them in the context of free DNA (15).  When these 
target sequences are buried within chromatin, eukaryotic TFs have to employ different 
strategies to facilitate optimal binding to these recognition sites.  There are numerous 
examples of chromatin remodeling enzymes being involved in stimulating the binding of 
TFs to their target chromatin elements (16, 17).  After binding the promoter, activators 
recruit a number of coactivators, many of which are also involved in chromatin 
remodeling.  This is not surprising since extensive modification of the chromatin 
structure is required for enhanced binding of the activators themselves, as well as for the 
docking of the large PIC and its many auxiliary factors on the DNA.  Histone acetylation 
has been linked with the promoters of actively transcribed genes (16).  Acetylation of the 
histone tails is known to be associated with a more “open” conformation of chromatin, 
allowing access of the transcriptional machinery to the underlying DNA.  Activators thus 
recruit histone acetyltransferases (HATs) which are capable of acetylating histones, thus 
maintaining the target chromatin in a transcriptionally active state (18).  Specific histone 
methylation marks are also known to be associated with transcriptional activation and 
these marks are deposited at initiation sites by the corresponding histone 
methyltransferases (HMTs).  In addition, promoter-bound activators also recruit ATP-
dependent chromatin remodeling enzymes to make the DNA more accessible (19). 
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After PIC assembly, Pol II-mediated transcription is further hindered by 
nucleosomal barriers, which may cause pausing of the polymerase at the transcriptional 
start site (20).  This pausing can also lead to backtracking of the Pol II.  The transcription 
elongation factor TFIIS reactivates Pol II transcription through such nucleosome barriers 
(21, 22).  Both classes of chromatin remodeling enzymes have been implicated in 
alleviating this kind of transcriptional pausing due to nucleosomal barriers (23, 24). 
Once Pol II has entered the elongation phase, two major phosphorylation sites in 
its CTD are targeted by either TFIIH at Ser 5 during early elongation, or by Ctk (CTD 
kinase) at Ser 2 later in the elongation phase (14).  These phosphorylation sites are 
responsible for the association of the elongating polymerase with various elongation 
factors and chromatin remodelers.  Chromatin remodeling enzymes of both classes are 
required to appropriately modify and mobilize the oncoming nucleosomes as Pol II 
transcribes through a gene.  As Pol II advances it also displaces histones, and chromatin 
remodeling factors are required to catalyze the redeposition of these histones as well as 
the reassembly of free histones onto the DNA behind the elongating polymerase.  
Depending on the phosphorylation status of the Pol II CTD, different chromatin 
remodeling enzymes are recruited to facilitate the process of transcriptional elongation by 
carrying out the above functions (13). 
Covalent Modification of Histones 
 The histones that form the protein core of the nucleosome are largely globular, 
except for their N-terminal tails which are unstructured and protrude away from the core 
bodies.  A large number of histone residues, with a majority of them being on the N-
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terminal tails, are known to be covalently modified.  There are eight known histone 
modifications, including acetylation, methylation, phosphorylation, ubiquitylation and 
sumoylation.  A further level of complexity is introduced by that fact that methylation 
can be of varying degrees, as histone lysine residues can be mono-, di- or tri-methylated 
(25).  The deposition and removal of each of these different histone modifications is 
catalyzed by distinct histone modifying enzymes like HATs, histone deacetylases 
(HDACs), HMTs or histone demethylases. 
 Histone modifications function through two different mechanisms.  The first is the 
alteration of chromatin structure by disrupting histone-DNA contacts via the covalent 
modifications.  Histone lysine acetylation, for example, is capable of unfolding chromatin 
by neutralizing the charged lysine residue.  Since inter-nucleosomal interactions have 
been seen to be necessary for maintaining chromatin structure, any changes in histone 
charge would affect the chromatin architecture (25).  In fact, by chemically modifying 
histones and reconstituting them into nucleosomes, it has been shown that H4K16 
acetylation prevents formation of the 30 nm chromatin fiber and of higher order 
chromatin structures (26). 
The other mechanism by which histone modifications function is by the 
recruitment of non-histone proteins to the modified sites.  These proteins recognize 
specific histone modifications through certain specialized domains.  For example, 
bromodomains bind to histone acetylation marks, chromodomains and PHD (Plant 
Homeodomain) domains bind methylation marks and certain domains found in 14-3-3 
proteins bind phosphorylation marks (25).  Thus these histone marks can be used to tether 
various enzymatic activities to the chromatin, further affecting regulation of its structure.  
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There are several examples of different chromatin remodeling activities being targeted to 
chromatin via interaction with modified histones.  These interactions are mediated either 
by specific recognition domains within the chromatin remodeling enzymes themselves or 
through such domains present in other intermediary proteins that are in complex with 
these enzymes. 
The ATP-dependent chromatin remodeling activity of SWI/SNF (mating type 
switching/sucrose non-fermenting) is targeted to chromatin by the recognition of 
acetylated histones by its bromodomains (27).  The histone demethylase JMJD2A 
(Jumonji domain-containing) contains Tudor domains which bind methylated H3 lysine 4 
(H3K4) residues (28).  This same methyl mark tethers the chromatin remodeling activity 
of CHD1 (Chromodomain Helicase DNA-binding) through its chromodomains (29, 30).  
The PHD domains of ING2  (Inhibitor of growth) and BPTF (Bromodomain PHD finger 
Transcription Factor) bind methyl-H3K4 marks and mediate the recruitment of other 
proteins containing different chromatin remodeling activities, like HDAC1 and the ATP-
dependent remodeling NURF (Nucleosome Remodeling Factor) complex, respectively 
(31, 32).  The chromodomains of HP1 (Heterochromatin Protein) tethers HDAC and 
HMTase activities to H3K9 methylated target sites (33-35).  Recruitment of these 
different chromatin remodeling activities to target sites facilitates further regulation of 
chromatin structure and consequently of gene expression.  In fact, the extensive 
modification of histones on a larger scale in the cell results in the establishment of 
distinct global chromatin environments.  The genome can thus be generally divided based 
on the modification and architecture of the chromatin into the transcriptionally active, 
accessible euchromatin and the transcriptionally inactive, inaccessible heterochromatin. 
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ATP-Dependent Chromatin Remodeling Enzymes 
 The chromatin-mediated regulation of transcription requires the coordination of 
the covalent modification of histones with the appropriate mobilization and positioning of 
nucleosomes on genomic DNA.  The latter function is achieved by the action of ATP-
dependent chromatin remodeling enzymes, which can use the energy from ATP 
hydrolysis to slide nucleosomes along a DNA template, disrupt DNA-histone contacts or 
eject nucleosomes entirely from the underlying DNA (Fig. 1.1).  These enzymes are also 
known to reassemble nucleosomes on DNA by incorporating free histones and to replace 
histones within nucleosomes with variant forms.  By affecting these changes in 
nucleosomal organization, these enzymes are able to regulate accessibility to the genomic 
DNA. 
All the identified enzymes in this class contain an ATPase domain called the Snf2 
helicase domain which is the characteristic feature of the SNF2 superfamily of proteins.  
The SNF2 superfamily of ATP-dependent remodeling enzymes is classified into different 
families according to the presence of other characteristic domains (Fig. 1.2).  All 
eukaryotes contain at least five families of SNF2 helicase-containing chromatin 
remodelers: SWI/SNF, ISWI (Imitation Switch), CHD, INO80 (Inositol requiring) and 
SWR1 (SWI/SNF Related) (36).  The Rad54 family of proteins can also be included with 
these since they can alter nucleosomes in vitro and may remodel nucleosomes to regulate 
access during DNA repair (37). 
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SWI/SNF Family 
The SWI/SNF family, which includes yeast SNF2 and STH1 as well as 
mammalian BRM (Brahma) and BRG1 (Brahma Related Gene), is characterized by the 
presence of bromodomains, which recognize acetylated residues on histone tails (27).  
Yeast SWI/SNF is targeted to acetylated chromatin by its bromodomain and the tandem 
bromodomains in the RSC (Remodels the Structure of Chromatin) complex recognize 
acetylated H3 K14 residues, thus targeting their chromatin remodeling activities to 
specific loci (27, 38).  These remodelers tend to reorganize nucleosomes into more 
disordered arrays (39, 40).  Hence they are thought to participate in transcriptional 
regulation by disrupting chromatin to allow the binding of transcriptional activators or 
repressors (36, 41, 42). 
ISWI Family 
The ISWI family includes yeast Isw1 and Isw2 and their mammalian homologs 
SNF2H (SNF2 homolog) and SNF2L (SNF2-like).  They are distinguished by the 
presence of SANT (SWI3, ADA2, NCOR, TFIIB) and SLIDE (SANT-like domain) 
histone binding modules.  The SANT domain is believed to be involved in binding to 
histone tails, while the SLIDE domain may bind to the linker DNA between adjacent 
nucleosomes (43, 44).  ISWI proteins primarily organize and position nucleosomes into 
ordered arrays (45, 46).  This family of remodelers is generally thought to have a role in 
chromatin assembly and maintenance and in the translational phasing of nucleosomes 
following DNA replication (47, 48).  Since their function is critical in maintaining 
heterochromatin, ISWI proteins can play a repressive role during transcriptional 
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regulation (46).  However, there are also examples where ISWI can promote 
transcriptional elongation (49). 
INO80 and SWR1 Families 
The INO80 and SWR1 families are characterized by the presence of a spacer 
region which splits the conserved ATPase domain within these proteins (50).  The INO80 
proteins are the only SNF2 proteins known to have DNA helicase activity and are 
involved in DNA repair (51).  SWR1 proteins are known to be capable of exchanging 
H2A for the H2A.Z variant form of histones (52).  Thus the SNF2 superfamily of ATP-
dependent remodeling enzymes is a diverse family of proteins, with varying specificities 
and functions in the context of chromatin. 
CHD Family 
The family of chromatin remodeling enzymes we are interested in studying is the 
CHD (Chromodomain Helicase DNA-binding) family.  While there is only one CHD 
protein found in yeast (CHD1), there are nine identified human enzymes belonging to this 
family, namely CHD1 thru CHD9.  These proteins are characterized by the presence of 
tandem chromodomains toward their N-terminus along with the Snf2 helicase domain 
located in the central part of these proteins (53, 54).  The chromodomain is an 
evolutionarily conserved sequence motif associated with many proteins involved in 
chromatin remodeling and transcriptional regulation.  Chromodomains are believed to 
mediate the contact of these proteins with chromatin by binding methylated residues of 
histones (55). 
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The CHD family of proteins can be further subdivided into three subfamilies 
based upon the presence of additional domains (55).  The CHD1-CHD2 subfamily 
contains a DNA-binding domain in their C-terminal region which binds AT-rich DNA 
sequences (54, 56).  The CHD3-CHD5 subfamily is characterized by the presence of a 
pair of N-terminal PHD Zn-finger-like domains.  PHD domains are protein-protein 
interaction domains found in several nuclear proteins associated with chromatin 
remodeling and transcriptional regulation and have been implicated in binding to 
methylated histones (31, 57-59).  The third subfamily includes the proteins CHD6 to 
CHD9 that contain other domains in their C-terminal region like paired BRK (Brahma 
and Kismet) domains, SANT domains and DNA-binding domains.  The BRK domain is 
conserved in a number of higher eukaryotic chromatin remodeling enzymes but not in 
their yeast homologs, indicating the possibility of them being involved in a function or 
interaction of chromatin components specific for higher eukaryotes (55).  SANT domains 
and DNA-binding domains are similar to those found in the other SNF2 families 
mentioned above. 
CHD1-2 Subfamily 
 CHD1 is the only member of this subfamily found in yeast, but higher eukaryotes 
also have a CHD2 protein, that is highly homologous to CHD1 in all its conserved 
domains.  However, they are significantly divergent in their C-terminal regions, 
suggesting that these two proteins could have different functions.  The majority of 
previous reports about CHD1 suggest that it is involved in transcriptional elongation due 
to associations with various elongation factors and with the elongating form of Pol II (60-
62).  Therefore this subfamily of CHD proteins appears to play a role in general 
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transcription downstream of the involvement of SWI/SNF remodelers which are more 
involved with transcription factor binding and transcriptional initiation (36, 61).  The 
nucleosomal remodeling properties of CHD1 have been shown to be quite distinct from 
those of SWI/SNF remodelers (63) and more similar mechanistically to certain members 
of the ISWI family (64).  In fact, a recent report has shown that CHD1 is involved in 
deposition of the histone variant H3.3 and plays a role in early developmental, 
replication-independent nucleosomal assembly (65), exhibiting further functional 
similarities to the ISWI family.  The limited studies on CHD2 report that it is involved in 
DNA-damage response (66) and in maintaining kidney function (67), both of which 
could be in connection with some of the general roles ascribed to this subfamily above.  
These proteins, therefore, appear to display a fair amount of functional diversity. 
 The chromodomains of human, but not yeast, CHD1 have been shown to 
recognize and bind methylated H3K4 tails from in vitro experiments and structural data 
(30).  Interestingly, due to variation in the length of a linker sequence within the 
chromodomains of CHD1 and CHD2, CHD2 shows weaker binding to H3K4me3 (68).  
This interaction has been shown to target human CHD1 to sites of active transcription 
and mediate the recruitment of the spliceosome, which is required for the proper splicing 
and maturation of the transcribed pre-mRNA (69).  This suggests a mechanism for the 
involvement of the CHD1 subfamily proteins in general transcription. 
Both CHD1 and CHD2 are ubiquitously expressed in all human tissues, further 
supporting a role in universal transcriptional elongation for these proteins.  In yeast, 
however, CHD1 has been shown to interact with H3K4me in vivo and to recruit the 
SAGA and SLIK (SAGA-like) multi-subunit HAT complexes to chromatin (29).  These 
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complexes are known coactivator complexes that are involved with transcriptional 
initiation at promoter regions rather than the elongation events occurring in the gene body 
(70).  Furthermore, H3K4 methylation is known to be associated with transcriptional start 
sites and CHD1 has been shown to be required for this methylation in yeast (71), 
indicating a point of action early in the transcriptional cycle.  While the binding of the 
CHD1 chromodomains to methylated histones appears somewhat ambiguous, it is clear 
that this subfamily is likely to have evolved in function from yeast to higher eukaryotes.  
It is to be noted that since CHD1 is the only CHD family member found in yeast, its 
function may have been more diverse in that model system.  Indeed, there are evidences 
of yeast CHD1 being involved in transcriptional elongation and mRNA processing as 
well (60, 72).  This supports the hypothesis of a more functionally redundant CHD1 in 
yeast evolving into a more specialized elongation factor in mammals.  This is consistent 
with the fact that a single CHD protein in yeast has evolved into nine CHD proteins in 
mammals.  Thus it is likely that there has been a trend towards the specialization of 
function of this family of proteins over the course of evolution. 
CHD3-5 Subfamily 
 The second subfamily of CHD proteins includes CHD3 and CHD4, also known as 
Mi-2α and Mi-2β, and CHD5.  These proteins lack a C-terminal DNA binding domain 
and instead have a pair of PHD domains in their N-terminal region.  This family has a 
single homolog in Drosophila called dMi-2.  The best known function of CHD3 and 
CHD4 is as the ATPase components of the NURD (Nucleosome Remodeling and 
Deacetylation) complex which is involved in transcriptional repression (73, 74).  This 
complex also contains HDAC1/2 subunits and is involved in the active deacetylation and 
15 
 
remodeling of chromatin, resulting in the establishment of transcriptional repressed loci 
(75, 76). 
CHD3 and CHD4 appear to be largely redundant in their functions in relation to 
this repressive complex, except for the evidence that CHD3-containing complexes, with 
similar composition as NURD, are specifically recruited by the corepressor KAP1.  This 
interaction is mediated by a C-terminal region that is unique to CHD3 and is responsible 
for recruiting these complexes to specific genes targeted for repression by KAP1 (77).  
Thus CHD 3 and CHD4 are both involved in NURD-mediated transcriptional repression, 
with CHD3 having some involvement in corepressor-specific repression of certain loci.  
On a more global scale, NURD has been reported to be targeted to sites of DNA 
methylation by its MBD (Methyl CpG-binding Domain) subunits, and this could be the 
mechanism of recruitment of the majority of NURD complexes to sites marked for 
transcriptional silencing by CpG methylation (78).  In fact, CHD4 has been reported to be 
more abundant in purified NURD complexes and is suspected to be the major, or perhaps 
the sole Mi-2 isoform present in these complexes (73, 76).  Thus, it may be possible that 
CHD4 is involved in these more generally recruited NURD complex involved in DNA 
methylation-mediated silencing, while the less abundant, more specialized, CHD3-
containing NURD complexes may be recruited by KRAB (Kruppel-associated box) 
domain proteins like KAP1 to specific target sites.  It is clear, however, that this 
subfamily has a repressive role in transcription and thus has evolved distinctly in function 
from the CHD1-2 subfamily, which is involved in transcriptional elongation. 
 Further differences in CHD3-5 and CHD1-2 subfamilies are seen in the binding 
characteristics of their chromodomains.  Structural analyses of the CHD3/4 
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chromodomains predict that they would not bind to methylated H3K4 residues (30).  
Consistent with this prediction, methylation of H3K4 has been found to preclude the 
binding of NURD to H3 tails (79, 80).  NMR studies of the CHD4 PHD domains have 
revealed that they preferentially bind methylated H3K9 and that H3K4 methylation 
reduces binding to unmodified H3 tails, further strengthening the hypothesis that CHD3-4 
bind to chromatin with a specificity and mechanism distinct from CHD1-2 (81).  H3K4 
methylation is associated with transcriptionally active chromatin and H3K9 is a mark of 
repressive chromatin.  Thus these observations about the binding properties of CHD3-4 
are consistent with their functional role in transcriptional repression.  The nucleosomal 
remodeling properties of Mi-2, however, have been shown to be similar to those of 
CHD1, with a preference to mobilize nucleosomes towards the center of a DNA template 
(82).  Thus it appears that while the catalytic properties of these subfamilies of CHD 
proteins have been conserved by maintaining the sequence homology in their SNF2 
domains, they have evolved considerably in function.  Their specificity for chromatin has 
been changed by the divergence in their chromodomains and by the presence of distinct 
histone-binding modules.  Their association with other factors, mediated through their 
non-conserved sequences, is likely to be responsible for the modulation of their catalytic 
activity so they can be adapted for distinct functional roles. 
 Unlike CHD3 and CHD4, very little is known about the cellular function of 
CHD5.  It has been shown to be expressed in neural tissue (83) and was found to be a 
tumor suppressor gene that was deleted in brain tumors (84).  More recent reports have 
shown that the CHD5 gene is silenced by hypermethylation of CpG islands in various 
cancers (85, 86).  From evolutionary analysis of this subfamily it appears CHD5 is the 
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product of a late gene duplication event of CHD4.  Thus it is possible it may be 
functionally similar to CHD4, playing a role in transcriptional repression, which would 
explain its potential as a tumor suppressor.  It is equally likely that its specificity and 
function would have changed some, since its expression pattern and role in human 
disease appear to be distinct from CHD3/4. 
CHD6-9 Subfamily 
 The last subfamily of CHD proteins is the CHD6-9 subfamily, characterized by 
the presence of C-terminal domains like SANT and BRK domains in addition to the 
chromodomains and the conserved SNF2 domain.  This subfamily also has a single 
Drosophila homolog, Kismet, which also contains a BRK domain in its C-terminal 
region.  While the CHD1-2 and CHD3-5 subfamilies have been extensively studied in 
terms of their functional roles, relatively little is known about the CHD6-9 subfamily. 
Kismet was identified as a trithorax group protein which acted as an extragenic 
suppressor of Polycomb mutations (87).  The Polycomb (Pc) group of repressors and the 
trithorax group of activators act in concert to regulate the expression of the homeotic 
(Hox) genes, which are transcription factors responsible for body segmentation and 
segment identity during Drosophila development (88).  Since Kismet acts 
antagonistically to Pc, it appears to have a role in transcriptional activation.  One report 
confirms this theory by elucidating a role for Kismet during an early step in 
transcriptional elongation (61).  By looking at the localization patterns of Kismet and 
other factors involved in transcriptional elongation on polytene chromosomes, this study 
found that Kismet localized to sites of transcriptionally active chromatin and was 
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required for the recruitment of elongating Pol II, dCHD1 and other elongation factors to 
these sites.  Kismet was thus found to be involved upstream of CHD1 in the 
transcriptional cycle, but downstream of BRM action in transcriptional initiation.  Thus 
Kismet was predicted to be required for the transition from early to late stages of 
transcription, perhaps in relieving the phenomenon of transcriptional pausing and 
facilitating promoter clearance by the polymerase, as discussed earlier in this chapter. 
It has also been observed that Kismet colocalized with the trithorax group proteins 
ASH1 and TRX, which are involved in the methylation of H3K4 (89).  The loss of 
Kismet resulted in a reduction in the level of these two proteins associated with 
chromatin and an increase in H3K27 methylation, while global H3K4 methylation levels 
did not change.  Since H3K27 methylation is a mark of Pc group silencing, Kismet 
appears to counteract this silencing by perhaps recruiting a H3K27 demethylase.  Thus 
Kismet is involved not only with the basic mechanism of transcriptional elongation, but 
also with gene-specific coactivator-mediated transcriptional response. 
 Consistent with the potential general and locus-specific transcriptional roles of 
Kismet, the human CHD6-9 members have been found to have varying cellular functions.  
CHD6, for example is associated with both hyper- and hypo-acetylated Pol II and 
localizes to sites of mRNA synthesis, suggesting a role in general transcriptional 
elongation (90).  It is also known to be involved in the transcriptional activation of 
specific genes involved in cellular redox homeostasis by the Nrf2 transcription factor 
(91). 
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CHD7 mutations are known to be associated with a complex human disorder 
called CHARGE syndrome, which is characterized by the following symptoms: ocular 
Coboloma, Heart defects, Atresia of chonae, Retardation of growth and development, 
Genital hypoplasia and Ear anomalies (92, 93).  CHD7 has also been implicated in early 
neural development (94).  CHD7 has also been shown to be important in the process of 
osteoblastogenesis from bone marrow mesenchymal stem cells by attenuating PPAR-γ-
(peroxisome proliferation activated receptor)-mediated adipogenesis in response to Wnt 
signaling in these cells (95).  CHD7 was found to be a component of a H3K9 HMTase-
containing complex which interacts with PPAR-γ in response to Wnt signaling at 
response elements of adipogenic target genes, attenuates recruitment of PPAR 
coactivators at these sites and facilitates the transcriptional repression of these genes 
driving the stem cells towards an alternative osteogenic cellular fate.  In the same study, 
the chromodomains of CHD7 were found to selectively interact with H3K4me3 and 
K3K9me3, but not with acetylated histones, showing the further specialization of these 
chromodomains of the CHD family proteins.  The recognition of both activating and 
repressive histone marks by CHD7 shows that the CHD6-9 subfamily may have 
contrasting roles in both these forms of transcriptional regulation unlike the other 
subfamilies. 
CHD9, also known as CReMM (Chromatin-Related Mesenchymal Modulator), 
has been shown to be differentially expressed in marrow mesenchymal cells during bone 
development (96) and to localize to promoters of genes involved in osteogenic cell 
function (97).  Thus CHD9 and CHD7 have parallel lines of evidence suggesting their 
involvement in developmental regulation of gene expression of skeletal tissue.  
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Furthermore, it was seen that CHD9, like CHD7, participates in osteogenic gene 
regulation via associations with nuclear receptors.  CHD9 was found to mediate the 
transcriptional response of hormones like dexamethasone (Dex) and 17β-estradiol by the 
glucocorticoid receptor (GR) and the estrogen receptor (ER) respectively during 
osteogenic stem cell differentiation (98, 99).  In another study CHD9 was shown to act as 
a transcriptional coactivator of PPAR-α and also interact in vitro with other nuclear 
receptors like constitutive androstane receptor (CAR), retinoid X receptor (RXR) and ER.  
CHD9 does not, however, interact with PPAR-γ like CHD7, exhibiting mutually 
exclusive associations with different isoforms of PPAR and indicating the divergence in 
specificity between different subfamily members.  Also, CHD9 has been reported to be a 
coactivator of nuclear receptors whereas CHD7 was shown to act in the repression of 
PPAR-γ signaling, once again showing distinguishing functionalities within this 
subfamily.  The above examples from literature suggest a role for CHD6-9 in nuclear 
receptor-specific transcriptional regulation and perhaps in a more general capacity in the 
developmental regulation of different tissues. 
CHD8 
 The focus of my thesis research is the fourth member of the CHD6-9 subfamily, 
CHD8.  Previous reports from our group have identified CHD8 as a bona fide ATP-
dependent chromatin remodeling enzyme and ascribed a transcriptional role for this 
protein.  In fact, among all the members of the CHD6-9 subfamily, CHD8 is the best 
understood enzyme from a functional aspect.  Reports from previous literature alluding to 
the cellular function of CHD8 indicate that this protein, like others member of this 
subfamily, is a functionally diverse molecule, with predicted roles in both locus-specific 
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and general transcriptional processes.  CHD8 has been shown to interact with elongating 
RNA Pol II and regulate the expression of the cyclin E2 cell cycle regulatory gene (100).  
It has also been reported to be involved in RNA Pol III-mediated transcription in 
association with human Selenocysteine tRNA Activating Factor (hStaf), in addition to its 
role in Pol II transcription (101).  Another report suggests that CHD8 recruits the linker 
histone H1 to p53 target genes and inhibits apoptosis during embryogenesis (102).  All 
these examples suggest that CHD8 could have an activating role in general transcriptional 
elongation, like the CHD1-2 subfamily, as well as in histone deposition and assembly of 
repressive chromatin structure like CHD3-5 proteins. 
 CHD8 also interacts with CTCF through its BRK domains and cooperates with 
CTCF in facilitating transcriptional repression through its insulator function at specific 
genomic loci (103).  Previous studies from our lab have also shown a role for CHD8 in 
the negative regulation of β-catenin responsive genes (104).  The remodeling properties 
of CHD8 are similar to those of CHD1 and ISWI, with a propensity to rearrange a 
random array of nucleosomes into a couple of ordered conformations, with a preference 
for positioning nucleosomes towards the center of a DNA template (104).  A couple of 
the studies mentioned above have also reported that the chromodomains of CHD8 can 
bind methylated H3K4 (100, 101), another similarity to both CHD1 and CHD7.  CHD8 
has also been recently reported to be involved in the ER-responsive activation of the 
cyclin E2 gene, once again highlighting the variety of roles that the CHD6-9 subfamily 
members are capable of exhibiting (105). 
All these examples from literature indicate that CHD8, like its CHD6-9 subfamily 
relatives, can be involved in both transcriptional activation and repression, in both 
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general and in specific contexts.  We also see the continued involvement of this 
subfamily in nuclear receptor-mediated transcriptional regulation making this an 
attractive field for further studies into the functional relevance of these proteins.  Thus we 
see that CHD8, and the other members of the CHD6-9 subfamily are chromatin 
remodeling enzymes with diverse cellular functions, and appear to have specialized 
evolutionarily to develop distinct functions in various transcriptional processes, both in 
different specific systems like those mediated by various nuclear receptors as well as in 
different steps in basic transcription. 
Research Aims 
 This dissertation is a description of my research work which was designed to 
address the following objectives: 
1. To investigate the transcriptional function of CHD8 by studying its role in the 
regulation of androgen-responsive transcription. 
2. To elucidate further mechanistic details of chromatin remodeling by CHD8 by 
characterizing its substrate specificity to determine how this aspect of its 
activity may affect its transcriptional function. 
3. To characterize the novel interaction of CHD8 with the MLL1-WAR histone 
methyltransferase complex and investigate how this may affect its functional 
role. 
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Figure 1.1:  ATP-dependent chromatin remodeling.  ATP-dependent chromatin 
remodeling enzymes contain a characteristic Snf2 domain, which is capable of binding 
and hydrolyzing ATP.  These enzymes can utilize the energy derived from ATP 
hydrolysis to mobilize nucleosomes along a DNA template, disrupt histone-DNA 
contacts within a nucleosome or displace histone octamers from one DNA template to 
another, as shown above. 
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Figure 1.2:  Evolutionary analysis of the SNF2 family of proteins.  Alignments for 
analysis were generated with representative sequences from humans (h), Drosophila (d), 
and S. cerevisiae (y/s) and included only the SNF2 domain. Neighbor-joining distance 
analysis employed the PHYLIP 3.6 software package. SEQBOOT and the aligned 
sequences were used to generate 500 bootstrap replicates. Pairwise distances were 
estimated using PROTDIST with the “Dayoff” option invoked. Neighbor-joining trees 
were generated using these pairwise distances in NEIGHBOR.  CONSENSE was used to 
derive the consensus tree. Branch lengths on the consensus tree were generated using 
FITCH, the pairwise distance output from PROTDIST using the aligned sequences, and 
the neighbor-joining consensus tree as a user tree.  Figure courtesy of D.A. Bochar. 
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Figure 1.3:  Domain architecture of the CHD family of chromatin remodeling 
enzymes.  The CHD family consists of nine proteins, all of which contain the 
characteristic N-terminal tandem chromodomains (red) and the central catalytic Snf2 
domains (purple).  The three subfamilies within this group are distinguished by the 
presence of additional domains, like the C-terminal DNA-binding domains (green) of the 
CHD1-2 subfamily, the N-terminal double PHD fingers (blue) of the CHD3-5 subfamily 
and the C-terminal SANT domains (light blue) and paired BRK domains (grey) of the 
CHD6-9 subfamily.  Domains identified using the SMART database (106, 107). 
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CHAPTER II 
Regulation of Androgen-Responsive Transcription by CHD8 
 
Introduction 
Androgens and Prostate Development 
The prostate is a male glandular organ located at the base of the urinary bladder 
comprised of glandular and muscular tissue (108).  The prostatic secretions of the 
glandular tissue, which are responsible for semen coagulation and liquefaction, are 
dispelled into the urethra by muscular contractions of the prostate upon ejaculation (109).  
The action of testicular androgens, like testosterone or dihydrotestosterone (DHT), 
mediated by the transcriptional activity of the androgen receptor (AR), plays a critical 
role in the development, growth  and normal function of  the prostate (110).  The prostate 
normally ceases to grow upon reaching maturity, but in some men androgen-dependent 
prostate growth may resume, resulting in benign prostate hyperplasia (BPH), pre-
malignant prostatic intraepithelial neoplasia (PIN) or prostate cancer (PCa), depending on 
the degree of malignancy of this continued growth (111). 
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Prostate Cancer 
Prostate cancer is currently the most commonly diagnosed form of cancer and the 
second leading cause of cancer deaths among males in the United States (112).  The 
dysregulation of androgen-responsive AR signaling has been implicated in the 
development and progression of prostate cancer.  Over 
 
80% of prostate cancers are 
androgen-dependent at
 
initial diagnosis, and thus most common therapeutic approaches 
are directed towards androgen ablation or inhibition of AR (113).  These methods prove 
to be effective initially in causing the regression of androgen-dependent tumors, thus 
highlighting the role of AR activity in early prostate tumorigenesis.  However, these 
treatments often ultimately fail due to progression of the prostate cancer to a hormone 
refractory state (114).  While it is known that the androgen receptor and its transcriptional 
coregulators play a key role in the progression of prostate cancer, the precise mechanism 
of their involvement are still not fully understood. 
The Androgen Receptor 
The androgen receptor is a member of the nuclear receptor superfamily (115).  It 
functions as a ligand-dependent transcription factor, mediating the effects of androgens 
on cellular responses.  The domain architecture of AR (Fig. 2.1) is similar to that of other 
nuclear receptors, and is comprised of an N-terminal transactivation domain, a central 
DNA-binding domain, and a C-terminal ligand-binding domain (116).  In the absence of 
ligand, AR is sequestered in an inactive state by a protein-chaperone complex in the 
cytoplasm (Fig. 2.2).  Upon exposure to androgens, AR dissociates from these complexes 
and binds the ligand, whereupon it dimerizes and translocates to the nucleus, where it can 
28 
 
then bind to specific DNA sequences, called androgen response elements (AREs), located 
in the target genes (116, 117). 
Two activation function (AF) domains, AF1 and AF2, then serve to recruit 
coactivators that can alter the chromatin structure to facilitate transcription, stabilize 
AR/DNA interactions, and recruit the general transcriptional machinery (118-120).  Some 
of the proposed mechanisms for the transition of androgen-dependent prostate cancer to 
an androgen-independent state include the increased expression of AR or its associated 
factors, mutations of AR that make it responsive to a broader spectrum of ligands, 
activation of the receptor through alternate pathways, and altered function of the AR 
coregulators (117, 121, 122). 
Androgen Receptor Target Genes 
The androgen receptor binds to and regulates the expression of a subset of genes 
which are important for prostate growth and function.  The Prostate-Specific Antigen 
(PSA) gene is one of the best characterized AR target genes.  PSA belongs to the human 
tissue kallikrein gene family and it is expressed in the prostate epithelium as well as in 
prostate cancer and is thus the most commonly used bio-marker for prostate cancer (123).  
It is an androgen-regulated serine protease that gets secreted by the glandular epithelium 
of the prostate into the lumen, where it is responsible for cleaving specific protein 
components of the semen coagulum (124).  The transcription of PSA is positively 
regulated by AR and it has been extensively studied as the model AR target gene (125).  
PSA contains a consensus
 
ARE site located between -156 to -170 base pairs (bp) from its 
transcriptional start
 
site (126) and a non-consensus ARE between -365 and -400 bp 
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upstream of the start site (127).  These are displayed as ARE I and ARE II in the 
schematic representation of the PSA gene in Fig. 2.3.  Further studies have mapped the 
region responsible
 
for androgen-responsive PSA expression to a fragment
 
of about 450 
base pairs, located approximately 4 kb upstream
 
of the transcriptional start site (128). 
This locus contains one strong consensus ARE as well as multiple non-consensus AREs 
and is called the PSA distal enhancer or ARE III (Fig. 2.3). 
Another well-characterized AR target gene is the Transmembrane Protease, 
Serine 2 (TMPRSS2) gene.  This is another androgen-regulated serine protease produced 
in basal prostate cells as well as in primary prostate cancer cells (129).  It has been 
reported that the TMPRSS2 gene is found to be fused with the ETS family oncogenes, 
ERG or ETV, in 80% of prostate tumors (130) making it also an attractive bio-marker for 
cancer.  The enhancer region of the TMPRSS2 gene, around 13.5 kb upstream from the 
start site (Fig. 2.3), has been characterized as an ARE to which AR binds in an androgen-
responsive fashion and upregulates the expression of this gene (131).  Other AR target 
genes implicated in prostate cancer include and FKBP5 (132), FGF8 (133), Cdk1 and 
Cdk2 (134). 
Androgen Receptor Coactivators 
The best characterized coactivators for nuclear receptors are members of the p160 
steroid receptor coactivator (SRC) family; SRC-1 (NCoA-1), SRC-2 (GRIP1, TIF2, or 
NCoA-2) and SRC-3 (p/CIP, RAC3, ACTR, AIB1, or TRAM-1) (135).  These primary 
coactivators can facilitate AR-mediated transcriptional activation either directly through 
their own intrinsic histone acetyltransferase activity (136), or indirectly through the 
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recruitment of secondary coactivators, such as CBP, p300, p/CAF, CARM-1, and 
PRMT1 (137).  These in turn catalyze site specific acetylation and methylation events at 
the target promoter that modify the chromatin structure (135, 138).  Chromatin 
remodeling events are not just limited to covalent modifications, as ATP dependent 
chromatin remodeling enzymes also play a key role in activation by AR.  These include 
the human SWI/SNF chromatin remodeling complex (139-143), SRCAP (144), and 
ARIP4 (145-147). 
Coactivators and Prostate Cancer 
Several of these coactivators have been implicated in prostate cancer, specifically 
in AR-mediated control of primary prostate cancer tumorigenesis and progression (148).  
Furthermore, alterations in AR-coregulator levels and function have also been proposed 
to contribute to the emergence of the hormone-refractory disease (149).  Members of the 
SRC family of coactivators have been found to be expressed at higher levels in prostate 
cancers and to have a role in tumor growth, progression and recurrence (150-152).  In 
addition to these primary coactivators, certain chromatin remodeling coregulators have 
also been implicated in prostate cancer.  The histone acetyltranferase p300 has been 
shown to promote prostate cancer progression and aggressiveness through the modulation 
of nuclear morphology (153, 154).  The histone demethylases LSD1 and JMJD2C have 
also been shown to coactivate AR and affect prostate cancer cell proliferation (155, 156).  
Finally, the ATP-dependent chromatin remodeling complex, SWI/SNF, coactivates AR-
mediated transcription and is targeted by its BAF57 (Brahma-associated factor) subunit 
which is aberrantly expressed in prostate cancer (140, 157).  In order to better understand 
the mechanisms of prostate cancer and develop more effective therapies against it, it is 
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desirable to study the association and interplay of AR with its many coregulators, both 
novel and those previously identified. 
ATP-dependent Chromatin Remodeling 
The regulation of transcription is contingent upon the coordination of the 
recruitment of the transcriptional machinery with the appropriate modification and 
remodeling of chromatin to allow access to nucleosomal DNA.  This regulation of 
chromatin structure is achieved by two classes of chromatin remodeling enzymes: one 
that is involved in the covalent modifications of histones, and the other that uses energy 
derived from ATP-hydrolysis to modulate the contacts between histones and DNA within 
the nucleosome.  The ATP-dependent remodeling enzymes usually occur in large 
complexes that alter chromatin structure by disrupting or mobilizing histones to regulate 
access to the nucleosomal DNA.  All the identified enzymes in this class contain an 
ATPase domain, called the Snf2 helicase domain, which is the characteristic feature of 
the SNF2 superfamily of proteins. 
CHD Family of Chromatin Remodelers 
The SNF2 superfamily of ATP-dependent remodeling enzymes is further 
classified into different families, like the SWI/SNF, ISWI and CHD families, based upon 
the presence of other characteristic domains in their domain architecture.  The CHD 
(Chromodomain Helicase DNA-binding) family includes CHD1 thru CHD9, and they are 
characterized by the presence of tandem chromodomains toward their N-terminus along 
with the Snf2 helicase domain located in the central part of these proteins.  The CHD 
family of proteins can be further subdivided into three subfamilies based upon the 
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presence of additional domains.  The CHD1-CHD2, the CHD3-CHD5 and the CHD6-
CHD9 subfamilies are each characterized by the presence of distinct domains in their C-
terminal region.  While the CHD1-2 and CHD3-5 subfamily proteins have been well 
studied in the context of their chromatin remodeling activity and their functional role in 
transcriptional regulation, relatively little is known about the CHD6-9 subfamily. 
CHD8 
Previous work from our group has shown that CHD8 is an ATP-dependent 
chromatin remodeling enzyme involved in transcriptional regulation of -catenin 
responsive genes (104).  Other studies have linked CHD8 to CTCF-mediated chromatin 
insulator function (103), to RNA polymerase III (RNAP III) transcription in association 
with hStaf (101), to control of p53-mediated apoptosis (102) and to RNAP II-associated 
transcription of the cyclin E2 gene (100).  Thus CHD8 displays a fairly versatile portfolio 
of functions in transcriptional regulation.  A recent report shows that CHD8 is required 
for optimal estrogen-responsive induction of the cyclin E2 gene (158).  There is 
additional evidence that the very closely related CHD family member CHD9, also known 
as PRIC320 or CReMM, acts as a coactivator of the nuclear receptor peroxisome 
proliferator activated receptor (PPAR) (159) and also interacts with the glucocorticoid 
receptor (98) and estrogen receptor (99)  These observations from previous studies, raise 
the possibility that CHD8 may be involved n transcriptional regulation by other nuclear 
receptors. 
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Hypothesis and Summary of Results 
The implication of CHD8, and its homologous subfamily member CHD9, 
functioning as coactivators for other nuclear receptors prompted us to further investigate 
connections between CHD8 and nuclear receptor-mediated transcriptional regulation.  In 
order to do this, publicly available gene expression sets were examined using the ONCOMINE 
database (160).  This investigation revealed that CHD8 was found to be significantly upregulated 
in several prostate cancer versus normal tissue data sets (161-165).  We have previously 
identified and characterized CHD8 as an ATP-dependent chromatin remodeling enzyme involved 
in the regulation of gene transcription (104).  Given the fact that many AR coactivators are 
upregulated in prostate cancer (147), the finding that CHD8 is upregulated in several studies 
suggests that CHD8 may function in the regulation of AR mediated transcription.   
In these studies we show that endogenous CHD8 associates with AR in prostate 
cancer cells by performing co-immunoprecipitations from nuclear extracts.  We further 
demonstrate that this association is due to a direct physical interaction, by co-expressing 
the proteins in insect cells using a baculovirus expression system and then performing co-
immunoprecipitations.  We then showed by chromatin immunoprecipitation (ChIP) that 
CHD8 is present at the AR target promoters PSA and TMPRSS2, and that it localizes 
there even prior to the recruitment of AR to this site upon DHT induction.  Also, we 
show that AR and CHD8 co-localize to the TMPRSS2 promoter at the same time by 
conducting re-ChIP experiments.  We then examined a functional role for CHD8 in AR-
mediated transcriptional activation of androgen responsive genes by depleting CHD8 
using shRNA treatment.  Upon CHD8 depletion in androgen-dependent LNCaP cells, the 
AR-dependent activation of TMPRSS2 and PSA in response to DHT induction was 
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severely curtailed.  However, knocking down CHD8 in androgen-independent cells did 
not affect the expression of the target genes.  Thus, CHD8 is required for optimal 
androgen-responsive transcriptional activation of AR target genes in an androgen-
dependent context.  ChIPs were repeated under conditions of CHD8 depletion and we 
found that the recruitment of AR to the TMPRSS2 promoter in response to DHT 
treatment was abrogated.  Taken together with the previous result, this suggests a 
mechanism by which CHD8, via the facilitation of androgen-responsive recruitment of 
AR, is involved in the transcriptional activation of AR target genes.  Finally we show that 
CHD8 depletion adversely affects androgen-responsive cell proliferation of LNCaPs.  In 
summary, we present evidence of a functional, and possible mechanistic role for CHD8 
in AR-mediated transcriptional activation of it target genes. 
 
Materials and Methods 
Cell Culture 
LNCaP, 22RV1, PC-3 and DU-145 cell lines were obtained from the American 
Type Culture Collection (ATCC).  All cell lines were maintained in RPMI Medium 1640 
(Invitrogen) containing 10% fetal bovine serum (FBS: Hyclone) and 1X penicillin-
streptomycin-glutamine (Invitrogen).  All human cell lines were maintained at 37°C in 
5% CO2.  Androgen treatments were done using dihydrotestosterone (DHT) dissolved in 
ethanol and used at a final concentration of either 10 nM or 50 nM, as specified.  Prior to 
androgen treatment, cells were switched to phenol red-free RPMI Medium 1640 
(Invitrogen) supplemented with Dextran/Charcoal-stripped FBS (Hyclone) and 1X 
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penicillin-streptomycin-glutamine (Invitrogen) for at least 24 hours.  SF9 insect cells 
were cultured at 24°C in 1X Grace’s Insect medium (Invitrogen) containing 10% FBS 
(Hyclone) and 1X penicillin-streptomycin-glutamine (Invitrogen). 
Antibodies and Reagents 
CHD8 rabbit polyclonal antibodies used were previously described (104).  Rabbit 
polyclonal (N-20) and mouse monoclonal (441) AR antibodies were obtained from Santa 
Cruz Biotechnology.  Rabbit IgG  and Actin control antibodies were from Sigma.  Anti-
rabbit IgG AP conjugate secondary antibodies were from Promega.  All oligonucleotides 
were ordered from Integrated DNA Technologies (Coralville, IN).  Primer sequences are 
listed in Table 2.1. 
Recombinant Protein Production 
Recombinant baculoviruses were used to express AR and CHD8 in SF9 insect 
cells.  The AR baculovirus was a kind gift from James Dalton (Ohio State University, 
Columbus, OH).  The Flag-CHD8 baculovirus was obtained by cloning the full-length 
protein in the pBlueBac-Flag vector and generating viral stocks using the Bac-N-Blue 
Baculovirus Expression System (Invitrogen).  For protein interaction studies, 5×10
6
 SF9 
cells were co-infected with 1 mL each of AR and Flag-CHD8 baculovirus and incubated 
at 25°C for 2 days.  Cells were then collected by centrifugation at 500×g for 2 minutes at 
room temperature, washed with cold phosphate buffered saline (PBS) and resuspended in 
500 L of IP buffer (20mM Tris-HCl [pH=7.9], 0.2 mM EDTA, 10% glycerol, 0.2 mM 
phenylmethylsulfonyl fluoride [PMSF]) with 150 mM KCl  and 0.1% NP-40.  Lysates 
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were cleared by centrifugation at 20,800×g for 10 minutes at 4°C and used for co-
immunoprecipitations as described below. 
Co-immunoprecipitations 
For the in vivo interaction studies between endogenous CHD8 and AR, nuclear 
extracts were prepared from the various cell lines as described by Dignam et al. (166).  
These extracts were incubated overnight at 4°C with protein A-agarose beads (Repligen) 
cross-linked to the specified antibodies.  The beads were then washed sequentially with 1 
mL each of 150 mM KCl in IP buffer, 150 mM KCl in IP buffer with 0.1 % NP-40 and 
then in 150 mM KCl IP buffer again.  Samples were eluted in SDS-loading buffer (125 
mM Tris-HCl [pH=6.8], 0.5% SDS, 10% glycerol, 0.175 M BME) and then subjected to 
SDS-PAGE followed by Western blot analysis with the indicated antibodies. 
Co-immunoprecipitations of recombinant proteins from baculovirus infected SF9 
cells were performed by incubating lysates prepared as described above with 20 L of 
anti-Flag M2 agarose beads (Sigma) at 4°C.  Beads were washed and eluted as above and 
subjected to SDS-PAGE and Western blot analysis with the indicated antibodies. 
Chromatin Immunoprecipitations 
ChIP experiments were performed essentially as described in the ChIP assay kit 
(Upstate).  Briefly, ~ 1×10
6
 cells per immunoprecipitation were fixed with 2.5% 
formaldehyde for 10 minutes at 37°C.  Cells were washed with cold PBS and lysed with 
ChIP lysis buffer.  The chromatin was sheared by sonication (~ 200 – 1000 bp fragments) 
and cleared by centrifugation at 20,000×g for 10 minutes at 4°C.  Samples were diluted 
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10-fold in ChIP dilution buffer and then pre-cleared with protein A agarose beads 
(Repligen) blocked with salmon sperm DNA (Invitrogen).  Chromatin was 
immunoprecipitated by incubating with the indicated antibodies overnight at 4°C.  
Antibody-chromatin complexes were precipitated by incubation with protein A agarose 
beads blocked with salmon sperm DNA.  Samples were then washed and eluted as 
described in the instructions, except washes were done for 15 minutes each. 
For re-ChIPs, the first ChIP was done as described above, except the washed 
chromatin-antibody complexes were eluted in 50 L TE with 10 mM dithiothreitol 
(DTT) and then diluted 20-fold in Re-ChIP buffer (150 mM NaCl, 0.5 mM DTT, 1% 
Triton X-100, 20 mM Tris-HCl [pH=8.1] 2mM EDTA).  These were then 
immunoprecipitated with the second specified antibody and washed and eluted again as 
above. 
RT-PCR and Quantitative PCR. 
cDNA was prepared by extracting total RNA from the indicated cells using the RNeasy 
kit (Qiagen) following the manufacturer’s instructions.  Reverse transcription reactions employed 
total RNA, random decamers (Ambion), and Superscript II reverse transcriptase (Invitrogen) 
following the manufacturers’ instructions.  Real-time quantitative analysis employed the 
indicated primers, iQ SYBR Green Supermix (Bio-Rad), and a MyiQ Single Color Real-Time 
PCR Detection System (Bio-Rad).  All real time PCR reactions were performed in triplicate.  For 
RNA expression analysis, threshold cycle (Ct) values were normalized to levels of RNA 
polymerase III-transcribed human H1 RNA.  For ChIP experiments, DNA quantities were 
expressed relative to input levels.  The following primers were used for ChIP experiments.  
TMPRSS2 -13.5 kb: TGGTCCTGGATGATAAAAAAAGTTT and 
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GACATACGCCCCACAACAGA.  TMPRSS2 -7 kb: ACGCCTTCGCTGTCCTACCT and 
TGCAATGAAGTTCCCTGCAA.  The following primers were used for quantitative RT-PCR 
analysis.  TMPRSS2: GGACAGTGTGCACCTCAAAGA and TTGCTGCCCATGAACTTCC.  
H1 control: ACTCCACTCCCATGTCCCTTG and CCGTTCTCTGGGAACTCACCT.   
RNAi Experiments 
CHD8 expression was knocked down in the various prostate cancer cells using 
RNAi technology utilizing the UI2-Puro SIBR shRNA vectors (167).  CHD8 was 
knocked down using two shRNA cassettes, 493 and 6410, cloned into the SIBR vector.  
UI2-Puro SIBR GFP-479, containing a shRNA cassette targeting the GFP mRNA, was 
used as a control shRNA vector.  2 or 10 g of each of these constructs was transfected 
into cells which were at ~80% confluency in either 6-well plates (for expression studies) 
or in 10 cm dishes (for ChIPs), respectively, using Lipofectamine 2000 (Invitrogen) as 
described by the manufacturer.  Transfections were done in phenol red-free RPMI 1640 
medium containing 10% dextran/charcoal-stripped FBS.  16 hours post-transfection, the 
cells were selected with 10 g/mL puromycin for 48 hours more.  Cells were then treated 
with DHT or ethanol for 6 hours.  For expression studies shRNA transfections were done 
in duplicate and one set was harvested for RNA extraction while the other was lysed in 
RIPA buffer (150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 0.1% SDS, 50 mM 
Tris-HCl [pH=7.4], 1 mM EDTA, 0.2 mM PMSF) and Western blotted with the indicated 
antibodies to verify the knockdown of protein expression.  For ChIPs, the cells were fixed 
with 2.5% formaldehyde after treatment and harvested for the ChIP protocol. 
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Cell Proliferation Assays 
LNCaP cells were transfected with the indicated shRNAs and selected as 
described above.  The cells were then PBS-washed, trypsinized and counted in 
suspension in media.  The cells were then plated in 96-well plates at 5000 cells per well 
in duplicate for the control and the CHD8 shRNA-transfected cells.  Cells were plated in 
sets of eight in four separate plates, one for each time point, and treated with either 50 
nM DHT or an equal volume of ethanol.  Cells were harvested at the specified time 
points and the cell viability was measured based on quantitation of ATP from 
metabolically active cells present using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega) following the manufacturer’s instructions.  Data was expressed as fold 
DHT-induced proliferation, which was calculated as the ratio of the luminescent signal 
from the induced cells to that obtained from the uninduced cells for each shRNA 
treatment at each indicated time point. 
 
Results 
Analysis of Microarray Data 
In order to explore the possibility of the CHD6-9 family of chromatin remodeling 
enzymes functioning as novel cofactors for R in the progression of prostate cancer, 
publicly available gene expression sets were examined using the ONCOMINE database 
(160).  One factor that was found to be significantly upregulated in several prostate 
cancer samples was CHD8, which we have previously identified and characterized as a 
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novel ATP-dependent chromatin remodeling enzyme involved in regulation of gene 
transcription (104).  Four distinct microarray data sets were examined and the expression 
levels of CHD8 were compared between normal prostate tissue, primary prostate cancer 
tumors and metastatic tumors.  It was observed that in three out of the four data sets there 
was a highly statistically significant (p = < 0.01) increase in the expression of CHD8 in 
metastatic tumors, but not in primary tumors, when compared to normal prostate tissue 
(data available at www.oncomine.org – search gene:CHD8).  This increase in expression 
was greater than two-fold the average expression level of CHD8 in the normal prostate 
tissue samples in 15, 19 and 17 samples respectively out of 25 total samples of metastatic 
tumors included in the studies.  This increase of expression was comparable in statistical 
significance and in magnitude to that of Enhancer of Zeste Homolog 2 (Ezh2) expression 
between normal and metastatic prostate samples from the same expression data set.  This 
was used as the basis of the study by Verambally et al. linking Ezh2 to prostate cancer 
progression (168).  However, the expression of CHD9 was not increased in tumors 
compared to normal prostate tissue, suggesting that CHD8 specifically is involved 
prostate tumorigenesis.  Given the fact that several AR coregulators that are known to be 
upregulated in prostate cancer, this observation gives rise to the possibility of CHD8 
functioning as a coregulator of AR. 
CHD8 Interacts with AR 
To verify whether this possible connection between AR and CHD8 was due to a 
physical interaction of the endogenous proteins, co-immunoprecipitations were 
performed from different prostate cancer cells.  Nuclear extracts were prepared from the 
androgen-dependent LNCaP prostate cancer cell line, as well as from the androgen-
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independent prostate cancer cell lines, 22RV1, PC-3 and DU-145 (169-171).  Androgen-
dependent cells require androgens for continued cell growth and proliferation, while 
androgen-independent cell lines are capable of growth independent of androgens.  
Immunoprecipitations were performed from these extracts using anti-CHD8 polyclonal 
antibodies.  When the co-IPs were washed, subjected to SDS-PAGE and Western blotted 
with anti-CHD8 polyclonal and anti-AR monoclonal antibodies, it was observed that 
endogenous AR and CHD8 do indeed interact in androgen-dependent LNCaP cells but 
not in the androgen-independent cell lines (Fig.  2.4), indicating that AR and CHD8 
associate with each other in an androgen-dependent context. 
To further investigate this interaction between AR and CHD8, co-
immunoprecipitations of the recombinant proteins expressed using a baculovirus 
expression system in SF9 insect cells were also carried out.  SF9 cells were infected with 
either AR alone, or co-infected with AR and Flag-CHD8 and then cell extracts were 
immunoprecipitated using anti-Flag antibodies.  AR immunoprecipitated with the Flag 
beads along with the Flag-tagged, recombinant CHD8, but not by itself (Fig. 2.5), thus 
verifying a direct physical interaction between these two proteins. 
CHD8 and AR Co-localize to the Promoters of Androgen-Responsive Genes 
Having established the interaction between AR and CHD8, it was then examined 
whether this association was evident at endogenous AR target promoters, with CHD8 
being localized to these sites along with AR.  We have previously shown that CHD8 
localizes to -catenin target promoters (104) and to the Hox locus (unpublished data) by 
chromatin immunoprecipitation.  To examine CHD8 occupancy at AR target promoters, 
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LNCaP cells were either mock-treated with ethanol or induced with DHT for 6 hours and 
ChIP assays were done using antibodies against AR, CHD8 or with normal rabbit IgG as 
a control.  The immunoprecipitated chromatin was analyzed by quantitative RT-PCR 
using primers directed against the previously defined enhancer regions in the promoters 
of PSA and TMPRSS2 (126, 131).  The ChIPs for AR and CHD8 were at considerably 
higher levels than those for IgG under each of the conditions and therefore the IgG ChIP 
data is not shown.  As expected, AR was recruited to the TMPRSS2 ARE upon induction 
by DHT (Fig.  2.6).  It was also observed that CHD8 localized to this ARE both with and 
without induction by DHT, thus indicating that CHD8 is targeted to this promoter in an 
AR-independent manner.  CHD8 was not present at the control site located about 7 kb 
upstream of the start site in the TMPRSS2 promoter, thus CHD8 is not non-specifically 
binding to this promoter.  Similar androgen-independent localization of CHD8 was also 
seen on the ARE I/II region of the PSA promoter (Fig. 2.7). although CHD8 levels are 
reduced upon androgen treatment. 
In order to confirm that AR and CHD8 are present at the same target sites 
simultaneously, re-ChIP assays were carried out in similarly treated LNCaP cells.  These 
were done by immunoprecipitating the cross-linked chromatin-protein complexes using 
first CHD8 and then AR antibodies in two successive chromatin immunoprecipitations.  
Control re-ChIPs were done using either two consecutive immunoprecipitations with IgG 
antibodies or with IgG followed by AR antibody.  Analysis of the immunoprecipitated 
chromatin using the same primers as for the TMPRSS2 ChIPs above indicated that 
indeed AR and CHD8 did co-localize to the TMPRSS2 ARE site upon DHT induction at 
the same time (Fig 2.8). 
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CHD8 Coactivates AR-Mediated Transcription 
Having established the direct association between CHD8 and AR and their co-
localization at the TMPRSS2 promoter, we then examined whether CHD8 has a 
functional role in the regulation of TMPRSS2 gene expression by using an shRNA-based 
approach to deplete endogenous CHD8.  LNCaP cells were transfected with either 
control shRNA constructs or with shRNA constructs directed against CHD8.  These 
vectors were designed so they also co-expressed the puromycin resistance gene along 
with the shRNAs.  Thus cells successfully transfected with the shRNA constructs should 
also be puromycin-resistant and this feature was used to select for transfected cells by 
treating the transfected cells with puromycin for 48 hours.  After selection, the cells were 
treated with either ethanol or DHT for 6 hours and then total RNA was extracted from 
these cells and reverse transcribed into cDNA.  These cDNA samples were used as 
template for quantitative RT-PCR analysis to measure TMPRSS2 and PSA expression 
levels. 
We found that, as expected, TMPRSS2 expression was induced almost 6-fold 
upon DHT treatment in the cells treated with control shRNA.  However, under conditions 
of CHD8 depletion we see that the transcriptional activation of the TMPRSS2 gene upon 
DHT induction was almost completely abrogated (Fig. 2.9).  This suggests that CHD8 is 
required for the optimal androgen-induced transcriptional activation of the AR target 
gene, TMPRSS2, in LNCaP cells.  Similar, albeit less dramatic, effects of CHD8 
knockdown were also observed on the expression of PSA in these cells (Fig. 2.10).  The 
effectiveness of the depletion of CHD8 by our shRNA treatment and selection strategy is 
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shown in Fig. 2.11, where we see significantly reduced levels of CHD8 protein by 
Western blotting. 
CHD8 is an Androgen-Dependent AR Coactivator 
The same CHD8 RNAi experiment was carried out in androgen-independent PC-
3, DU-145 and 22RV1 cells.  These cells do not respond to androgen treatment due to 
absence of functional AR (PC-3 and DU-145) or due to transition into an androgen-
independent state (22RV1) (150, 172).  In all three of these cell lines we found that 
induction by DHT treatment did not activate TMPRSS2 expression and CHD8 depletion 
did not significantly affect the expression of this gene either (Fig. 2.12).  Similar results 
were obtained with PSA expression levels in each of these cell lines (2.13).  While there 
were minimal changes in TMPRSS2 and PSA expression in upon CHD8 depletion in PC-
3s and 22RV1s, these changes were insignificant compared to the drastic reduction of 
expression level seen in androgen-dependent LNCaP cells.  The knockdown of CHD8 
expression in each of these cell lines was verified by Western blot, as was done for the 
LNCaP cells, and a similar depletion of CHD8 was observed in each case (data not 
shown).  These data support the hypothesis that CHD8 plays an important role in 
transcriptional activation of the TMPRSS2 gene by AR in an androgen-dependent 
context. 
CHD8 Facilitates AR Binding to Target Promoters 
Next, we attempted to observe the effects of CHD8 depletion on the localization 
of AR and CHD8 at the TMPRSS2 ARE site.  CHD8 expression was knocked down in 
LNCaP as above and the transfected, puromycin-selected cells were treated with DHT for 
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6 hours.  Since AR only binds to the TMPRSS2 ARE upon DHT induction the 
experiment was done only under induced conditions.  ChIPs were carried out as before 
using antibodies against AR and CHD8 as well as IgG as a control.  Quantitative RT-
PCR analysis was carried out to observe the localization of AR and CHD8 at the target 
site using the same ChIP primers as in Fig. 2.6.  It was observed that, as expected, the 
level of CHD8 at the ARE was significantly reduced in the cells where CHD8 had been 
knocked down (Fig. 2.14).  Interestingly, while AR was appropriately recruited to the 
promoter upon DHT induction in control cells, this androgen-induced recruitment of AR 
was abrogated in the CHD8 depleted cells.  This indicates that CHD8 is required for the 
recruitment and binding of AR to target promoters in response to androgen treatment.  
The fact that CHD8 is present at target promoters prior to AR recruitment to these sites 
upon DHT treatment, validates the possibility that CHD8 may be involved in the 
recruitment of AR to the TMPRSS2 ARE upon induction by androgens. 
CHD8 is Involved in Androgen-Dependent Cell Proliferation 
We have shown that CHD8 is required for the optimal transcriptional activation of 
the TMPRSS2 gene upon induction by DHT and that it may be required for the 
appropriate androgen-responsive recruitment of AR to target promoters.  In order to 
examine whether this functional role for CHD8 in transcriptional regulation of AR-
responsive genes has any physiological relevance, proliferation assays were conducted in 
LNCaP ells.  Cells were transfected with either control or CHD8-targeting shRNA and 
selected as before.  They were then induced with 50 nM DHT or mock-treated with 
ethanol.  Proliferation assays were carried out at the indicated time points using the 
CellTiter-Glo kit from Promega in 96-well plates, using eight replicate sets for each 
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condition.  Data was expressed as a ratio of the luminescent signal from the induced cells 
to that obtained from the uninduced cells for each shRNA treatment at each given time 
point, and displayed as fold DHT-induced proliferation.  We saw that, while DHT 
treatment resulted in a significant increase in proliferation of control cells, the CHD8-
depleted cells did not show similar increases in proliferation upon DHT induction after 2 
or 4 days (Fig. 2.15).  Thus it appears that CHD8 is required for androgen-dependent 
expression and also for androgen-induced cell proliferation of LNCaP cells.  CHD8 could 
therefore be an important and novel regulator of androgen-dependent prostate tumor 
growth. 
Discussion 
A Model for Coactivation of AR-Mediated Transcription by CHD8 
The analysis of microarray data from the ONCOMINE database comparing 
expression profiles of normal prostate tissue to prostate tumors led to the discovery that 
CHD8 is upregulated in prostate cancer.  Several AR coactivators are known to be 
similarly upregulated in prostate cancer.  Given the background of CHD8 as a chromatin 
remodeling enzyme and the abundance of chromatin-related coactivators known to 
associate with AR in the course of its transcriptional regulatory function, this led us to 
hypothesize that CHD8 is a coactivator of AR. 
We verified this hypothesis by showing a direct physical interaction between both 
endogenous and recombinant AR and CHD8 (Fig. 2.4 and Fig. 2.5).  The interaction 
between the endogenous proteins was only evident in androgen-dependent cells and not 
in cells that are unresponsive to androgens, indicating this interaction is mediated in some 
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way by androgens (Fig. 2.4).  This is typical of other AR coactivators which are known to 
physically associate with ligand-bound AR in an androgen-dependent manner (118, 135).  
These coactivators contain one or more of the conserved signature NR box motifs, 
LXXLL, which are both necessary and sufficient for interaction with the AF-2 region in 
the C-terminal ligand-binding domain (LBD) of nuclear receptors (173).  This 
interaction, in turn, serves to recruit these coactivators to target promoters.  A novel 
variant to this signature NR box motif, defined by the sequence FXXLL, has also been 
found to be capable of mediating interactions of coactivators with nuclear receptor LBDs 
(174).  It has also been reported that, compared to other nuclear receptors, the LBD of 
AR has a unique coactivator binding groove in its LBD that binds FXXLF motifs with 
greater affinity than the traditional NR box motif (175-177).  In fact, one such motif is 
found in the NTD of AR and is known to strongly bind to the coactivator groove in the 
LBD (178, 179), facilitating optimal transactivation of the receptor (180-182).  This 
interaction between the N- and C- terminal domains takes place only in the mobile 
fraction of AR and the interaction is relieved upon the binding of the receptor to DNA, 
allowing the coactivator groove to become accessible by other cofactors (183). 
Protein sequence analysis of CHD8 revealed the presence of similar consensus 
motifs within its helicase domain.  The traditional NR box in CHD8 is a LFSLL motif 
located at 996–1000 aa within the SNF2 helicase domain of the protein.  This motif is 
conserved only in members of the CHD 6-9 family and is not found within the helicase 
domains of other SNF2 family proteins and thus could be the candidate binding motif for 
its specific interaction with AR.  Closely homologous to this signature motif is the 
FXXLL sequence, which in CHD8 is a FVFLL motif located at 1212–1216 aa in the 
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helicase domain.  Alignments of the evolutionarily conserved helicase domains of 
members of the SNF2 superfamily, this motif was found to be conserved within several 
other SNF2 family helicases including CHD 3-5, INO80, KIAA 1122 and Brg1, besides 
CHD 6-9.  A closely homologous sequence, FVFML, was found in ISWI.  This indicates 
that this motif may not be responsible for AR binding since it is a widely conserved motif 
in all SNF2 helicases and may be of functional importance for the activity of the helicase 
domain.  None of the variations of the AR-specific interaction motif, FXXLF, were found 
in the CHD8 protein sequence. 
The AR-specific FXXLF motif is capable of stimulating stronger binding with the 
coactivator groove of AR than the general LXXLL NR box motif, due to the fact that the 
bulkier F residues make better hydrophobic contacts with the amino acids lining the 
coactivator groove than L residues (176, 177).  However, LXXLL motif interactions are 
still made possible by an induced fit mechanism which allows the coactivator groove to 
alternatively allow L or F residues at the terminal positions of the binding motif (184-
186).  Thus it is possible for there to be differential strength of binding of coactivators to 
AR, based on the kind of binding motif present.  In the case of CHD8, it may not be 
desirable to have a strong interaction with AR, and thus this interaction may be mediated 
by the less potent LXXLL motif.  In fact, common nuclear receptor coactivators, like 
SRC1 and TIF2, interact with AR through traditional NR box motifs (176, 184, 187).  
This may be to enable the more general transcriptional coactivators to selectively bind 
with AR during transcriptional activation and then easily dissociate from the receptor 
once their role is completed, to carry on their other cellular functions.  CHD8 has also 
been shown to be an enzyme with diverse functions and thus its interaction with AR may 
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be mediated by an NR box motif by design, so as to allow this association to be more 
transient.  In fact, since most FXXLF-mediated interactions appear to be those of more 
AR-specific coactivators, like ARA54 and ARA70 (188), it makes sense that CHD8 does 
not have one of these motifs, as it is clearly more diverse in function and it would not be 
ideal for it to be tethered to AR.  Furthermore, the fact that CHD8 interacts with AR 
through an LXXLL motif may indicate that it could be involved in coactivation of other 
nuclear receptors.  This theory is supported by the fact that the closely homologous 
subfamily member, CHD9, is known to interact with several other nuclear receptors, like 
the peroxisome proliferator activated receptor (PPAR), glucocorticoid receptor (GR), 
constitutive androstane receptor (CAR), retinoid X receptor (RXR) and the estrogen 
receptor (ER) through its LXXLL motifs (159).  Further work is required to more 
accurately map the interaction of AR with CHD8 to verify these speculations. 
We observed that CHD8 co-localized with AR to target AREs in the PSA and 
TMPRSS2 promoters.  However, unlike other coactivators, CHD8 was associated with 
these promoters independent of androgen induction (Fig.2.6 and Fig. 2.7).  In this respect 
CHD8 is distinct from most common AR coactivators which get recruited to the target 
promoters by AR in response to androgen treatment.  This raises the possibility that 
perhaps CHD8 is functioning differently than other typical coactivators in its role in AR-
mediated transcriptional regulation. 
When CHD8 was depleted in androgen-dependent cells, the androgen-stimulated 
transcriptional activation of TMPRSS2 and PSA was abrogated (Fig. 2.9 and Fig. 2.10).  
Since this activation is mediated by the action of AR, we can conclude that CHD8 is a 
required coactivator for the optimal activation of androgen-responsive genes.  Depletion 
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of CHD8, however, had no effect on the expression of these genes in androgen-
independent cells (Fig. 2.12 and Fig. 2.13).  Thus we have established that CHD8 is a 
coactivator of AR and functions in an androgen-responsive manner to regulate the 
expression of target genes upon induction by androgens. 
While we have shown that the transcriptional role of CHD8 in regulating the 
expression of androgen-responsive genes is similar to other coactivators of AR, its 
mechanistic function is still unclear. How can a chromatin remodeling enzyme that is 
present at target promoters in an androgen-independent fashion function as an androgen-
responsive AR coactivator?  This is partly addressed by our observation that depletion of 
CHD8 prevented AR from binding AREs in the target promoters (Fig. 2.14).  We know 
that CHD8 is a nucleosome remodeling enzyme that is present at these promoters even 
prior to androgen treatment and that it interacts with AR in an androgen-dependent 
fashion.  Hence, we can postulate that ligand-bound AR homodimers bind to CHD8 at the 
target promoters, modulating its remodeling activity to reposition nucleosomes in a 
manner that facilitates the binding of AR to the underlying DNA.  Thus our model is that 
CHD8 is present at AR target promoters, where it may have some basal activity in 
maintaining the chromatin in a transcriptionally inactive state.  Upon induction by 
androgens, ligand bound AR homodimers translocate from the cytoplasm to the nucleus, 
where they interact with CHD8 at the AREs of target promoters.  They then modulate the 
nucleosomal remodeling activity of CHD8 in a way that facilitates nucleosome 
repositioning to allow AR to bind to the ARE DNA sequences.  The promoter-bound AR 
subsequently regulates the transcriptional activation of the target gene by recruiting other 
coactivators and the transcriptional machinery to these sites.  Recent studies from our 
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group have indicated a similar role for CHD8 in the recruitment of the histone 
methyltransferase complex, WAR, to Hox promoters (unpublished data). 
While this is an attractive model based on the results described above, it needs to 
be examined in greater detail to verify the precise mechanistic role of CHD8 in AR-
mediated transcriptional regulation.  The role of CHD8 is, however, physiologically 
relevant in terms of the growth and proliferation of prostate cancer cells, as evidenced by 
our observation that CHD8 depletion adversely affects the androgen-responsive 
proliferation of LNCaP cells (Fig. 2.15).  This validates our hypothesis of CHD8 as an 
androgen-dependent AR coactivator and also supports a model in which CHD8 is 
required for optimal recruitment and subsequent transcriptional activation of AR target 
genes.  This result also suggests that CHD8 is involved in the regulation of a larger subset 
of AR target genes, due to its effect on the overall growth of these prostate cancer cells in 
response to androgens. 
Comparisons to SWI/SNF, another ATP-dependent Chromatin Remodeling 
Coactivator of AR 
SWI/SNF has been well established as an ATP-dependent chromatin remodeling 
complex known to function as an AR coactivator.  It is recruited by AR to target 
promoters in response to androgen and plays a role in the transcriptional activation of 
these genes through its nucleosome remodeling activity (189).  The catalytic activity of 
human SWI/SNF is conferred by one of two core ATPases, Brg1 or hBRM.  Of these 
alternative SWI/SNF complexes, hBRM-containing complexes were preferentially 
recruited by AR as a coactivator in the course of its transcriptional regulatory function 
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(143).  The interaction of the SWI/SNF complex to AR has been shown to be mediated 
through a direct interaction with the BAF57 subunit of the complex, which is responsible 
for the specificity of this association (140).  In contrast, CHD8 appears to directly 
associate with AR as there were no additional components bridging the interaction 
demonstrated between the recombinant proteins in the baculovirus co-infection 
experiment (Fig. 2.5).  Also BAF57 reportedly interacts with AR in an androgen-
independent manner (140), whereas CHD8 does not interact with AR in androgen-
independent cell lines.  Further experiments mapping the AR-CHD8 interaction are 
necessary to fully understand their association, possibly through the unique LFSLL motif 
found in CHD8. 
Another prominent difference in these two coactivators is the pattern of their 
recruitment.  SWI/SNF gets recruited by AR in response to androgens to target 
promoters.  On the other hand CHD8 is present at these promoters even in the absence of 
AR.  Upon androgen treatment, it interacts with the nuclear, ligand-bound AR in a way 
that stimulates its nucleosome remodeling activity to facilitate AR binding to these sites.  
Thus CHD8 may be involved in the AR-mediated transactivation process upstream of the 
involvement of SWI/SNF. Indeed it may be responsible for the subsequent recruitment of 
SWI/SNF via AR.  There is apparently a temporal separation between the points of action 
of these two chromatin remodeling coactivators of AR in androgen-responsive 
transcriptional regulation.  This in itself is not an unprecedented observation since it is 
known that during RNA polymerase II-mediated transcription in Drosophila, BRM 
facilitates transcriptional initiation at a step prior to polymerase recruitment to promoters, 
while the CHD8 homolog Kismet, is implicated at a later stage involving promoter 
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clearance by the polymerase complex and the transition from early to late stages of 
elongation (61). 
The CHD6-9 Subfamily and Nuclear Receptors 
There are a few lines of evidence from previous studies connecting CHD6-9 
subfamily members with nuclear receptors and other similar transcription factors.  CHD9 
is known to interact with the glucocorticoid receptor and the estrogen receptor (98, 99) 
and another report demonstrates its role as a coactivator of PPAR   This same 
study also reported the interaction of CHD9 with other nuclear receptors like constitutive 
androstane receptor (CAR), retinoid X receptor (RXR) and the estrogen receptor (ER).  
CHD7 has been shown to interact with PPAR-γ as part of a complex and repress the 
expression of its target genes in conjunction with an HMTase component of this complex 
(95).  All these reports point towards a role for this subfamily of chromatin remodeling 
enzymes in nuclear receptor-mediated transcriptional regulation.  Our results have 
revealed CHD8 to be a coactivator of AR and thus have further expanded this nuclear 
receptor-associated role of the CHD6-9 subfamily. 
There are, however, subtle yet significant differences between the role of CHD8 
and its other subfamily members in their capacity as nuclear receptor coregulators.  
CHD9 appears to interact with PPAR through one or more of five LXXLL motifs 
located within its protein sequence, since different fragments of this protein were pulled 
down with GST- PPAR, with the greatest affinity appearing to be of a C-terminal 
fragment containing two of these motifs (159).  On the other hand CHD8 only has one 
LXXLL and one FXXLL motif, both located within in SNF2 helicase domain.  There are 
54 
 
no homologous C-terminal NR box motifs in CHD8 and thus the basis of its interaction is 
likely different from that of CHD9.  Also, CHD9 interacts with PPAR bound to DNA.  
In the case of CHD8, it appears that CHD8 is bound to the target DNA elements prior to 
AR binding, and, in fact, it appears to facilitate the binding of AR to these sites.  This 
model of CHD8 function does indeed seem unique among the previously reported 
transcriptional regulatory roles of all other CHD family members, even though CHD6 
and CHD9 have been shown to have a similar coactivating effect in association with 
other nuclear receptors and similar transcription factors. 
Several other reports help validate our findings about CHD8 and AR.  CHD8 has 
also been linked to ER and has been reported to be required for  the ER-dependent 
upregulation of the cyclin E2 gene (105).  Another study also reported that CHD8 
upregulates cyclin E2 through interaction with elongating RNA polymerase II (100).  
This report also demonstrates that CHD8 is constitutively bound to the CCNE2 promoter, 
in the same way we see it bound to AR target promoters.  Also, its regulation of cell cycle 
genes would be consistent with a role for CHD8 in promoting androgen-responsive cell 
proliferation.  A similar constitutive recruitment of CHD9 has been observed at the ER-
responsive osteocalcin promoters during bone development (99).  It has also been 
reported that CHD8 suppresses p53-mediated apoptosis (102), once again supporting the 
tumorigenic role for this protein in our model.  Finally there are reports connecting the 
inappropriate activation of AR by the -catenin pathway, suggesting that -catenin 
interacts with AR, translocates with it to the nucleus and binds target promoters as a 
complex (190).  This again links CHD8 to AR since CHD8 has been previously shown by 
our group to interact with -catenin (104).  The transcriptional role of CHD8 appears to 
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be contradictory in these two systems, with CHD8 acting as a coactivator of AR and as a 
negative regulator of -catenin-mediated transcription.  However, there are examples 
both of CHD8 (100, 102-105, 190) and of other chromatin remodeling enzymes (191) 
having differential transcriptional activities depending on its interaction with different 
cofactors. 
CHD8 as a Novel Therapeutic and Diagnostic Target for Prostate Cancer 
An interesting observation that emerged from the microarray data analysis was 
that CHD8 levels were significantly upregulated in metastatic prostate tumors compared 
to normal tissue but not in primary prostate tumors.  This may indicate a role for CHD8 
in the transition to hormone refractory prostate cancer and not in primary tumorigenesis.  
This may seem counter-intuitive since we show that CHD8 is not involved in AR-
mediated transcription in the androgen-independent cell lines studied here, but PC-3 and 
DU-145 are AR-negative and perhaps aberrant AR function in the hormone refractory 
22RV1 cells precludes CHD8 involvement.  However, if we consider the observation that 
CHD8 depletion results in abrogation of AR recruitment to target genes, and the fact that 
CHD8 is upregulated only in metastatic tumors, one can envision a scenario where 
overexpression of CHD8 may be responsible for the aberrant recruitment of AR to target 
genes thus enabling the androgen-independent transactivation of these genes.  Since 
CHD8 is in fact constitutively present at these target promoters even in the absence of 
androgens, it is possible that its overexpression would result in a constitutive, androgen-
independent recruitment of AR to these sites, giving rise to aberrant transcription of these 
genes and leading to a hormone refractory state.  While we know that androgen-signaling 
is typically required for AR translocation to the nucleus, this requirement is clearly 
56 
 
circumvented in the hormone refractory phase due to the dysregulation of AR by various 
mechanisms including AR mutations changing its ligand-specificity, overexpression of 
AR or its activation by alternate pathways.  In addition, AR that is targeted to the nucleus 
during the early androgen-dependent phase of primary tumors may not have been 
expelled from the nucleus.  Upon the overexpression of CHD8 in tumors that have 
progressed to a metastatic state, both aberrantly targeted AR and remnant nuclear AR 
from the androgen-dependent state would get constitutively recruited to target promoters, 
hence establishing and maintaining tumors in a hormone refractory state. 
These observations indicate that CHD8 could be critical in the transition of 
tumors from androgen-dependence to an androgen-independent state and in the 
subsequent maintenance of this state.  This makes it a novel therapeutic target for the 
treatment of androgen-independent prostate cancer.  Most current therapies like 
androgen-ablation and targeting AR, are not effective against androgen-independent 
prostate cancer.  CHD8 is a particularly intriguing prospective target because of its 
potential role in the transition of tumors to a hormone refractory state, and thus by 
targeting it one could prevent this transition.  Due to the fact that overexpressed CHD8 in 
metastatic tumors could constitutively recruit aberrantly translocated AR to its target 
genes, it may also be involved in maintaining these tumors in an androgen-independent 
state.  Thus targeting CHD8 should abolish this recruitment pattern and would effectively 
ablate AR transactivation of these genes and could also be used to treat androgen-
independent malignancies.  In addition, due to its upregulation in metastatic tumors, 
CHD8 could also be used as a diagnostic marker for prostate cancer.  Future studies will 
have to be directed towards understanding the specifics of CHD8 expression in prostate 
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cancer and the precise mechanism of its coactivation of AR, before such therapeutic and 
diagnostic strategies can be pursued. 
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Figure 2.1:  Domain structure of the androgen receptor.  The androgen receptor is 
comprised of an N-terminal transactivation domain (red), a central DNA-binding domain 
(blue) and a C-terminal ligand-binding domain (green).  The hinge region between the 
DNA-binding and ligand-binding domains serves as a structurally flexible element that 
allows the protein undergo a conformational change upon transactivation to allow 
interaction of the N-terminal domain with the ligand-binding domain. 
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Figure 2.2:  The androgen receptor signaling pathway.  Under uninduced conditions 
the androgen receptor (AR) remains sequestered in the cytoplasm in a protein chaperone 
complex (A).  Upon induction by androgens, AR dissociates from this complex and binds 
the ligand, whereupon it dimerizes (B) and translocates to the nucleus where it can bind 
to androgen response elements (AREs) on the promoters of target genes (C).  Here, AR 
recruits a complex of coactivators which facilitate the transcriptional activation of the 
target androgen-responsive genes.  
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Figure 2.3:  Schematic representation of the TMPRSS2 and PSA promoters.  The 
TMPRSS2 promoter (above) has a single characterized ARE located 13.5 kb upstream of 
the transcriptional start site.  The PSA promoter (below) has three characterized androgen 
response elements (AREs), which are shown in red.  The consensus ARE I is located 
between -156 to -170 bp from the transcriptional start
 
site and the non-consensus ARE II 
lies between -365 to -400 bp upstream of the start site.  In addition, the ARE III region 
spanning about 450 bp and located approximately 4 kb upstream
 
of the transcriptional 
start site contains one consensus and multiple non-consensus sites. 
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Figure 2.4:  Androgen-dependent interaction of endogenous CHD8 and AR.  Nuclear 
extracts were prepared from the indicated cell lines and immunoprecipitated with α-
CHD8 antibodies.  After washing, the input and immunoprecipitated samples (IP) were 
subjected to Western blot analysis using the indicated antibodies. 
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Figure 2.5:  Direct association of recombinant CHD8 and AR.  Cellular extracts were 
prepared from SF9 cells following co-infection with the indicated viruses.  
Immunoprecipitations were performed with anti-Flag antibody-linked M2 agarose beads.  
Immunoprecipitated samples were subjected to Western blot analysis using the indicated 
antibodies. 
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Figure 2.6:  Co-localization of CHD8 and AR to the ARE of the TMPRSS2 
promoter.  LNCaP cells were treated with ethanol or 10 nM DHT for 6 hours.  
Chromatin was crosslinked in vivo with formaldehyde.  Cells were lysed and chromatin 
immunoprecipitations were performed with the indicated antibodies.  Bound DNA was 
detected by quantitative PCR using primers to the ARE of TMPRSS2 (ARE) or a control 
TMPRSS2 promoter region (-7 kb).  Control IgG-precipitated samples were less than 
0.005% of input and therefore are not shown.  Data is representative of multiple 
experiments. 
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Figure 2.7:  Co-localization of CHD8 and AR to the ARE of the PSA promoter.  
LNCaP cells were treated with ethanol or 10 nM DHT for 6 hours and harvested for ChIP 
using antibodies to AR and CHD8.  Immunoprecipitated chromatin was analyzed by 
qPCR using primers targeting the PSA ARE I/II region.  Control ChIPs done with IgG 
antibodies were less than 0.005% of input and were therefore not shown.  Data is 
representative of multiple experiments. 
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Figure 2.8:  Simultaneous co-localization of CHD8 and AR to the TMPRSS2 ARE.  
LNCaP cells were treated as in Fig. 2.6.  Re-ChIP experiments were performed by 
successively immunoprecipitating the cross-linked chromatin with the indicated 
antibodies.  Bound DNA was detected by quantitative PCR using primers to the 
TMPRSS2 ARE.  Data is representative of multiple experiments. 
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Figure 2.9:  Coactivation of AR-mediated transcription of the TMPRSS2 gene by 
CHD8.  LNCaP cells were transfected with the indicated siRNA constructs.  Following 
selection of the transfected cells, cultures were treated with ethanol or 10 nM DHT for 6 
hours.  Total RNA was isolated and TMPRSS2 expression was analyzed by quantitative 
RT-PCR.  Data is representative of multiple experiments.  ** = p<0.01 by Student’s t-
test. 
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Figure 2.10:  Coactivation of AR-mediated transcription of the PSA gene by CHD8.  
LNCaP cells were transfected with the indicated siRNA constructs, selected and treated 
with ethanol or 10 nM DHT for 6 h.  Total RNA was isolated and PSA expression was 
analyzed by RT-qPCR.  Expression of PSA was normalized to a reference RNA.  Data is 
representative of multiple experiments.  * = p<0.05 and ** = p<0.01 by Student’s t-test. 
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Figure 2.11:  Efficacy of CHD8 knockdown in LNCaP cells.  Efficiency of CHD8 
depletion by siRNA treatment in Fig. 2.9 and Fig. 2.10 was determined by Western blot 
analysis with CHD8 antibodies.  Actin is blotted as a loading control. 
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Figure 2.12:  Effect of CHD8 depletion on TMPRSS2 expression in androgen-
independent cell lines.  The indicated androgen-independent cell lines were transfected 
with the specified siRNA constructs.  Following selection of the transfected cells, 
cultures were treated with ethanol or 10 nM DHT for 6 hours.  Total RNA was isolated 
and TMPRSS2 expression was analyzed by quantitative RT-PCR.  Data is representative 
of multiple experiments. 
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Figure 2.13:  Effect of CHD8 depletion on PSA expression in androgen-independent 
cell lines.  The indicated androgen-independent cell lines were transfected with the 
specified siRNA constructs.  Following selection of the transfected cells, cultures were 
treated with ethanol or 10 nM DHT for 6 hours.  Total RNA was isolated and PSA 
expression was analyzed by quantitative RT-PCR.  Data is representative of multiple 
experiments. 
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Figure 2.14:  Abrogation of androgen-responsive recruitment of AR to the 
TMPRSS2 ARE upon CHD8 depletion.  LNCaP cells were transfected with the 
indicated siRNA constructs.  Following selection of the transfected cells, cultures were 
treated with ethanol or 10 nM DHT for 6 hours.  Chromatin was crosslinked in vivo with 
formaldehyde.  Cells were lysed and chromatin immunoprecipitations were performed 
with the indicated antibodies.  Bound DNA was detected by quantitative PCR using 
primers to the TMPRSS2 ARE.  Control IgG-precipitated samples were less than 0.005% 
of input and therefore are not shown.  Shown is a typical result from multiple 
experiments. 
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Figure 2.15:  Adverse effect of CHD8 depletion on androgen-dependent cell 
proliferation.  LNCaP cells were transfected with the indicated siRNA constructs.  
Following selection of the transfected cells, cultures were treated with ethanol or 50 nM 
DHT.  At the indicated time points, proliferation was determined using a luminescent-
based assay of metabolically active cells.  Data is expressed as fold DHT-induced 
proliferation, which is calculated as the ratio of the luminescent signals from the induced 
to the uninduced cells for each siRNA treatment at each indicated time point.  *=p<0.02 
by student’s t-test. 
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CHAPTER III 
Substrate Specificity and Requirements for Remodeling by CHD8 
Introduction 
Interplay of Histone Modifications and Nucleosome Remodeling 
As discussed previously, eukaryotes manipulate chromatin structure by 
employing diverse strategies.  These include covalent modification of histones, as well as 
ATP-driven nucleosome remodeling.  The interplay between the factors responsible for 
these two classes of chromatin remodeling can exist at different levels.  The proteins 
involved in these two processes can interact by direct association with one another.  They 
can also interact via the histone marks deposited by chromatin modifying enzymes, 
which can then be recognized and bound by various domains found in nucleosome 
remodeling factors.  Both of these mechanisms are discussed further in Chapter IV.  In 
this chapter, we will address another form of interplay between histone modification and 
nucleosome remodeling; namely the modulation of the substrate specificity of ATP-
dependent chromatin remodeling enzymes for nucleosomal substrates, due to the 
modification and alteration of histone structure. 
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Histone Tails and Chromatin Structure 
The majority of covalent modifications of histones occur in the N-terminal tail 
regions, which can account for up to 30% by mass of the histone proteins (192).  These 
tails extend away from the globular core of the nucleosome and are thought to be largely 
unstructured, allowing for maximal structural flexibility and accessibility for covalent 
modification (5).  Modifications of the histone tails generate epitopes for recognition by 
other chromatin remodeling factors, which can then affect changes in chromatin 
structure.  Histone tails can also affect the chromatin structure by altering the dynamic 
properties of nucleosomes.  Nucleosomes are highly dynamic structures that can be 
modulated in different ways.  Nucleosomes can form arrays that condense into chromatin 
fibers, their positioning can be altered by nucleosomal sliding and their structures can be 
disrupted to dissociate the DNA from the histone octamers (39, 193-195).  These 
processes occur both spontaneously as well as in an ATP-dependent fashion by the action 
of chromatin remodeling enzymes.  Nucleosome dynamics are dependent on their 
inherent structure, which in turn is influenced by the presence and nature of the histone 
tails.  Therefore it is not surprising that histone tails and their covalent modifications have 
been shown to directly affect these dynamic properties of nucleosomes (196-199).  A 
recent study examined the effects of histone tail deletions on the intrinsic stability and 
mobility of nucleosomes (200).  Deletion of H2A tails increased the intrinsic mobility of 
nucleosomes, while H4 and H2B tail deletions reduced the same, showing these tails 
assist in nucleosome sliding.  Deletion of H3 caused striking structural changes of the 
nucleosome, disrupting DNA wrapping and destabilization of dimers.  Thus histone tails, 
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being critical in inherent nucleosome structure and dynamics, would also be expected to 
be important for ATP-dependent remodeling. 
Histone Tails and ATP-dependent Chromatin Remodeling 
The histone tails provide ideal contact points between the nucleosome and the 
chromatin remodeling enzymes, being the only part of the nucleosome structure that 
extends away from the otherwise compact nucleosomal core.  There are several examples 
from previous literature that suggest that histone tails are important for ATP-dependent 
nucleosome remodeling.  The genetic link between histone tails and chromatin 
remodeling was originally elucidated by deletion studies in yeast.  In vivo, the deletion of 
histone tails in yeast was found to profoundly affect chromatin structure and gene 
regulation on a genome-wide scale (201-203).  Deletion of H3 or H4 histone tails 
eliminates heterochromatin-based transcriptional repression of several genes (204, 205).  
Histone tails have also been linked to more specific effects on chromatin remodeling.  
For example, deletion of H2A or H2B tails affected the chromatin remodeling activity of 
SWI/SNF at specific subsets of genes (206, 207). 
Several studies have examined the effect of histone tail deletions on nucleosome 
remodeling in vitro as well.  The histone tails are required for nucleosomal remodeling by 
ISWI, SWI/SNF and RSC complexes (208, 209).  Mi-2 containing complexes, on the 
other hand do not require the presence of histone tails for efficient nucleosomal 
remodeling (210, 211).  In fact, the specificity of certain chromatin remodelers for 
histone tails extends even further.  ISWI specifically requires H4 tails to remodel 
nucleosomes, by recognizing a critical epitope consisting of a DNA bound N-terminal 
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sequence of H4 (212, 213).  H3 tail deletion or mutation reduced nucleosome remodeling 
by RSC and SWI/SNF but did not significantly affect remodeling by CHD1 (214). 
Histone Modifications and Nucleosome Remodeling 
 The importance of histone tails in chromatin remodeling is further emphasized by 
evidence that histone tail modifications can also affect nucleosome remodeling.  
Acetylation of H3K14 has been shown to enhance remodeling by RSC (215), while it 
inhibits remodeling by ACF, (26) showing that specific modifications can have 
differential effects on different remodeling enzymes.  Indeed RSC has been found to 
interact genetically with H3K14 but not with H3K9 (38).  Acetylation of multiple lysines 
on the H4 tail, on the other hand, has no effect on RSC-catalyzed sliding of nucleosomes, 
but it inhibits remodeling by Isw2 (215).  Furthermore, it was seen that CHD1 also 
required H4 tails to efficiently catalyze nucleosome sliding and acetylation of the H4 tail 
reduced its rate of remodeling as well (215).  As mentioned before, however, another 
CHD family protein, Mi-2, did not require the presence of histone tails to catalyze 
nucleosome remodeling (211)  Thus it is possible that even within the same family of 
remodelers one may find that particular histone modifications can have differential 
effects on remodeling activity.  Indeed, the ISWI-containing Remodeling and Spacing 
Factor (RSF) was also found to assemble nucleosome arrays more efficiently upon p300-
mediated acetylation of the H4 tails of its nucleosomal substrates (216), while remodeling 
by Isw2 is adversely affected by the same modification.  The acetylation of H4K8 has 
been reported to facilitate remodeling by INO80 and SWR1 complexes (217). 
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The effect of H3K14 acetylation on remodeling by RSC acetylation can be 
attributed to the increased binding capacity of RSC for the acetylated nucleosomes (24, 
27, 215).  In this case, the rate of catalysis is being affected by tighter binding of the 
enzyme to the substrate.  On the other hand, acetylation of H4 does not have any effect 
on the binding of either Isw2 or CHD1 to nucleosomes and appears to affect nucleosome 
remodeling by both these enzymes by decreasing the turnover rate of ATP hydrolysis 
(215).  This shows that histone modification can affect nucleosome remodeling at 
different stages of catalysis and by different mechanisms.  While acetylation of H4 was 
shown to not affect nucleosome sliding by RSC, it appears to increase the rate of octamer 
transfer by RSC, probably by destabilizing the nucleosome.  Thus the same modification 
can also control different aspects of chromatin remodeling by the same enzyme in 
different ways. 
Substrate Specificity of Chromatin Remodeling Enzymes 
Several chromatin remodeling enzymes have different specificities towards 
preferred nucleosomal substrates based on the presence and modifications of histone tails.  
Studying the substrate specificities and requirements for the remodeling activities of 
these enzymes could provide valuable insights into their cellular functions.  It is logical 
that RSC, which is typically associated with transcriptional activation, prefers acetylated 
nucleosomal substrates for its remodeling activity, since this modification is usually 
enriched at sites of active transcription.  The SWI/SNF family of chromatin remodelers, 
to which RSC belongs, contains bromodomains that bind histone acetyl marks and this 
reinforces the possibility that these enzymes recognize nucleosome substrates bearing 
acetylation marks.  Conversely, remodeling by Isw2, which is known to have a 
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transcriptionally repressive role, is adversely affected by histone acetylation.  The ISWI 
family appears to recognize an epitope in the unmodified H4 tail in the course of 
catalysis.  This epitope may be masked by acetylation of H4 causing the observed 
inhibition of remodeling by these enzymes. 
The CHD subfamilies appear to be regulated differentially by histone tails and 
their modifications, and this too is not unexpected given the functional variation among 
these proteins.  CHD1 of the CHD1-2 subfamily requires the H4 but not the H3 tail for 
optimal remodeling activity, and this activity is inhibited by H4 acetylation, much like 
ISWI.  This may seem counter-intuitive since CHD1 is known to be involved in active 
transcription via association with elongating RNA Pol II, and is known to interact with 
the HAT complexes, SAGA and SLIK (29).  However, CHD1 contains methylation-
specific chromodomains and not the acetyl-recognizing bromodomains. Thus it is 
possible that the mode of substrate recognition by the CHD1-2 subfamily is through the 
H4 tail, like ISWI remodelers, and acetylation of this tail prevents the necessary 
enzyme-substrate contacts for optimal remodeling activity.  Mi-2 of the CHD3-5 
subfamily, on the other hand, appears to not require histone tails at all for its remodeling 
activity.  However, the binding of CHD3/4-containing NURD complexes to histones is 
abrogated by H3K4 methylation, indicating that these proteins require the presence of 
unmodified H3 tails for binding to the substrate (80).  We can reconcile this 
contradiction by proposing that the CHD3-5 proteins require an epitope in the histone 
core bodies, which may be modified or unmodified, and that this recognition is affected 
by the methylation of H3K4.  The CHD6-9 subfamily has been relatively poorly studied 
from the aspect their remodeling activity.  This will be examined further in this chapter. 
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Nucleosome Remodeling by CHD8 
 While it has been previously shown that CHD6 and CHD9 have DNA-stimulated 
ATPase activity (90, 96), nucleosome remodeling by other CHD6-9 subfamily members 
has not previously been characterized.  Studies from our lab were the first to identify and 
characterize CHD8 as a bona fide ATP-dependent chromatin remodeling enzyme (104).  
It was demonstrated that CHD8, like other typical chromatin remodelers, has intrinsic 
ATPase activity that was stimulated in the presence of nucleosomes.  It also has a 
conserved lysine residue within the ATP-binding site of its catalytic Snf2 helicase 
domain, which is conserved among Snf2-containing chromatin remodeling enzymes and 
is required for their catalytic activity.  Mutation of this cognate lysine severely impaired 
the nucleosome-stimulated ATPase activity of CHD8, showing that it has canonical Snf2-
domain driven catalytic activity.  It was also shown that CHD8 was able to remodel 
mononucleosomes in an ATP-dependent manner.  Results obtained from nucleosome 
sliding assays revealed that CHD8, like CHD1 and CHD3, repositions nucleosomes 
toward the center of the DNA template upon which they are assembled.  However, the 
substrate specificity of CHD8 has not been examined, to date.  Thus an investigation into 
the substrate preference or requirement of CHD8 for remodeling nucleosomes, would 
further elucidate new aspects of the remodeling activity and cellular functions of the 
CHD family of remodelers. 
 CHD8, like other members of the CHD family, has a pair of tandem 
chromodomains.  Since these domains are known to recognize and bind histone 
methylation marks, it is possible that those of CHD8 could be involved in the recognition 
of specific methylated histone tails on its nucleosomal substrates.  The chromodomains of 
80 
 
CHD1 are known to bind dimethylated H3K4 (30), while this same modification 
precludes the binding of CHD3/4 to the H3 tail (79, 80).  Thus the chromodomains of 
CHD6-9 may also specify or prevent binding to specifically methylated histone tails, 
defining its substrate preference for remodeling.  Indeed the chromodomains of CHD8 
have been shown to bind dimethylated H3K4 (100).  It should be noted that for other 
CHD family proteins, the binding specificity of their chromodomains is independent of 
their requirements for remodeling, since despite their binding properties to H3 tails, both 
CHD1/2 and CHD3/4 do not require the H3 tail for their remodeling activity.  In these 
cases the chromodomains may be involved in the appropriate targeting of their 
remodeling activity and not in substrate recognition.  In the case of RSC, however, the 
interaction of its bromodomains with acetylated H3K14 is responsible for the substrate 
specificity of this enzyme for remodeling (215).  It would thus be intriguing to examine 
whether the substrate requirements for remodeling by CHD8 are defined by its 
chromodomains or not.  In addition, while the effects of histone tail acetylation have been 
widely demonstrated on nucleosome remodeling, histone methylation has never been 
well-studied in this context.  It would thus be interesting to narrow down the 
requirements for remodeling and the substrate specificity of CHD8, by examining the 
effect of tail deletions and histone methylation on its remodeling activity. 
Hypothesis and Summary of Results 
Based on the evidence that the chromodomains of CHD8 binds methylated H3K4, 
we hypothesized that CHD8 would preferentially remodel nucleosomes containing H3K4 
methylation marks.  To determine this we examined the effects of various histone 
alterations on the remodeling activity of CHD8.  We began by examining the remodeling 
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of CHD8 on nucleosomes reconstituted using recombinant histones, which are 
presumably unmodified, and comparing this to nucleosomes assembled using core 
histones extracted from HeLa cells containing a plethora of histone modifications, to see 
whether these modifications affect remodeling by CHD8.  We found that CHD8 could 
remodel unmodified, recombinant nucleosomes, and from a competitive remodeling 
assay where both nucleosome types were present in the same reactions we saw that 
CHD8 prefers the core nucleosomes as a substrate.  Next we attempted to narrow in on 
the histone tail upon which these preferred modifications were located by doing 
remodeling assays on nucleosomes containing truncated histone tails.  We found that 
deletion of the H3-H4 tails did not prevent nucleosome sliding of these nucleosomes on a 
DNA template.  In fact, the deletion of these tails appeared to enhance nucleosome 
remodeling by CHD8 when compared to nucleosomes containing wild-type, full-length 
recombinant histones using a competitive nucleosome sliding assay.  Finally we looked at 
the effect of H3K4 methylation on remodeling by CHD8.  Histone H3 was synthetically 
modified so that its H3K4 residue was replaced by either unmodified or dimethylated 
lysine analogs.  Remodeling of nucleosomes reconstituted using these synthetically 
modified histones was compared in a competitive nucleosome sliding assay.  It was 
observed that CHD8 did preferentially remodel the dimethylated nucleosomes over the 
unmodified ones.  Thus we concluded that CHD8 does not require the H3-H4 tails for its 
remodeling activity, but prefers nucleosomal substrates bearing H3K4 methylation. 
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Materials and Methods 
Recombinant Protein Production 
Recombinant baculovirus containing Flag-tagged CHD8 was created using the 
Bac-N-Blue baculovirus expression system (Invitrogen).  This was used to express 
recombinant, full-length CHD8 for use in the enzymatic assays described below.  For 
protein expression, Sf9 cells at 1×10
6
 cells per mL were infected with the recombinant 
Flag-CHD8 virus and grown for 4 days.  Cells were harvested, washed with PBS and 
resuspended in IP buffer (20 mM Tris-HCl [pH 7.9], 0.2 mM EDTA, 10% glycerol, 0.2 
mM PMSF) containing 500 mM KCl and 1% NP-40 as well as 1 µg/mL of each of the 
protease inhibitors, aprotinin, leupeptin and pepstatin.  The cells were then lysed using a 
Dounce homogenizer and lysates were cleared by centrifugation at 30,000×g at 4°C for 
30 minutes.  Samples were then dialyzed against IP buffer with 50 mM KCl and inverted 
overnight at 4°C with 250 µL of agarose beads conjugated with anti-Flag antibody M2 
(Sigma).  The beads were then washed sequentially with 10 column volumes each of 150 
mM KCl in IP buffer, 350 mM KCl in IP buffer and again in 150 mM KCl in IP buffer.  
The protein was eluted with 400 µg/mL Flag peptide (Sigma) in 150 mM KCl IP buffer 
with 1 µg/mL each of aprotinin, leupeptin and pepstatin. 
Recombinant histones were expressed and extracted from BL21 (DE3) E. coli 
cells essentially as described by Luger et al (218).  Briefly, 1 L cultures of cells 
expressing recombinant histones were grown up to an OD600 of 0.4 to 0.6, induced by the 
addition of 0.2 mM IPTG (isopropyl-β-D-thiogalactopyranoside) and grown for another 3 
hours at 37°C.  The cells were harvested by centrifugation at 4,500×g for 10 minutes at 
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4°C and then resuspended in 20 mL IP buffer with 100 mM KCl and 5 mM BME (β-
mercaptoethanol).  The cell suspension was lysed by two passages through a French 
pressure cell and the lysate was centrifuged at 12,000×g for 20 minutes at 4°C to pellet 
the inclusion bodies.  The inclusion bodies were then washed once in IP buffer with 100 
mM KCl and 1% Triton X-100 and then once in IP buffer with 100 mM KCl.  Inclusion 
bodies were pelleted again by centrifugation at 12,000×g for 20 minutes at 4°C and 
extracted in unfolding buffer (7 M guanidine hydrochloride, 20 mM Tris-HCl [pH 7.5], 
10 mM DTT [dithiothreitol]) at room temperature for 1 hour.  The extracted inclusion 
bodies were centrifuged again at 12,000×g for 20 minutes at 4°C.  The supernatant 
containing the extracted histone protein was removed and saved and the pellet was 
extracted once again in the same way as before.  The supernatant from the second 
extraction was combined with that from the first extraction and this sample was dialyzed 
against 4 L of low-salt urea buffer (7M urea, 20 mM Tris-HCl [pH 7.5], 100 mM NaCl, 1 
mM EDTA, 5mM BME) overnight at 4 °C.  The dialysate was centrifuged at 23,000×g 
for 20 minutes at 4°C and the supernatant was injected onto tandem Q Sepharose and SP 
Sepharose (Sigma-Aldrich) columns, arranged in that order, pre-equilibrated in low-salt 
urea buffer.  The Q Sepharose column was then removed and the SP Sepharose column 
was eluted over a salt gradient set up using low-salt urea buffer and high-salt urea buffer 
(7M urea, 20 mM Tris-HCl [pH 7.5], 600 mM NaCl, 1 mM EDTA, 5mM BME), while 
collecting fractions over the entire gradient.  The fractions were analyzed by Bradford 
assay and SDS-PAGE and the peak fractions were pooled and dialyzed overnight against 
4 L of water at 4°C.  The dialyzed histones were then aliquoted, lyophilized and saved. 
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Chemical Modification of Histones 
 Recombinant histones produced as described above were chemically modified so 
that their H3K4 residue was replaced with either a synthetic lysine analog or methyl-
lysine analogs which functionally mimic their natural counterparts.  This was done 
essentially as described by Simon et al (219).  Briefly, a double point mutant histone H3 
K4C/C110A was expressed and purified as described above.  The chemistry to generate 
these analogs utilized the ability to alkylate cysteines using electrophilic ethylamines to 
yield aminoethylcysteine, a lysine analog.  In addition, alkylation of target cysteines by 
(2-halo-ethyl) amines would yield the desired methyl-lysine analogs as well.  Since the 
only natural cysteine residue in H3 is C110, this was mutated to an alanine, so that we 
could then generate lysine analogs at a specific position by introducing mutant cysteines 
at the desired site and alkylating that site with the appropriate reagent.  To achieve this 6 
mg of lyophilized H3 K4C/C110A histones were dissolved in 900 µL of alkylation buffer 
(1 M HEPES [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid] [pH 7.8], 4 M 
guanidine hydrochloride, 10 mM L-methionine, 10 mM TCEP [tris(2-
carboxyethyl)phosphine] and incubated at 37°C for 1 hour.  1 M solutions of 2-
bromoethylamine and 2-(dimethylamino) ethyl chloride were prepared in alkylation 
buffer and 50 µL of each of these were added to the dissolved histones.  Alkylation 
reactions were allowed to proceed in the dark at room temperature for 2 hours before 
renewing the reactions by adding another 50 µL and allowing them to proceed for 
another 2 hours.  Reactions were stopped by adding 50 µL of 14.3 M BME and were 
dialyzed into water overnight at 4°C.  Generation of the desired lysine and dimethyl-
lysine analog-bearing histones was verified by mass spectrometric analysis. 
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Nucleosome Reconstitution 
 The lyophilized histones were resuspended in unfolding buffer to a concentration 
of 2 mg/mL and the unfolding reaction was allowed to proceed by inverting the samples 
for 2-3 hours at 4°C.  The unfolded histones were then combined in equimolar ratios and 
the final concentration was adjusted to 1 mg/mL with unfolding buffer.  This was 
dialyzed overnight against 4 L of refolding buffer (2M NaCl, 10 mM Tris-HCl [pH 7.5], 
1mM EDTA, 5mM BME) at 4°C.  The refolded octamers were then concentrated to 1 mL 
using an Amicon Ultra Ultracel-10K (Millipore) and the concentrated sample was 
centrifuged at 20,000×g for 20 minutes at 4°C.  This sample was injected onto a Hi-Prep 
16/60 Sephacryl S-200 column (GE Healthcare), equilibrated with refolding buffer, and 
run at 0.5 mL/min while collecting 2.5 mL fractions.  The fractions were analyzed by 
SDS-PAGE.  The fractions containing the histone octamer peak were pooled and 
concentrated to 1 mL using an Amicon Ultra Ultracel-10K. 
 Fluorescently labeled 277 bp DNA templates for nucleosome reconstitution were 
generated using standard PCR techniques with pGEM3z-601 as a template (220).  The 
601 forward (CGGGATCCTAATGACCAAGGAAAGCA) and 601 reverse 
(CTCGGAACACTATCCGACTGGCA) primers were used to generate the DNA 
templates for restriction enzyme accessibility assays and the 601slid forward 
(GTGATGGACCCTATACGCG) and 601slid reverse 
(ACTCACTATAGGGCGAATTC) primers were used for the nucleosome sliding assays.  
These primers generated DNA templates upon which the nucleosome would either be 
positioned in the middle or the end respectively of the template.  A 0.1/0.9 ratio of the 
fluorescent primers (either 5’-Cy5 or 5’-AlexaFluor 488-N-hydroxysuccinimide ester) to 
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the non-fluorescent primers was used in the PCR reactions.  The PCR product was 
analyzed on a 2% agarose gel, ethanol precipitated and resuspended in TE. 
 The appropriate combination of histone octamers and fluorescent DNA templates 
prepared as described above were combined in a range of ratios into reconstitution 
reactions.  Multiple reactions were set up using a mean ratio of 1:1 between the histones 
and DNA and varying the amount of histones by a fraction of 0.125 to cover a range of 
ratios between 0.5:1 to 1.25:1.  100 µL reactions were set up in Slide-A-Lizer Mini 
Dialysis Units (MWCO = 3,500) (Pierce) with 2M NaCl and 0.5 mg/mL BSA (Bovine 
Serum Albumin) (New England Biolabs) along with the appropriate amounts of histone 
octamers and DNA.  The reconstitution reactions were then dialyzed over a gradual salt 
gradient going from high-salt TE buffer (2M NaCl, 10 mM Tris-HCl [pH 8.0], 1mM 
EDTA, 0.2 mM PMSF] to low-salt TE buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA, 
0.2 mM PMSF).  The dialysis units were placed in a beaker containing 500 mL of high-
salt TE buffer and the buffer was pumped out from this beaker at the same rate (1.6 
mL/min) as 4 L of low-salt TE buffer was pumped into it over a period of 42 hours.  
Nucleosomes were analyzed on a 5% non-denaturing acrylamide/bisacrylamide (49:1) 
0.2X Tris-Borate-EDTA (TBE) gel.  Concentrations of reconstituted nucleosomes were 
calculated based on the final volumes of the reactions after dialysis. 
Restriction Enzyme Accessibility Assay 
 Accessibility assays were performed essentially as described by Smith and 
Peterson (221).  Nucleosomes containing the regular 601 sequence as the DNA template 
were generated as described above.  They were then subjected to nucleosome digest tests 
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to determine which samples contained nucleosomes that were suitable for restriction 
enzyme accessibility experiments based on the level of protection of their intrinsic 
restriction sites.  Assays were conducted in triplicate using 50 nM of the selected 
nucleosomes.  Competitive assays contained 25 nM of each species of alternatively 
labeled nucleosomes.  Each 15 µL reactions contained 20 nM Flag-CHD8 in the presence 
of 1 mM ATP in DNase buffer (20 mM HEPES [pH 8.0]3 mM MgCl2, 50 mM NaCl, 2 
mM DTT, 0.1 mg/mL BSA).  Reactions also contained saturating amounts of HhaI 
restriction enzyme (New England Biolabs).  They were incubated at 30°C for the 
indicated times and were terminated by adding 2X stop solution (10 mM Tris [pH 8.0], 
0.6% SDS, 40 mM EDTA, 5% glycerol, 0.1 mg/mL proteinase K) and incubating at 50°C 
for 20 minutes.  Samples were analyzed on a 3% agarose gel and bands were quantified 
using a Typhoon Trio+ Imager and the ImageQuant TL software (GE Healthcare).  Data 
presented is representative of the average value of each triplicate. 
Nucleosome Sliding Assay 
 Nucleosome sliding assays were performed similar to the restriction enzyme 
accessibility assays above, without including restriction enzyme.  Suitable nucleosomes 
assembled on 601slid DNA templates were selected for these assays based on the gel 
analysis of the reconstitutions.  Each 15 µL reaction contained a total of 50 nM of 
reconstituted nucleosomes, 1 mM ATP and 20 nM Flag-CHD8 in DNase buffer.  For 
competitive sliding assays, 50 nM each of two alternatively labeled nucleosome species 
were used.  Reactions were incubated at 30°C for the indicated times and then terminated 
by adding 3 µL of 6X stop solution (30% glycerol, 10 mM Tris [pH 7.8], 1 mM EDTA, 
334 µg/mL HeLa core nucleosomes, 334 µg/mL salmon sperm DNA [Invitrogen]) and 
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incubating for a further 15 minutes at 30°C.  Samples were then analyzed on a non-
denaturing 5% acrylamide/bisacrylamide (49:1) 0.2X TBE gel and fluorescent bands 
were detected using a Typhoon Trio+ Imager and ImageQuant TL software. 
 
Results 
CHD8 Preferentially Remodels Core Nucleosomes over Recombinant Nucleosomes 
 We began examining the substrate preferences for CHD8 by reconstituting 
nucleosomes from recombinant wild-type histones.  These histones would presumably 
lack any covalent modifications, since they were expressed in E. coli where there is no 
known pathway for the post-translational modficiation of histones, and we could thus 
examine whether CHD8 is capable of remodeling unmodified nucleosomes.  
Mononucleosomes were reconstituted by incorporating recombinant histone octamers 
into a DNA template containing the 601 nucleosome positioning sequence with a unique 
HhaI restriction site located near its dyad axis (220).  This restriction site is protected 
from access by the restriction enzyme when the template is reconstituted into a 
nucleosome by salt dialysis with histone octamers.  We used this feature to carry out 
restriction enzyme accessibility assays to determine the remodeling activity of CHD8 on 
recombinant nucleosomes, as was done previously for HeLa core nucleosomes (104).  
Recombinant nucleosomes were incubated with either no CHD8 or with 10 nM or 20 nM 
CHD8 in the presence of restriction enzyme.  We found that in the presence of CHD8 
there was increased cutting of the DNA template as compared to the control reactions 
(Fig. 3.1).  The fraction of template that was cut in the presence of CHD8 was 
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comparable to but slightly lower than that seen with HeLa core nucleosomes (104).  This 
demonstrates that CHD8 is capable of remodeling unmodified, recombinant 
nucleosomes, albeit to a slightly lesser degree than modified core nucleosomes. 
 While this assay confirmed the remodeling activity of CHD8 on recombinant 
nucleosomes, we cannot quantitatively compare the extent of CHD8 remodeling between 
core and recombinant nucleosomes.  To do this we performed competitive restriction 
enzyme accessibility assays in which equimolar amounts of core and recombinant 
nucleosomes were incubated in the same reactions and remodeling on each of these 
templates was then directly compared.  To do this recombinant and core octamers were 
incorporated into 601 DNA templates that were differentially labeled with the Cy5 and 
Alexa488 fluorophores respectively.  This allows us to distinguish between each of the 
nucleosomal species on a gel based on the differing fluorescent signals.  Equimolar 
amounts of each of these nucleosomes were then incubated in reactions along with 20 nM 
CHD8 with excess restriction enzyme and restriction enzyme accessibility assays were 
performed as before.  A time course of remodeling was conducted to determine whether 
either nucleosomal substrate was preferentially remodeled over the other.  We found that, 
while CHD8 remodeled both species fairly robustly, it did so with a preference for the 
core nucleosomes (Fig. 3.2).  The core nucleosomes were remodeled at both a faster 
initial rate, which implies that CHD8 has a substrate preference for one or more of the 
modifications that are present on the core nucleosomes but not on the recombinant 
species.  The following experiments were designed to determine which modifications on 
which of the histone tails specifies the substrate requirement or preference of CHD8. 
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CHD8 does not Require the H3-H4 Tails for Remodeling Activity 
 The restriction enzyme accessibility assays described above allowed us to 
quantitate the capacity of CHD8 to remodel wild-type recombinant nucleosomes by 
exposure of the protected restriction site within the nucleosomal DNA template.  This is 
an important result because it allows us to use and manipulate recombinant nucleosomes 
by introducing various mutations and modifications to examine the substrate preference 
of CHD8.  While the restriction enzyme assay was quantitative, it does not yield any 
information on the qualitative nature of CHD8-remodeled nucleosomes as pertaining to 
nucleosome repositioning.  Our previous studies on CHD8 remodeling on experimental 
templates lacking a nucleosome positioning sequence revealed that CHD8 prefers to 
reposition nucleosomes towards the center of a DNA template as determined by 
nucleosome sliding assays (104).  Thus we employed similar sliding assays to look at the 
remodeling activity of CHD8 on mutated or modified nucleosomes assembled on 601slid 
DNA templates where the nucleosome positioning sequence was located at one end of the 
DNA template.  These templates should be targeted by CHD8 in a manner that would 
reposition these nucleosomes from the DNA ends towards the center of the DNA 
template. 
 Wild-type recombinant octamers or octamers with their H3-H4 tails deleted were 
reconstituted into nucleosomes on the 601slid template.  These were then subjected to 
nucleosome sliding assays to observe whether CHD8 is capable of repositioning 
nucleosomes lacking H3-H4 tails.  As mentioned before, the requirement for histone tails 
is a key determinant of remodeling activity for several chromatin remodeling enzymes.  
ISWI and CHD1 require H4 tails for their remodeling activity, while nucleosome 
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remodeling by CHD3/4 does not require the presence of histone tails.  We found that 
CHD8 was able to shift both the wild-type and the H3-H4 tailless nucleosomes away 
from the DNA ends and towards the center of the DNA template (Fig. 3.3), as seen 
before with core nucleosomes on unpositioned templates (104).  We observed a shift in 
the fluorescently-labeled nucleosomes towards higher bands on the gel upon remodeling 
by CHD8.  It has been previously observed that centrally positioned nucleosomes migrate 
slower than end-positioned nucleosomes (104).  Since we observe a slower migrating 
species in Fig. 3.3, we concluded that CHD8 repositions both tailed and H3-H4 tailless 
nucleosomes towards the center of the DNA template.  This may indicate that deletion of 
H3-H4 tails causes the nucleosomes to reconstitute into just one predominant species 
upon assembly, while wild-type nucleosomes form a couple of different species.  Both 
remodeling reactions appeared to occur at comparably robust rates, but we cannot make a 
true comparison between the two from this experiment.  We can, however, conclude that 
CHD8 does not require either the H3 or the H4 tail to catalyze nucleosome remodeling. 
 In order to directly compare CHD8 remodeling on wild-type and H3-H4 tailless 
recombinant nucleosomes, competitive nucleosome sliding assays were carried out.  
These were set up similar to the sliding assays described above, except 50 nM each of 
Alexa488-labeled wild-type and Cy5-labeled H3-H4 tailless nucleosomes were added to 
the same reactions.  A time course of remodeling was then carried out as described in the 
presence of 20 nM CHD8 and the simultaneous remodeling of both nucleosome species 
was examined by detection of the alternately labeled fluorescent bands on the gel.  CHD8 
would be expected to shift the fluorescent bands corresponding to the preferred substrate 
at an earlier time point than the less preferred substrate and this way we could determine 
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whether CHD8 preferred substrates with or without H3-H4 tails.  We observed that 
CHD8 remodeled both tailed and tailless nucleosomes at similar rates (Fig. 3.4).  
Interestingly, each of these nucleosome species appeared to migrate to slightly different 
positions on the gel, indicating that they were being repositioned by CHD8 to different 
locations on the DNA template.  Therefore, we concluded that while CHD8 did not 
exhibit any particular preference for substrates with or without H3-H4 tails, it appeared to 
shift nucleosomes to different positions based on the presence or absence of these tails.  
In this respect, CHD8 appears to be more akin to CHD3/4 in its lack of dependence on 
histone tails for remodeling activity, however it does seem to exhibit unique specificity 
for repositioning nucleosomes based on the presence of the H3-H4 tails. 
CHD8 Preferentially Remodels H3K4 Methylated Nucleosomes 
 The chromodomains of CHD8 have been implicated in binding dimethylated 
H3K4 marks on chromatin (100).  In order to examine whether this binding determines 
the substrate specificity of the remodeling activity of CHD8, synthetically modified 
nucleosomes were generated to contain either unmodified or H3K4 dimethylated lysine 
analogs replacing their natural H3K4 residues.  These nucleosomes were also assembled 
on to 601slid DNA templates and were utilized in competitive nucleosome sliding assays 
as described above.  20 nM each of the control H3K4C/C110A unmodified lysine analog-
bearing nucleosomes and the corresponding dimethylated nucleosomes were added 
together in the same sliding reactions.  We observed that in a time course of simultaneous 
remodeling by CHD8 of the unmodified and H3K4 methylated nucleosomes, the 
methylated substrate was remodeled earlier than the unmodified control (Fig. 3.5).  This 
indicates that CHD8 preferentially remodels nucleosomes that are dimethylated at H3K4, 
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suggesting that the recognition of this mark by its chromodomains may influence its 
remodeling activity. 
 
Discussion 
 The experiments described above were intended to elucidate the remodeling 
activity of CHD8 at several different levels.  We first tried to address the basic substrate 
requirements for remodeling by CHD8.  Does CHD8 require histone tails for remodeling 
nucleosomes?  What, if any, are the required epitopes for efficient nucleosomal 
remodeling by CHD8?  Next, we attempted to observe the effects of histone mutations 
and modifications on the substrate specificity of CHD8 remodeling by examining the 
differences between the various resultant remodeled nucleosome species.  Lastly, we 
address the preference of CHD8 for certain nucleosomal substrates, by examining 
whether it preferentially remodels substrates bearing specific modifications. 
Remodeling by CHD8: Substrate Requirements 
 The histone N-terminal tails extend well beyond the globular histone core and 
could serve as important points of contact with both the histone proteins of adjacent 
nucleosomes as well as non-histone proteins like chromatin remodeling enzymes.  
Internucleosomal contacts mediated by histone tails are important for the stabilization of 
higher order chromatin structure and the contacts of nucleosomes with chromatin 
remodelers via these tails are critical for maintenance and regulation of chromatin 
structure as well (222, 223).  Thus it is not surprising that the deletion of histone tails has 
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been shown to affect the nucleosome remodeling activity of a number of ATP-dependent 
chromatin remodelers.  We therefore examined the effect of histone tail deletions on 
CHD8 remodeling activity. 
 The experimental results from Fig. 3.1 and Fig. 3.3 show the basic requirements 
of CHD8 for remodeling nucleosomes.  In Fig. 3.1 we see that CHD8 can remodel 
unmodified recombinant nucleosomes, indicating that histone modifications of any kind 
are not a necessity for CHD8 remodeling and that these recombinant nucleosomes can be 
used as a suitable substrate upon which to study the remodeling activity of CHD8.  Fig. 
3.3 shows that CHD8 can also remodel nucleosomes with their H3-H4 tails deleted.  
Since histone tails are convenient points of contact between chromatin remodeling 
enzymes and nucleosomes, several chromatin remodeling enzymes show very stringent 
requirements for specific histone tails in the course of catalysis.  RSC and SWI/SNF 
appear to require all four of the histone tails for efficient remodeling.  Genetic deletion of 
the H2A and H2B tails eliminates optimal chromatin remodeling and transcriptional 
regulation of target genes by SWI/SNF (206, 207).  In addition deletion of the all four 
histone tails or even of the H3 tail alone in vitro adversely affects remodeling by RSC 
and SWI/SNF (208, 214).  Thus the SWI/SNF family remodelers appear to utilize the 
histone tails to remodel nucleosomes.  ISWI and CHD1 have been shown to require the 
H4 tails for remodeling (212, 213, 215), while CHD3/4 do not require the presence of 
histone tails (210, 211).  Our observation that CHD8 does not require the presence of 
histone tails emphasizes the similarities between the CHD3-5 and CHD6-9 subfamilies in 
the context of their requirements for remodeling activity.  This indicates that CHD8, like 
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CHD3/4, probably remodels nucleosomes by making contacts with the globular histone 
core bodies rather than their tails in the course of catalysis. 
 The similarity in mechanism of chromatin remodeling may also extend to the 
functional role of these proteins, since CHD8, like CHD3-5 has been implicated in 
transcriptional repression at select loci.  However, the CHD8 has also been shown to play 
a role in transcriptional activation in several instances.  Therefore, the mechanism of 
nucleosome remodeling is unlikely to be the sole determinant of the functional role of 
these enzymes.  Their association with other factors, as well as their spatial and temporal 
regulation, is likely to be important in modulating their functional role at different target 
genes and in various cellular systems.  The slightly lower values for the fraction of DNA 
template cut by restriction enzyme due to remodeling by CHD8 for the recombinant 
nucleosomes compared to core nucleosomes (Fig. 3.1) is indicative of a possible 
enhancement of its activity due to one or more of the modifications present in the core 
nucleosomes.  This possibility was investigated in further experiments and is an attractive 
model for determining the identity of the chromatin sites which CHD8 would remodel in 
vivo.  The capability of chromatin remodeling enzymes to target chromatin bearing 
particular histone modifications is a well-established paradigm.  While the deletion of 
histone tails is not a naturally relevant physiological phenomenon, it does give us the 
opportunity to restrict the list of possible preferred modifications to particular histone 
tails.  It also helps us to understand the mechanism by which CHD8 may operate even at 
the cellular level, using contacts with the histone core bodies to leverage nucleosomal 
repositioning, as suggested by the results in Fig. 3.3.  These contacts would be distinct 
from those allowing other histone tail-dependent chromatin remodelers like ISWI, 
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SWI/SNF or CHD1 to remodel nucleosomes, permitting multiple such remodelers to be 
acting on nucleosomes at the same time. This mode of contact of CHD8 with its substrate 
would also be conducive to allowing histone modifying enzymes which predominantly 
associate with the histone tails to interact with the same nucleosome at the same time.  
Given the examples presented in Chapter IV of associations between CHD8 and other 
chromatin remodeling factors, this would be a useful feature of its remodeling activity, 
allowing simultaneous modification of the histone tails and nucleosome mobilization via 
the histone core of the same nucleosome.  Thus this distinct mechanism of CHD8 
remodeling may also allow it to cooperate with other remodeling factors, by contacting 
different parts of the nucleosome in the course of their action. 
Remodeling by CHD8: Substrate Specificity 
 The second aspect of nucleosome remodeling by CHD8 that we studied was how 
the specificity of CHD8 towards its substrate influenced the generation of remodeled 
products by its catalytic activity.  This pertains to the differential mobilization by CHD8 
of nucleosomes that have been variously modified.  We examined this effect in Fig. 3.4, 
when we compared the remodeling of nucleosomes lacking H3-H4 tails to that of intact 
nucleosomes in a competitive sliding assay.  This assay allowed us to look at the 
generated products of CHD8 remodeling activity and detect the presence of different 
species via their differential migration on a non-denaturing gel.  We found that indeed 
CHD8 did remodel tailless nucleosomes differently from intact ones, as demonstrated by 
the detection of distinct fluorescent bands for each of the remodeled species.  The non-
overlapping products of CHD8 remodeling on these distinct nucleosome forms showed 
that in the absence of H3-H4 tails CHD8 repositions nucleosomes to slightly different 
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positions on a gel than in the presence of them.  It did, however, mobilize both 
nucleosomal species towards the center of the DNA template as evidenced by the net 
upward shift of the bands containing both fluorescent labels, indicating the generation of 
slower migrating, more centrally positioned nucleosomes.  This was verified by running a 
control centrally-positioned nucleosome alongside the remodeled ones, to compare their 
migration through the gel.  Upon close examination of the bands, it appears that CHD8 
remodeling on the intact nucleosomes yielded a single centrally positioned product along 
with the original unremodeled, end-positioned substrate.  Remodeling of the tailless 
nucleosomes, however, generated two distinct product species, both shifted towards the 
center compared to the substrate nucleosomes.  Thus while CHD8 can adequately contact 
and mobilize nucleosomes lacking tails by interacting with the globular core, it might use 
the tails to stabilize remodeled products into a single centrally positioned form. 
 The directionality of CHD8 remodeling is consistent with that of both CHD1 and 
CHD3, which have also been shown to reposition nucleosomes towards the center of a 
DNA template (224).  Whether this directionality of remodeling has any physiological 
relevance remains to be seen, but given the fact that CHD8 is able to remodel a 
nucleosome positioned at one end of a DNA template raises the possibility that it does 
not require interaction with DNA segments on both sides of the nucleosome to catalyze 
remodeling.  This distinguishes it from ISWI which has been predicted to remodel 
substrates with DNA segments on either side of a central nucleosome, since ISWI cannot 
remodel end-positioned nucleosomal templates (211).  Thus remodeling by ISWI was 
predicted to involve two molecules of ISWI interacting with one central nucleosome.  In 
this case then, it would appear that monomeric CHD8 would be capable of remodeling 
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nucleosomes.  The ability of CHD8 to reposition nucleosomes to specific positions is 
evidence that chromatin remodelers like CHD8 are complex organizers of chromatin and 
are capable of determining the genomic distribution of nucleosomes by their action.  The 
nucleosome-remodeler interactions are likely determinants of these positions based on the 
binding affinity of these interactions.  One can imagine that nucleosome positioning is the 
net result of transient interactions of the remodeler with the nucleosome, allowing it to 
associate and mobilize the nucleosome to certain thermodynamically favored positions, 
and then disassociate at these preferred sites.  For CHD8, it appears that the histone tails 
foster some such interactions which alter the dynamics of nucleosome-remodeler 
interactions so that the remodeling reaction yields nucleosomes positioned at different 
positions when the tails are eliminated.  Thus while contacts with the histone core are 
sufficient for remodeling by CHD8, histone tail contacts may facilitate the process by 
defining the association-dissociation dynamics of the substrate and the enzyme so as to 
determine the positioning of end products. 
Remodeling by CHD8: Substrate Preference 
 The last aspect of chromatin remodeling by CHD8 that we investigated was the 
preference of CHD8 for substrates containing specific features.  In this case we looked at 
histone methylation as a possible preferred modification.  The connection between ATP-
dependent chromatin remodeling enzymes and histone methylation has been well 
established.  This association can occur at different levels.  Histone methylation could 
serve as a recognition mark for the recruitment of ATP-dependent remodelers.  
Alternatively HMTs could directly associate with nucleosome remodelers bringing 
together these two chromatin–related activities within the same complex.  Both of these 
99 
 
scenarios are revisited in Chapter IV.  Finally, the interplay between these two processes 
could exist at the level of modulation of chromatin remodeling activity, where histone 
methylation could affect the activity of nucleosome remodelers, or vice versa, ATP-
dependent repositioning of nucleosomes could modulate histone methylation. 
 Based on the result in Fig. 3.2, where we saw that core nucleosomes were 
remodeled at a faster initial rate and to a greater final extent by competitive restriction 
enzyme accessibility assays, we concluded that CHD8 preferentially remodeled core 
nucleosomes over recombinant ones.  Thus the presence of certain histone modifications 
appears to enhance the enzyme-substrate interactions so that remodeling proceeds with 
greater efficiency.  The higher initial rate of modification could be due to a specifically 
remodeled nucleosome species being preferentially remodeled by CHD8 ahead of an 
unmodified substrate.  The greater final extent of remodeling is also indicative of a 
particular substrate bearing a preferred modification being remodeled in sustained 
manner over the period of the reaction at the expense of unmodified substrates.  We 
initially attempted to identify potential preferred modifications by eliminating histone 
tails to determine which ones were required for remodeling, which would subsequently 
help us narrow down the range of candidate modifications to the ones on the required 
tails.  However the result from Fig. 3.3 and 3.4 revealed that CHD8 did not require 
histone tails for its remodeling activity.  Thus while a particular tail or its modified 
residues may not be required for CHD8 remodeling, one or more histone modifications 
could enhance its activity.  Indeed, it has been observed that H3K14 acetylation is 
responsible for enhanced remodeling by RSC (215).  We attempted to examine whether 
CHD8 similarly preferred any particular histone modification for catalysis. 
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 We took a candidate approach towards exploring histone modifications that could 
be preferred by CHD8 in the course of its remodeling activity.  Histone methyl marks 
have been shown to be critical for the recruitment and activity of several other ATP-
dependent chromatin remodelers, which is discussed further in Chapter IV.  
Characteristic domains found in many nucleosome remodelers, like PHD and 
chromodomains have been shown to recognize and bind histone methylation in the course 
of action of these remodeling enzymes.  The chromodomains of CHD8, like those of 
CHD1, have been reported to bind to dimethylated H3K4 (100).  This makes this histone 
mark a promising candidate for the substrate preference of CHD8 remodeling activity. 
We examined this possibility in Fig. 3.5, where synthetic analogs of nucleosomes 
containing unmodified or dimethylated H3K4 were used in competitive sliding assays.  
We found that the H3K4 dimethylated nucleosomes were preferentially remodeled by 
CHD8.  Given the evidence of CHD8 binding to this histone mark through its 
chromodomains, this effect on remodeling is not unexpected.  Indeed the enhanced 
activity of RSC due to H3K14 acetylation, was found to be due to the increased binding 
of RSC to the substrate through its bromodomains (38, 215).  A similar mechanism could 
be responsible for the preference that CHD8 shows for remodeling nucleosomes bearing 
the dimethyl-H3K4 mark.  However, this binding-based mechanism is not the only way 
chromatin remodelers may show substrate preference.  Remodeling by ISWI and CHD1 
were adversely affected by H3K14 acetylation, but not due to their binding properties to 
this mark, rather by reducing the rate of ATP turnover.  Thus it is possible that other 
histone modifications could also effect CHD8 remodeling by either of these mechanisms.  
However, H3K4 dimethylation does provide an attractive target modification which, 
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through recognition by the chromodomains of CHD8, could be involved in both the 
recruitment and enhancement of chromatin remodeling activity of CHD8.  Indeed, 
methylation of H3K4 has been shown to be required for AR binding to target enhancers 
in LNCaP cells (225) and it is tempting to speculate that this recruitment is mediated by 
the recognition and remodeling of H3K4-methylated nucleosomes by CHD8, which then 
facilitates AR binding to these sites.  Connections between CHD8 and this histone 
modification are further explored in Chapter IV. 
 While the effect of histone acetylation on the chromatin remodeling activities of a 
number of nucleosome remodelers has been well studied (215-217), histone methylation 
has not been previously known to exert such an influence on nucleosome remodeling.  
Here, we show that CHD8 preferentially remodels H3K4 dimethylated nucleosomes.  
The possibility exists that mono- and trimethylation of this mark may also influence 
CHD8 remodeling.  Also, this modification could affect remodeling by other CHD family 
remodelers which are known to have binding specificity for this mark.  These 
possibilities need to be verified by further experiments. The work described here, 
however, lays the foundation for understanding the intricacies of the chromatin 
remodeling activity of CHD8 and consequently of the CHD6-9 subfamily. 
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Figure 3.1:  Comparable chromatin remodeling of core and recombinant 
nucleosomes by CHD8.  Recombinantly produced histone octamers were incorporated 
into fluorescently labeled DNA templates to form mononucleosomes.  50 nM of these 
nucleosomes were assayed for restriction enzyme accessibility by incubating with the 
indicated concentrations of CHD8 along with ATP and the HhaI restriction enzyme for 
30 minutes at 30 °C.  Reactions were done in triplicate and were analyzed by running on 
an agarose gel.  Gels were imaged on a Typhoon Trio+ Imager and the indicated bands 
were quantified using the ImageQuant TL software.  The average fraction cut was 
calculated from this and is plotted in the panel to the right with an image of samples from 
the gel above it.  The results from the restriction enzyme accessibility assays performed 
with core mononucleosomes by Thompson et al.(104) is included in the left panel for 
comparison. 
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Figure 3.2:  Preferential remodeling of core nucleosomes over recombinant 
nucleosomes by CHD8.  Competitive restriction enzymes accessibility assays were set 
up using equimolar amounts (25 nM) of alternately labeled core (Alexa488) or 
recombinant (Cy5) nucleosomes.  These mixes were incubated with 20 nM CHD8 in the 
presence of HhaI restriction enzyme for the indicated time.  The fraction of DNA 
template cut due to nucleosome remodeling at each time point for each nucleosomal 
substrate was measured and plotted. 
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Figure 3.3:  Remodeling Activity of CHD8 on Nucleosomes lacking H3-H4 Tails.  
Nucleosome sliding assays were conducted using either wild-type or H3-H4 tailless 
histone octamers incorporated into a fluorescent DNA template designed so that the 
nucleosomes are positioned at one end of the template.  50 nM of each of these 
nucleosomes was incubated along with 20 nM CHD8 for the indicated time.  Reactions 
were subjected to electrophoresis on a non-denaturing gel and the resultant bands of the 
remodeled products were analyzed using fluorescence imaging. 
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Figure 3.4:  Differential Remodeling of Wild-Type and H3-H4 Tailless Nucleosomes 
by CHD8.  Competitive nucleosome sliding assays were conducted by incubating 
equimolar amounts (50 nM each) of alternately labeled wild-type (fluorescein) and H3-
H4 tailless (Cy5) nucleosomes for the indicated time points with 20 nM CHD8.  
Remodeled products were analyzed on a non-denaturing gel by fluorescence imaging.  
Differentially generated products of the remodeling reaction were analyzed by merging 
the two fluorescent signals. 
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Figure 3.5:  Preferential Remodeling of H3K4-Dimethylated Nucleosomes by CHD8.  
H3K4C/C110A double mutant histones were expressed and were then chemically 
modified to give synthetic analogs that mimic either an unmodified lysine or a 
dimethylated lysine at the H3K4 position.  These chemically modified histones were 
incorporated into octamers and then reconstituted into nucleosomes on a DNA template 
with a nucleosome positioning sequence located at one end.  These were then included in 
competitive sliding assays as in Fig. 3.4, using 20 nM of each nucleosomal substrate and 
10 nM of CHD8.  Remodeled products were analyzed on a non-denaturing gel by 
fluorescence imaging. 
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CHAPTER IV 
CHD8 and the MLL1-WAR Complex 
 
Introduction 
ATP-dependent Chromatin Remodeling Complexes 
 As discussed in Chapter I, control of DNA accessibility is an important regulatory 
point for several cellular processes, like replication, repair and transcription.  Due to the 
packaging of DNA into chromatin, eukaryotic cells have evolved different mechanisms to 
regulate chromatin structure.  These include DNA methylation, covalent modification of 
histones and ATP-dependent chromatin remodeling which are catalyzed by different 
classes of enzymes.  ATP-dependent remodeling enzymes utilize the energy from ATP-
hydrolysis to modulate nucleosome structure and positioning.  The catalytic ATPase 
subunit is usually present within large, multiprotein complexes containing several other 
components.  SWI/SNF was originally identified as an ~11 subunit complex in yeast 
(226).  RSC is another SWI/SNF family remodeling complex found in yeast and has 15 
subunits (227).  These complexes are very large and can be up to 2 MDa in size.  On the 
other hand, ISWI family ATPase-containing complexes like ACF (ATP-utilizing 
Chromatin Factor), NURF (Nucleosome Remodeling Factor) and CHRAC (Chromatin 
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Accessibility Complex) are much smaller; only about 300-800 kDa in size containing 
only 2 to 4 subunits (226).  CHD family proteins have been reported to function as 
monomers (CHD1) as well as in complexes (CHD3-4/Mi-2) such as NURD (228, 229).  
INO80 and SWR1 are also large multiprotein complexes consisting of 15 and 14 subunits 
respectively (226). 
 The non-ATPase subunits of ATP-dependent chromatin remodeling complexes 
are involved in the direct regulation of the nucleosome remodeling activities of the 
ATPases (230).  The BAF155, BAF170 and INI1/SNF5 subunits form a core functional 
complex along with BRM and BRG1 and stimulate the nucleosome remodeling activities 
of human SWI/SNF complexes (231, 232).  As mentioned in Chapter II, the BAF57 
subunit of SWI/SNF is responsible for targeting its remodeling activity in AR-mediated 
transcriptional regulation (140).  The ACF1 subunit found in ISWI-containing ACF and 
CHRAC complexes and the NURF301 subunit of the NURF complex, have been shown 
to enhance nucleosome remodeling by ISWI and to affect the specific targeting of these 
complexes (233-236).  While the monomeric ISWI ATPase subunit by itself requires the 
presence of all four histone tails in order to efficiently remodel nucleosomes, in the 
presence of ACF1 only the H4 tail is required for its remodeling activity on nucleosomes 
(212).  Both the ACF1 and NURF301 subunits appear to contribute to ISWI remodeling 
by providing additional points of contact with the nucleosome through their PHD fingers 
(32, 58).  Thus the protein subunits of chromatin remodeling complexes can contribute to 
the activity of their ATPase components by stimulating the efficiency of their 
nucleosome remodeling activity, targeting them to specific chromatin sites, altering their 
substrate requirements or enhancing their binding to nucleosomes. 
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 Based on the subunit composition of ATP-dependent chromatin remodeling 
complexes, their cellular functions can be modulated in many different ways.  The RSC 
and SWI/SNF complexes in yeast are differentiated by the presence of unique subunits 
within each of these complexes that distinguish them apart both functionally and 
compositionally.  Yeast RSC complexes contain an Sth1 catalytic subunit and additional 
Rsc1-Rsc15 subunits, while SWI/SNF contains a SWI2/SNF2 ATPase as well as  the 
additional subunits, Swi1 –Swi11.  RSC and SWI/SNF are found to regulate entirely 
different subsets of genes due to the specificity imparted to them by their unique subunits 
(230).  Furthermore, RSC complexes also exist in two functionally distinct forms based 
upon the mutually exclusive presence of either of the subunits Rsc1 or Rsc2 within the 
complex (237).  This divergence in SWI/SNF remodeling complexes is conserved from 
yeast to higher eukaryotes as well.  Just as in yeast, there are two compositionally diverse 
SWI/SNF complexes in both Drosophila and mammals.  These are the RSC-homologous 
dBAP/BAF complex, which is characterized by the presence of the dOSA/BAF250 
subunits, and dPBAP/PBAF, which contains unique dPolybromo/BAF180 subunits and is 
homologous to yeast SWI/SNF.  Furthermore, in humans, BAF complexes may contain 
either one of the two SWI/SNF-homologous catalytic units, hBRM or BRG1, whereas 
PBAF complexes only contain BRG1 as their catalytic component.  These two 
functionally distinct human SWI/SNF complexes have been shown to associate with 
different promoters and regulate their expression by interacting with different 
transcription factors (238, 239).  BRG1 interacts with Zn-finger proteins like GATA1 
through a unique N-terminal domain not present in BRM, while BRM interacts with 
ankyrin-repeat proteins which are critical components of the Notch signaling pathway 
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(239).  There is also considerable tissue-specific variation in the subunit composition of 
human SWI/SNF, where different factors like BRCA1 and components of the HDAC 
complex Sin3 differentially associate with the remodeling components (227).  From these 
instances we see that the activity of ATP-dependent chromatin remodeling enzymes is 
significantly regulated by their association with different subunits found within their 
naturally occurring complexes. 
Histone Modifications and Chromatin Remodeling 
ATP-dependent chromatin remodeling complexes often including various 
chromatin modifying enzymes like histone acetylases, deacetylases, methyltransferases 
and demethylases.  The coordination of these two different kinds of chromatin 
remodeling events is necessary for the establishment of the appropriate chromatin state.  
This is achieved by functional interactions between these two classes of chromatin 
remodeling factors within complexes.  Histone modifications can alter chromatin 
structure either directly by sterically altering the chromatin structure, or indirectly by 
recruiting trans-acting factors like chromatin remodeling enzymes (240).  These trans-
acting factors often have specialized domains which are capable of recognizing and 
binding specific histone modifications.  Some of the characteristic domains involved in 
recognition of histone modifications that are found in ATP-dependent chromatin 
remodeling enzymes have been discussed in Chapter I. 
The association of histone modifying and chromatin remodeling enzymes is 
demonstrated in the NURD complex which contains the Mi-2 ATPase subunit as well as 
the deacetylases HDAC1 and HDAC2 and is involved in transcriptional repression.  
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CHD1 has been reported to associate with the SAGA complex, which contains Gcn5-
mediated HAT activity as well as the deubiquitylation activity of its Ubp8 subunit (241).  
Components of the repressive mSin3 HDAC complex were found to co-purify with both 
varieties of human SWI/SNF complexes, those containing hBRM as well as those with 
BRG1, which usually regulate the activation of transcription (242).  Further work 
revealed that the HMTase PRMT5 was also found in a complex containing mSin3 and 
BRG1 that was involved in transcriptional repression of target genes (243).  Since BRM 
and BRG1 are usually involved in transcriptional activation, these examples reveal that 
the association of different histone modifying activities with chromatin remodelers is 
capable of modulating the function of these complexes from transcriptional activation to 
repression and vice versa. 
The MLL Methyltransferase Complex 
 Histone methylation can be either an activating or repressive chromatin mark for 
transcription, depending on the specific residue being methylated (244).  Di- and tri-
methylation of H3K4 is associated with transcriptional activation, while H3K9 and 
H3K27 methylation is implicated in repression.  All of the identified HMTases involved 
in the methylation of histone tails contain the conserved catalytic SET (Su(var), Enhancer 
of Zeste, Trithorax) domain.  In humans, four SET domain-containing proteins have been 
identified as H3K4 HMTases: Set1A, Set1B and MLL1-4 (245).  MLL1, which is a 
homolog of the Drosophila protein Trithorax, is involved in certain oncogenic 
chromosomal translocations found in a number of acute lymphoid and myeloid leukemias 
(246).  These chromosomal rearrangements result in the fusion of the genomic sequence 
encoding the N-terminus of the MLL1 protein with the C-terminal encoding sequences of 
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other translocation partners, generating oncogenic fusion proteins (247).  The MLL1 
protein contains a central PHD domain, which along with the characteristic SET domain 
at its C-terminus, is homologous to Trithorax.  The N-terminal AT-hook and DNA 
methyltransferase (DNMT) homology regions are retained in MLL1 rearrangements and 
are thought to bind to specific chromosomal regions (247).  Full-length MLL1 is 
comprised of heterodimers of MLL-N (including the AT-hooks, DNMT domain and 
PHDs) and MLL-C (containing the SET domain).  MLL-N by itself appears to be 
repressive in function due to interactions with Pc group repressors and the recruitment of 
HDACs by its DNMT region (248).  However, heterodimerization with MLL-C results in 
transcriptional activation by the complex as evidenced by its interactions with a 
coactivator, CREB-binding protein (CBP), and its recruitment of HATs and SWI/SNF, 
chromatin remodeling complexes (249, 250).  Finally, the SET domain of MLL-C has 
been shown to have intrinsic HMTase activity specific for H3K4, a mark of active 
chromatin (250, 251).  Therefore MLL1 acts as a platform for bringing together various 
chromatin remodeling activities into a complex with alternative transcriptional functions, 
depending on its dimerization status. 
 A common element to the hSet1 and MLL family members is a core complex 
comprised of WDR5 (WD-40 Repeat protein), Ash2L (Absent Small or Homeotic-like) 
and RbBP5 (Retinoblastoma Binding Protein) (252-256).  This core complex, hereafter 
referred to as WAR, was found to be required for optimal HMTase activity of MLL1, 
both in vivo and in vitro (252, 257, 258).  The WAR complex also appears to associate 
independent of MLL1, providing a structural platform for association with other H3K4 
HMTases of the hSet1/MLL families (257).  While there has been considerable debate 
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about the binding specificity of WAR with histones, structural studies have shown that 
WDR5 binds the H3 tail, raising the possibility that WAR may be involved in targeting 
MLL1 activity to catalyze H3K4 methylation (259, 260).  More recent studies have 
suggested that WDR5 binds MLL through the same binding pocket with which it 
interacts with H3 and that this interaction is essential for complex formation and 
consequently for catalytic activity (261-263).  Additionally, the WAR complex by itself 
has been recently shown to have H3K4-specific HMTase activity, and its association with 
MLL1 results in greatly enhanced methylation of H3K4 (264).  All these examples lead 
to the conclusion that WAR is essential for targeting MLL1 to H3K4 sites, where it plays 
an important role in catalysis of H3K4 methylation by MLL1. 
Hox Gene Regulation by the MLL-WAR Complex 
 In vertebrates, the homeobox (Hox) gene clusters encode a group transcription 
factors that play a highly conserved role in the control of cell fate during embryonic 
development (88, 265).  Their Drosophila counterparts are known to specify body 
segment identity by regulating the transcription of a number of downstream target genes 
(87).  Mutations or dysregulation of the Hox genes result in homeotic transformations 
involving either duplication or loss of body structures (266).  Therefore, it is very 
important for the transcription of these genes to be precisely regulated so that specific 
combinations of Hox transcription factors are expressed in a spatially and temporally 
coordinated manner. 
The Hox gene clusters are organized as discrete groups named HoxA, HoxB, 
HoxC etc.  The Hox genes towards the 3’ end of these clusters tend to be expressed in 
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tissues towards the anterior end of the developing embryo earlier on in development, 
while the genes located progressively towards the 5’ end of the clusters are expressed 
subsequently in the posterior tissues (267).  Treatment with all trans retinoic acid 
(ATRA) is known to induce such a transcriptional cascade of Hox gene expression from 
the 3’ to the 5’ end of each cluster.  Retinoic Acid Response Elements (RARE) have been 
identified near the 3’ end genes of each cluster, like HoxA1 and HoxB1, and removal of 
these RAREs or ATRA depletion results in delayed Hox gene activation (268).  Once 
established, the expression pattern of these Hox genes has to be faithfully maintained for 
the duration of their function in development. 
This is achieved by the opposing but coordinated action of the Trithorax group 
(TrxG) of activators and the Polycomb group (PcG) of repressor proteins.  Both these 
groups of transcriptional regulators contain both HMTase activity and proteins that bind 
histone lysine methylation marks.  PcG mutations are known to result in ectopic 
expression of the Hox genes giving rise to posterior homeotic transformations (266).  
Polycomb Repressive Complex 2 (PRC2) maintains the long-term repression of specific 
Hox genes by depositing repressive H3K27 methyl marks (269).  PRC1, which gets 
recruited by methylated H3K27, inhibits chromatin remodeling and promotes chromatin 
condensation into a transcriptionally repressive form (270).  Conversely, TrxG proteins 
activate Hox genes by regulating the methylation of H3K4, which is generally associated 
with active transcription.  Trx genes were identified in screens for extragenic suppressors 
of the homeotic phenotype displayed by PcG mutations (271).  Thus the TrxG and PcG 
proteins counteract one another by regulating histone methylation of alternative sites. 
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MLL1 is one such TrxG activator known to methylate H3K4 at target Hox genes 
and positively regulate their transcription (251, 272).  Knockout studies in mice have 
shown that Hox gene expression patterns are appropriately initiated but not maintained 
during development in the absence of MLL1 (272).  While the deletion of MLL1 
(MLL
-/-
) is embryonic lethal, mice expressing MLL1 with a deleted SET domain 
(MLLΔSET) were both viable and fertile, showing that functions of MLL1 outside those 
of its SET domain are necessary for embryonic development (273).  However, Hox gene 
expression levels were found to be lower in MLLΔSET mice when compared to wild 
type mice, showing that methylation of H3K4 by MLL1 is important in Hox gene 
expression (274).  Mouse embryo fibroblasts (MEFs) derived from MLL
-/-
 mice were 
found to have specifically downregulated expression levels of the 5’ genes of the HoxA 
and HoxC clusters (275).  In addition, ChIP analyses have shown that MLL1 localizes to 
broad transcriptionally active regions of the HoxA cluster, particularly at the late 5’ genes 
HoxA9-HoxA13, and also to the promoter of the HoxC8 gene (251, 276).  Thus MLL1 
plays a critical role in the regulation of Hox gene expression. 
Given the functional role of the WAR complex in the regulation of HMTase 
activity of MLL1, as discussed above, one would expect WAR to also be involved in Hox 
gene regulation.  Indeed, when each of the components of WAR was knocked down 
individually using siRNAs, the expression levels of the well-characterized MLL1 target 
genes HoxA9 and HoxC8 were reduced (257).  Methylation levels of H3K4 were also 
reduced upon knockdown of each WAR component at both of these loci, highlighting the 
importance of WAR in MLL1-mediated methylation (245, 257).  The recruitment of 
MLL1 to these target genes was not affected by knocking down WAR components, 
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showing that the involvement of WAR in Hox gene regulation is due to its regulation of 
the HMTase activity of MLL1 (245, 257).  Other studies have also highlighted the role of 
individual components of WAR, like WDR5 (252) and Ash2L (258), in the regulation of 
H3K4 methylation, and subsequently expression, of MLL1 targeted Hox genes.  Thus the 
WAR complex acts in conjunction with MLL1 in regulating Hox gene expression via 
H3K4 methylation. 
CHD8 and WAR 
As discussed above, most ATP-dependent chromatin remodeling enzymes are 
found in large molecular weight multiprotein complexes.  In order to examine whether 
CHD8 is also present in such a complex a partial purification of CHD8 from HeLa cell 
nuclear extract was performed in a previous study from our group (104).  The analysis of 
the purification revealed that CHD8 was a component of a complex of about 900 kDa.  
Since Chd8 itself is only about 290 kDa in size, this result suggests that CHD8 associates 
with other proteins in a higher molecular weight complex.  Affinity purification of CHD8 
followed by mass spectrometry of the predominant CHD8-associated polypeptides 
identified a number of chromatin-related proteins.  These included components of the 
WAR and CoREST chromatin modifying complexes and of the SWI/SNF and NURD 
remodeling complexes among others.  Due to the previous identification of CHD8 as a 
component of an MLL HMTase complex (256), the association of CHD8 with 
components of the WAR complex was further examined.  CHD8 co-purified with WDR5, 
Ash2L and Rbbp5, but not with MLL1 (104), indicating that CHD8 may associate with 
WAR in an MLL-independent manner.  Indeed, WAR has been reported to form a 
subcomplex independent of MLL (257, 258).  WDR5 has been reported as a component 
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of ATAC and MOF HAT complexes (277-279).  The WAR complex has also been 
shown to associate with nuclear receptor coregulator interacting factor (NIF-1) and 
enhance transcriptional activation of nuclear receptor responsive genes (280).  Thus to 
verify an association between WAR and CHD8, coimmunoprecipitation experiments 
were performed in HEK293 cells transfected with Flag-WDR5.  Immunoprecipitation of 
cellular extracts followed by Western blot analysis revealed that WDR5 interacts with 
endogenous CHD8.  This interaction was verified using coimmunoprecipitation of 
recombinant GST-WDR5 and CHD8 proteins.  Thus we have evidence of a direct 
interaction between both endogenous and recombinant CHD8 and WDR5. 
Hypothesis and Summary of Results 
Given the evidence of interaction between WDR5 and CHD8, the examples of 
WAR associating with factors other than MLL, and the propensity of ATP-dependent 
chromatin remodelers to form complexes, we hypothesized that CHD8 and WAR could 
form a discrete complex, either with or without MLL1.  To show this, co-infection 
experiments were done using baculovirus to express the different component of WAR, as 
well as CHD8 and MLL1, in insect cells.  Complexes were purified utilizing epitope tags 
on either CHD8 or WDR5 and analyzed by Western blot with antibodies specific for each 
complex component.  It was seen that CHD8 forms a complex with WAR, both with and 
without MLL1, indicating that CHD8 can form a complex with WAR independent of 
MLL1.  Also, loss of any one component of the CHD8-WAR-MLL1 complex did not 
preclude complex formation by the other components, showing that CHD8-WAR-MLL1 
complex formation is not dependent on any one component.  The pairwise binding of 
each component of the complex with CHD8 was then examined.  This was done by 
118 
 
coexpressing each individual component in insect cells along with Flag-CHD8 and 
performing co-immunoprecipitations using anti-Flag antibodies.  It was seen that CHD8 
interacted directly with each component of MLL1-WAR.  This, along with the previous 
co-infection experiments emphasizes the fact that there are extensive contacts within the 
CHD8-WAR-MLL1 complex holding it together.  We then purified extracts from co-
infected insect cells by size exclusion chromatography to see whether CHD8 co-elutes 
with WAR and MLL1.  We found that CHD8 co-eluted in the same fractions as 
components of WAR, as well as MLL1, indicating their presence in the same complexes.  
Finally, we tested the effect of the association of CHD8 with these complexes on its 
chromatin remodeling activity.  We found that association with WAR or with MLL1-
WAR had no effect on CHD8 remodeling activity on core nucleosomes.  In summary, we 
characterize distinct complexes of CHD8 with WAR alone and with WAR-MLL1, define 
the nature of the interactions within these complexes and the examine effect on 
remodeling of these complexes. 
 
Materials and Methods 
Cell Culture and Reagents 
SF9 cells were cultured at 24°C in 1X Grace’s Insect medium (Invitrogen) 
containing an additional 10% fetal bovine serum and 1X penicillin-streptomycin-
glutamine.  CHD8 rabbit polyclonal antibodies were previously described (104).    The 
anti-Flag M2 (F3165) antibody and rabbit normal IgG immunoglobulin (I8140) were 
purchased from Sigma.  The anti-RbBP5 (A300-109A) anti-Ash2L (A300-489A) and 
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anti-MLL1 (A300-086A) antibodies were purchased from Bethyl.  The anti-WDR5 
(22512-100) antibody was purchased from Abcam.  .All oligonucleotides were 
synthesized by Integrated DNA Technologies (Coralville, IA). 
Production of Recombinant Proteins and Protein interaction Studies 
The Bac-N-Blue Baculovirus Expression System (Invitrogen) was used to prepare 
recombinant baculovirus containing MLL-C, WDR5, Ash2L, and RbBP5.  The WDR5 
construct was a kind gift of Y. Dou.  MLL-C, Ash2L and RbBP5 constructs were the 
generous gift of J. F. Couture.  The Flag-tagged CHD8 baculovirus used was previously 
described (104).  For protein interaction studies, co-infection experiments were 
performed utilizing these recombinant baculoviruses.  SF9 cells (5×10
6
) were infected 
with the indicated viruses and incubated at 24°C for 3 days before harvesting.  Cells were 
collected by centrifugation at 500×g for 2 minutes at room temperature.  Cell pellets were 
washed once with cold PBS and resuspended in 500 μl of IP lysis buffer (0.2 mM EDTA, 
1% NP-40, 10% glycerol, 0.2 mM PMSF, 20 mM Tris-HCl [pH 7.9]) with 150 mM KCl.  
Lysates were centrifuged at 20,800×g for 15 minutes at 4°C.  Cleared lysates were then 
incubated overnight at 4°C with 20 μl of anti-Flag M2 agarose beads (Sigma).  Beads 
were washed 3 times with IP lysis buffer prior to elution with 40 μl of 2X SDS loading 
dye.  Samples were subjected to Western blot analysis using the indicated antibodies. 
For chromatin remodeling assays, recombinant Flag-CHD8 alone or Flag-CHD8 
in complex with WAR or MLL1-WAR was prepared by infecting 1×10
8
 SF9 cells with 
the appropriate recombinant baculoviruses.  Cells were harvested 3 days post-infection, 
washed with PBS, and suspended in IP lysis buffer with 150 mM KCl, 1 μg/ml aprotinin, 
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1 μg/ml leupeptin, and 1 μg/ml pepstatin.  The lysates were centrifuged at 20,800×g for 
15 minutes at 4°C.  Cleared lysates were incubated with 80 μl anti-Flag M2 conjugated 
agarose beads overnight at 4°C with rotation.  Flag-IPs were washed with 10 column 
volumes of each of the following buffers: IP lysis buffer with 150 mM KCl, IP lysis 
buffer with 350 mM KCl, and IP lysis buffer with 150 mM KCl.  Flag-IPs were eluted in 
buffer A (20 mM Tris-HCl [pH 7.9], 0.2 mM EDTA, 10% glycerol, 0.2 mM PMSF) 
containing 500 μg/ml Flag peptide (Sigma), 150 mM KCl, 1 μg/ml aprotinin, 1 μg/ml 
leupeptin, and 1 μg/ml pepstatin. 
Fractionation of Complexes by Size Exclusion Chromatography 
 SF9 cells were co-infected with combinations of baculovirus to co-express either 
the core components of the WAR complex, with Flag-CHD8 and WAR, or with Flag-
CHD8, MLL-C and WAR, as described above.  Cells were lysed in IP lysis buffer with 
150 mM KCl as above and the lysates were centrifuged at 20,000×g for 20 minutes at 
4°C.  Cleared lysates were fractionated by size exclusion chromatography over a 
Superose 6 HR 10/30 column (GE Healthcare) equilibrated and run in IP lysis buffer with 
350 mM KCl.  Samples of the eluted fractions containing the protein peak were subjected 
to SDS-PAGE followed by Western blot analysis using the specified antibodies. 
Chromatin Remodeling Assay 
A restriction enzyme accessibility assay was employed to measure chromatin 
remodeling.  This assay was adapted from methods outlined by Smith and Peterson (221) 
and was performed as described in Chapter III.  Samples were analyzed on a 3% agarose 
gel and bands were quantified using a Typhoon Trio+ Imager and ImageQuant TL 
121 
 
software (GE Healthcare).  Data points represent the average value of triplicate 
experiments.  Quantitative Western blotting was used to ensure that the final 
concentration of CHD8 used in the restriction enzyme accessibility assays was 20 nM, 
allowing for direct comparison between CHD8 alone and CHD8 in complex. 
 
Results 
CHD8 forms a Complex with WAR and with MLL1-WAR 
Previous work from our lab has identified several CHD8 associated polypeptides 
(104).  We previously reported that CHD8 can interact with WDR5 both in vivo and in 
vitro.  Initially we focused in on WDR5 as this polypeptide has been reported to be part 
of an MLL histone methyltransferase complex (252-256, 281-283), possibly linking 
chromatin remodeling and chromatin modification in a single complex.  Further evidence 
for this link was provided by the discovery of CHD8 in a WDR5-containing complex 
(256).  As WAR can associate as an independent core complex in the absence of MLL 
(257, 258), we asked whether CHD8 could also associate with WDR5, both in the context 
of the WAR core complex as well as in association with MLL1-WAR.  This association 
was tested through the reconstitution of the complex using a baculovirus expression 
system.  As previously reported, co-infection of SF9 cells with recombinant viruses that 
encode WDR5, Ash2L, and RbBP5 results in the formation of a stable complex, and this 
complex can also form with the C-terminal fragment of MLL1 (MLL-C) (257).  Co-
infection of SF9 cells with WDR5, Ash2L, RbBP5, MLL-C and Flag-CHD8, followed by 
affinity purification demonstrated that indeed CHD8 can associate with the MLL1-WAR 
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complex (Fig. 4.1).  When the same experiment was repeated excluding MLL-C, it was 
seen that CHD8 can also form a complex with the WAR core complex by itself. 
While these results demonstrate that CHD8 can associate with WDR5 in the 
context of the complex, they do not address whether other interactions also exist in this 
complex.  To systematically test the assembly of the WAR/CHD8 complex, further 
baculovirus co-infection experiments were performed, each time omitting one 
component.  As shown in Fig. 4.1, the removal of any one of the subunits does not 
preclude a stable association of the remaining subunits.  These results demonstrate that 
CHD8 can interact with subunits other than WDR5.  To further explore these 
interactions, baculovirus co-infection experiments using pairwise combinations with 
CHD8 were performed.  As shown in Figure 4.2, CHD8 is capable of interacting directly 
with each component of the MLL1-WAR complex.  These results demonstrate that 
CHD8 has extensive contacts with the MLL1-WAR complex, unlike the interactions of 
WAR with MLL that are dependent solely on WDR5 (257, 258, 261, 262, 284, 285). 
CHD8 Co-fractionates with Components of the MLL1-WAR Complex 
 SF9 cells were co-infected with baculovirus encoding the following combinations 
of proteins: the components of the WAR core complex alone, CHD8 and the WAR 
complex or CHD8 and MLL1-WAR.  As a control, cells were mock-infected.  Each of 
these cell lysates were fractionated over a Superose 6 size exclusion chromatography 
column.  Fractions containing the protein peak from each of these runs were subjected to 
SDS-PAGE followed by Western blot analysis with the indicated antibodies.  Co-elution 
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of proteins in the same fractions, is suggestive of a physical interaction between them, 
causing them to migrate together through the size exclusion column. 
It was observed that the components of the WAR core complex co-eluted in the 
same range of fractions from the size exclusion column, indicating they form a discrete 
complex in these cells (Fig. 4.3A).  When the lysates of cells co-infected with CHD8 and 
WAR were fractionated, we found that the elution profile of CHD8 was largely 
coincident with those of WDR5, Ash2L and RbBP5 (Fig. 4.3B).  Interestingly, the 
fractions containing the major CHD8 peak did not coincide with the elution peak for 
WAR.  This indicates that while CHD8 can associate with the WAR complex, the 
majority of CHD8 is found independent of the WAR complex.  Finally, the elution 
profiles of lysates containing CHD8 and MLL1-WAR were examined (Fig. 4.3C).  Once 
again, CHD8 co-eluted with the components of the WAR core complex and with MLL1 
as well.  These results demonstrate that CHD8 can form a complex with both WAR and 
MLL1-WAR, confirming the results of the co-immunoprecipitation experiments shown 
in Fig. 4.1 and Fig. 4.2. 
Association with WAR or MLL1-WAR does not Affect Chromatin Remodeling by 
CHD8 
To gain insight into the significance of the association CHD8 with the WAR and 
MLL1-WAR complexes, we performed in vitro chromatin remodeling assays to test the 
consequence of this association.  SF9 cells were co-infected to express either CHD8 
alone, CHD8 and the WAR complex or CHD8 and the MLL1-WAR complex.  CHD8 
and its associated complexes were affinity purified.  The amount of CHD8 in each of 
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these samples was determined by quantitative Western blots.  Chromatin remodeling was 
measured for each of these complexes by using equal amounts of CHD8 enzyme in 
restriction enzyme accessibility assays as described in Chapter III.  As shown in Figure 
4.4, the presence of either of the WAR complexes with CHD8 neither enhances nor 
hinders CHD8 remodeling activity in the context of this assay.  This result indicates a 
possible role for the WAR and MLL1-WAR complexes outside of direct involvement in 
the enzymatic function of CHD8, perhaps in targeting or binding of CHD8 to promoters. 
 
Discussion 
The CHD8-WAR-MLL1 Complex 
 We have shown that the ATP-dependent chromatin remodeling enzyme CHD8 is 
capable of interacting with both the WAR core complex alone as well as with the MLL1-
WAR HMTase complex.  We have demonstrated that both the CHD8 complexes are 
formed by extensive contacts between the component proteins and elimination of any one 
component does not preclude the formation of a stable complex.  This indicates extensive 
contacts between CHD8 and the the components of the MLL1-WAR complex.  This is 
confirmed by the observation that CHD8 also interacts individually and directly with 
each component of the MLL1-WAR complex.  In this respect, the interaction of WAR 
with CHD8 is different from that between WAR and MLL1, which is mediated by 
WDR5 alone (257, 258).  In fact, recent reports have shown that a single 6-13 amino acid 
motif in MLL1, called the WDR-interaction (Win) motif, is responsible for the interaction 
with WDR5, which stabilizes the complex with WAR (261, 262, 285).  However, another 
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recent report suggests that there are more extensive interactions of MLL1 with WAR, as 
the interaction of RbBP5 and Ash2L with MLL1, even in the absence of WDR5, have 
been shown to stimulate the catalytic activity of the MLL1-SET domain (286).  CHD8 
does not possess the conserved motif by which WDR5 is known to bind SET domain 
proteins, further supporting a different mechanism of association of CHD8 with the 
MLL1-WAR complex.  Further work is required to elucidate the exact nature of the 
interactions of CHD8 within this complex. 
 CHD8, as well as MLL1 and WAR, have been reported to exist in complex with 
other factors related to chromatin.  CHD8 has been isolated in association with 
complexes containing hStaf, involved in transcriptional elongation by RNA Pol III, as 
well as in a complex containing the elongating form of RNA Pol II (100, 101).  In 
addition, CHD8 has been found to be associated with various chromatin-related proteins 
like the chromatin insulator CTCF, the transcription factor β-catenin and the nuclear 
receptor ER (103-105).  It has also been found to promote association between p53 and 
the H1 histone to form a trimeric complex on chromatin that is involved in suppressing 
the transcription of genes involved in p53-mediated apoptosis (102).  Indeed, CHD8 was 
identified as a component of an MLL1-WAR complex isolated from HeLa cells 
overexpressing Flag-WDR5 (256). 
MLL1 is inherently found in a multi-subunit protein complex as discussed earlier 
in this chapter.  In addition, it can be aberrantly associated with other chromatin factors 
during cancer.  An MLL-ENL (eleven-nineteen leukemia) fusion protein is known to be 
associated with a SWI/SNF chromatin remodeling complex that is involved in the 
oncogenic activation of Hox A7 (287).  This MLL-ENL fusion protein is also known to 
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be associated with various other complexes containing other factors like the RNA Pol II 
CTD, positive transcriptional elongation factor (P-TEFb), the H3K79 HMTase 
Distribution of Organized Tributaries 1-like (DOT1L) and multiple PcG proteins (288).  
Another fusion partner of MLL, AF4, also interacts with P-TEFb and DOT1 to activate 
transcriptional elongation by Pol II (289).  Finally, WAR has also been implicated in 
complexes other than with MLL HMTases, like with the HAT complexes ATAC and 
MOF and the nuclear receptor coactivator NIF-1, as discussed in the Introduction to this 
chapter (277-280).  WDR5 has also been found to be associated with the ISWI-containing 
ATP-dependent chromatin remodeling complex, NURF, providing further evidence of 
the components of MLL-WAR being associated with nucleosome remodelers (32).  Thus 
there is ample evidence of each of these component proteins being present in complexes 
other than the ones they are traditionally found in. 
Hypothetical Model 1: Methylation by MLL1-WAR Targets CHD8 Binding to 
Histones 
 Based on the extensive interactions of CHD8 with the MLL1-WAR complex, one 
could hypothesize that CHD8 gets recruited by this complex to function in gene 
regulation at its target sites.  The purification of CHD8 in complex with WAR and 
MLL1-WAR by size exclusion chromatography supports the hypothesis that these 
proteins form a stable complex that could be involved in the regulation of MLL target 
genes.  Indeed, recent experiments in the lab have shown that CHD8 can bind and 
regulate the expression of the MLL-regulated HoxA genes (unpublished data).  The fact 
that the overlap in coelution profiles of CHD8 in complex with MLL1-WAR was greater 
than that for the CHD8-WAR complex alone could indicate a preferred specificity of 
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CHD8 for MLL1-WAR.  Thus it is possible that CHD8 and MLL1, through interactions 
enhanced by the WAR complex, are working in coordination to regulate the expression of 
the Hox genes.  This possibility is made even more likely given the fact that the 
Drosophila homolog of CHD8, Kismet, is a TrxG protein known to be involved in the 
regulation of Hox genes.  Methylation of the H3K4 mark at target promoters by MLL1 
might reinforce the localization of CHD8 to these sites.  This possibility is supported by 
recent work that suggests that the chromodomains of CHD8 can specifically bind 
dimethylated H3K4 (100). 
 Chromatin remodeling assays performed using each of the indicated CHD8-
containing complexes (Fig. 4.4) indicated that the interaction with WAR or MLL1-WAR 
does not affect the chromatin remodeling activity of CHD8.  This suggests that the 
association with these complexes regulates some aspect of CHD8 other than its 
enzymatic activity, like the binding or targeting of CHD8 to promoters, as mentioned 
above.  Thus the recognition of H3K4 methylation by the chromodomains of CHD8 
seems to be involved in histone binding by CHD8 in the context of its recruitment to 
chromatin rather than the substrate specificity of its nucleosome remodeling activity.  It is 
also a possibility that, once recruited to target sites, chromatin remodeling by CHD8 
could affect the HMTase activity of the MLL1-WAR complex.  A recent study revealed 
that the SET domains of MLL1 and SET7 specifically recognize nucleosomes remodeled 
by ISWI and subsequently catalyze methylation of these nucleosomes (290).  More 
experiments are needed to verify the precise role of CHD8 with regards to its association 
with this complex.  However, the data presented here can be used to propose a model 
where CHD8 is targeted via its chromodomains to sites of H3K4 methylation by MLL1-
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WAR, whereupon it associates with this complex and rearranges nucleosomes in a way 
that allows for optimal transcriptional regulation of the target genes, either by enhancing 
further methylation by MLL1-WAR, or by allowing the binding of other factors. 
 WAR has been shown to exist in complexes independent of MLL or SET proteins 
and also that CHD8 can bind WAR independent of MLL1.  This gives rise to an 
interesting variation of the proposed model.  The binding of WAR to histones and to 
MLL appear to be mutually exclusive, since both H3 and MLL bind WDR5 through the 
same motif (262).  Thus it is possible that WAR can foster the interaction of CHD8 with 
MLL1, or recruit CHD8 to chromatin by binding to H3.  It is also possible that WDR5 
could competitively bind to methylated H3K4, dissociating in the process from MLL1 
after the methylation event, as suggested by Song et al (262).  In this case, CHD8 could 
be tethered on to H3K4 methylated chromatin via its extensive interactions with WAR 
after prior methylation of these sites by MLL1.  Thus there are several modes by MLL1-
WAR could be recruiting CHD8 to target promoters, the precise mechanism of which 
needs to be explored by further studies.  Given the fact that AR binding to its target 
promoters has been shown to be dependent on H3K4 methylation (225), this model could 
be elaborated upon further.  Methylation of H3K4 by MLL1-WAR could be involved in 
targeting the associated CHD8 to target promoters, where its enhanced remodeling of 
nucleosomes bearing H3K4 dimethylation marks would then serve to facilitate the 
binding of AR  
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Hypothetical Model 2: Remodeling by CHD8 Recruits MLL1-WAR 
 An alternative hypothesis for the role of CHD8 is that it is involved with the 
proper establishment of histone methylation patterns at target genes by recruiting the 
MLL1-WAR HMTase complex.  Depletion of its Drosophila homolog, Kismet, has been 
shown to result in elevated global levels of H3K27 methylation (89).  The action of 
Kismet appears to counteract the H3K27 methyltransferase E(Z) and promote the 
association of H3K4 HMTases, including the MLL homolog TRX and ASH1 with 
chromatin (89).  Thus it is possible that CHD8 interacts with MLL1 in a similar capacity 
to facilitate its binding to target chromatin sites via its remodeling activity.  However, it 
is to be noted that CHD6-9 in humans have a single ortholog in Drosophila, namely 
Kismet.  Thus it is also possible that the CHD6-9 proteins have diverged evolutionarily 
and developed different, more specific functions within the cell.  Given the evolutionary 
distance between flies and humans, it would not be entirely unexpected if CHD8 and 
Kismet do not have the exact same mechanisms of action in transcriptional regulation in 
association with MLL. 
 A variation of this hypothesis of CHD8 recruiting the H3K4 HMTase activity to 
target sites could be based on our observation that CHD8 can associate with the WAR 
core complex independent of MLL1.  This gives rise to another possibility that CHD8 
could be directly involved in recruiting WAR to MLL target sites, bringing it in contact 
with MLL1 and thus enhancing H3K4 methylation.  Several lines of evidence support 
this possibility as well.  Previous studies have demonstrated that WAR is required for 
complete methylation of target promoters by MLL1, but loss of WAR does not prevent 
proper recruitment of MLL1 to these promoters (257, 258).  Taken together with our 
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data, this would suggest a model where chromatin remodeling by CHD8 is involved in 
recruiting WAR to allow the proper methylation of target promoters via association with 
MLL1.  It has also been reported recently that the WAR complex itself is a H3K4 
HMTase, even in the absence of MLL (285).  This raises the possibility that the 
CHD8/WAR complex is also a HMTase complex, and the coordinated function of 
nucleosomal remodeling and histone methylation by this complex is capable of 
establishing appropriate chromatin modifications at target promoters independent of 
MLL1.  Future experiments will need to be performed to verify which of these proposed 
models is actually operational during transcriptional regulation by this novel CHD8-
containing complex.  However, in the context of androgen-responsive transcriptional 
regulation by CHD8, we can speculate that the targeting of MLL1-WAR or WAR alone 
by CHD8 remodeling at AREs allows the establishment of the H3K4 methylation pattern 
that is subsequently responsible for the recruitment of AR (225) to these genomic loci. 
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Figure 4.1:  Direct Interaction of CHD8 with the MLL1-WAR Complex.  Cellular 
extracts were prepared from SF9 cells following co-infection with the indicated viruses.  
Immunoprecipitations were performed with anti-Flag-M2 antibodies.  After extensive 
washing, purified samples were subjected to SDS-PAGE followed by Western blotting 
analysis using the indicated antibodies. 
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Figure 4.2:  Direct Interaction of CHD8 with each Component of the MLL1-WAR 
Complex.  Pairwise coinfections were performed using the indicated baculoviruses and  
immunoprecipitated as in Fig. 3.1.  Inputs (top panel) and IPs (bottom panel) were 
analyzed by SDS-PAGE followed by Western blotting with the indicated antibodies. 
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Figure 4.3:  Size Exclusion Chromatography of CHD8-Associated Complexes.  SF9 
cells were coinfected with baculovirus encoding the components of either the WAR 
subcomplex alone (A), CHD8 and WAR (B) or CHD8 and the MLL1-WAR complex 
(C).  Cellular extracts were prepared and fractionated by size exclusion chromatography 
over a Superose 6 column.  Peak fractions were analyzed by SDS-PAGE followed by 
Western blotting with the indicated antibodies. 
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Figure 4.4:  Remodeling Activity of CHD8 in Association with MLL1/WAR 
Complexes.  Recombinant CHD8 or CHD8 in complex with either WAR or MLL1-
WAR was assayed for chromatin remodeling as measured by increased restriction 
enzyme accessibility on mononucleosomes.  Three separate experiments were performed 
in triplicate and representative data is shown. 
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CHAPTER V 
Conclusion 
 
Background 
The DNA within eukaryotic cells is packaged into highly condensed chromatin, 
which inherently serves as a physical barrier to critical cellular processes like DNA 
replication, repair and transcription.  The class of enzymes that modulate the chromatin 
structure to allow access to the underlying DNA are called the ATP-dependent chromatin 
remodeling enzymes.  These enzymes belong to the SNF2 superfamily which is 
characterized by the presence of a characteristic SNF2 domain that is capable of 
hydrolyzing ATP to derive energy that is utilized by the enzyme to remodel chromatin in 
different ways.  There are several families of SNF2 ATP-dependent chromatin 
remodelers, one of which is the CHD family.  This family is comprised of nine proteins, 
named CHD1 through CHD9, that are further divided into subfamilies based on domain 
architecture.  While the remodeling activity and cellular functions of the CHD1-2 and 
CHD3-5 subfamilies have been well studied, relatively little is known about the third 
subfamily, CHD6-9. 
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The studies described in this thesis were designed to elucidate the function of one 
of the members of this subfamily, CHD8.  Specifically, the role of CHD8 in androgen-
responsive transcription was studied to expand upon the previously known functional 
association between the CHD6-9 subfamily and nuclear receptors.  These studies also 
highlight the potential role of CHD8, not only in the regulation of transcription, but also 
in prostate cancer tumorigenesis and the progression of diseased states.  In addition to 
these functional studies, the substrate specificity for chromatin remodeling by CHD8 was 
also studied so as to derive further mechanistic insights into its transcriptional function.  
Finally, its association with a known histone methyltransferase complex, MLL1-WAR, 
was characterized in order to understand its interplay with other chromatin-related factors 
and processes involved in transcriptional regulation.  This additional knowledge can then 
be applied to the role of CHD8 in androgen receptor-mediated transcription and to 
understand how CHD8 may be involved in the regulation of transcription and cancer. 
Functional Studies of CHD8 in Androgen-Responsive Transcription 
 Evidence from previous literature suggests that the CHD6-9 subfamily proteins 
are involved in transcriptional regulation by nuclear receptors and are implicated in 
several diseases.  CHD8 specifically has been shown to have a diverse role in 
transcriptional regulation and in a variety of pathways related to human disease.  We 
investigated the potential role of CHD8 in nuclear receptor-mediated transcription in 
Chapter II.  Our preliminary analysis of publicly available microarray data from the 
ONCOMINE database revealed that CHD8 was upregulated in several prostate cancer 
samples, implicating it in androgen receptor signaling, which is commonly dysregulated 
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in prostate cancer.  Thus we focused in on the androgen receptor pathway to study the 
cellular function of CHD8 and investigate its implied role in cancer. 
We investigated the possible association between AR and CHD8 by doing 
interaction studies, where we found a direct interaction between both the recombinant 
and endogenous proteins.  Interestingly, endogenous CHD8 only interacted with AR in 
androgen-dependent cell lines, indicating that this association was dependent on 
androgen induction.  The fact that these two proteins interact directly was demonstrated 
by co-immunoprecipitation if the recombinant proteins by co-expression in a baculovirus 
expression system.  While the interaction studies reveal a direct physical and 
physiologically relevant association of these proteins, further studies are required to 
elucidate the specifics of this interaction.  The interaction could be mapped further by 
using recombinantly expressed, epitope-tagged fragments of either protein and 
conducting pull down studies similar to those described in Chapter II.  It would be 
interesting to map this interaction to see whether the consensus LFSLL nuclear receptor 
interaction motif in CHD8, located at 996-1000 aa within its SNF2 domain, is responsible 
for the binding to AR as predicted in Chapter II.  Conversely, we could map the 
interaction site on AR to see whether it lies within the C-terminal LBD as is typical for 
most interactions between nuclear receptors and their coactivators.  It would also be 
interesting to examine the association between endogenous AR and CHD8 in more 
prostate cancer cell lines to verify that this interaction is indeed androgen-dependent. 
ChIP and re-ChIP experiments were done to see whether this interaction fostered 
co-localization of these proteins at endogenous AR-mediated promoters.  It was found 
that CHD8 did indeed occupy AREs on the androgen-responsive TMPRSS2 and PSA 
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genes at the same time as AR.  The constitutive binding of CHD8 to these promoters 
independent of androgen induction distinguishes it from other typical AR coregulators.  
The precise localization pattern of CHD8, and concurrently of AR, on these target 
promoters could be determined by performing ChIP experiments tiling over the promoter 
sequence to see where these proteins localize to before and after androgen treatment.  
Also, ChIPseq or re-ChIPseq experiments could be designed to obtain the sequences from 
ChIPs of AR and CHD8, done either separately or sequentially, which can then be 
analyzed to identify new target genes that are regulated by AR and CHD8. 
Based on the co-localization patterns of CHD8 with AR on the AREs of 
androgen-responsive target promoters, we hypothesized that CHD8 is involved in the 
transcriptional activation of these genes upon induction by androgens.  This was 
confirmed by showing that CHD8 depletion significantly diminished the transcriptional 
activation of AR target genes in response to androgen induction in androgen-dependent 
LNCaP cells.  It was further demonstrated that this transcriptional role of CHD8 in AR-
mediated gene activation was androgen-dependent, by showing that the effect of CHD8 
depletion observed in LNCaP cells was not replicated in several androgen-independent 
cell lines.  Our results indicate that CHD8 is involved in the transcriptional activation of 
two well-characterized androgen-responsive genes, TMPRSS2 and PSA, which are 
aberrantly activated in prostate cancer.  This implicates CHD8 in the aberrant gene 
expression observed in prostate cancer.  It would be interesting to identify other genes 
that are regulated by CHD8 in an androgen-dependent manner by generating a stable 
knockdown of CHD8 in a prostate cancer cell line like LNCaPs.  We could then observe 
by microarray analysis which particular genes’ androgen-responsive activation is affected 
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by CHD8 depletion upon induction by androgens, as compared to a control cell line.  In 
addition, we could individually examine novel target genes identified from this 
microarray analysis or from the ChIPseq experiments proposed above to identify 
common targets of CHD8 and AR, and look for effects on androgen-responsive 
activation by CHD8 by the same siRNA-based strategy employed in Chapter II.  Thus the 
identification of CHD8 as a novel AR coactivator presents us a unique opportunity to 
investigate novel AR-mediated transcriptional targets in prostate cancer. 
While we have verified the functional role of CHD8 in AR-mediated 
transcriptional activation, the mechanism behind how chromatin remodeling by CHD8 
contributes to this process is not clear.  Our ChIP experiments under conditions of CHD8 
depletion revealed that CHD8 was required for optimal recruitment of AR to the target 
promoter.  This role for its remodeling activity resembles that of other chromatin 
remodelers which have been found to be involved in the binding of transcriptional 
activators to promoters (19).  There is a possibility since CHD8 directly interacts with 
AR that it is this interaction and not the remodeling of nucleosomes by its catalytic 
activity that is responsible for recruitment of AR by CHD8.  This could be tested by 
doing an experiment where the K842R point mutant of CHD8, which has been shown to 
be a catalytically dead mutant (104), could be overexpressed as a dominant-negative form 
of CHD8.  This mutant CHD8 is unable to remodel nucleosomes due to the mutation of 
the conserved lysine in its SNF2 domain that is required for ATPase activity and hence 
for remodeling activity.  The loss of AR targeting upon expression of this inactive form 
of CHD8 would verify that it is the remodeling of nucleosomes by CHD8 and not its 
interaction with AR that is responsible for its recruitment of AR to target sites.  Indeed 
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we have shown that CHD8 is capable of remodeling nucleosomes assembled on a DNA 
template sequence encoding the ARE of TMPRSS2 in vitro in the presence of AR.  This 
verifies aspects of our model that CHD8 remodels nucleosomes at target loci to allow AR 
to bind.  Further experiments could be done using these nucleosomal templates to 
examine whether ARE nucleosomes that have been remodeled by CHD8 show enhanced 
binding with AR by gel shift assays.  The loss of AR binding upon CHD8 depletion could 
be verified at other novel or known AR target promoters by ChIP and also in different 
androgen-dependent and androgen-independent cell lines to verify whether this 
recruitment is hormone dependent.  The genome-wide targeting of AR could be evaluated 
by performing AR ChIPs under normal and CHD8-depleted conditions from LNCaP cells 
and analyzing by a ChIPseq or ChIP-on-chip approach whether the recruitment pattern of 
AR is disrupted at a subset of target genes.  These experiments will expand upon this 
novel and unique mode of coactivation by CHD8. 
Finally we verified the physiological importance of CHD8’s role in the AR 
signaling pathway, by showing that it is required for androgen-dependent cell 
proliferation of LNCaP cells.  This result shows how CHD8 might be important for 
prostate cancer tumorigenesis and progression.  Similar proliferation assays as described 
in Chapter II could be performed in androgen-independent cell lines to verify the 
hormone dependency of this growth effect upon CHD8 depletion.  Alternative 
physiological assays like tumor invasion assays could be performed to determine the 
effects of CHD8 depletion on different aspects of tumor growth.  Doing cell growth or 
proliferation assays on stable knockdowns of CHD8 would provide a better indication of 
its physiological role as well by eliminating variability due to transfection or knockdown 
141 
 
efficiency.  Taken together, however, the results presented in Chapter II provide evidence 
of a novel functional role for CHD8 in a prostate cancer model system. 
The role of CHD8 in nuclear hormone signaling is supported by other lines of 
evidence.  CHD8 is a member of the highly related CHD6-9 subfamily of proteins.  
Several members of this family have been shown to functionally associate with nuclear 
hormone receptors.  CHD9 (CReMM/PRIC320) has been shown to interact with PPARα, 
CAR, ERα, RXR, and GR, and has also been shown to function as a coactivator for 
PPARα (98, 159).  CHD7 has also been isolated as a component of a corepressor 
complex that inhibits PPARγ mediated transcription (95).  Recently, CHD8 has also been 
reported to be required for the estrogen mediated upregulation of the cyclin E2 gene 
(105).  Taken together with our studies on CHD8 and AR, these results suggest that the 
CHD6-9 family is an important regulator of nuclear hormone signaling.   
Deciphering the mechanistic role of CHD8 in transcriptional regulation is 
complicated by the numerous functions reported for CHD8.  Previous work from our 
group has shown that CHD8 is an ATP-dependent chromatin remodeling enzyme 
involved in transcriptional regulation of β-catenin responsive genes (104).  However, 
CHD8 was found to act in the negative regulation of activated β-catenin responsive 
genes, unlike our current report here of a role for CHD8 in the activation of TMPRSS2 in 
response to androgens.  This suggests that CHD8 can differentially regulate numerous 
target genes.  Indeed, expression profiling of control and CHD8-depleted cells identified 
transcripts both positively and negatively regulated by CHD8 (100). 
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Further insight into the function of CHD8 can be found by examining the reported 
functions of Kismet, the Drosophila ortholog of CHD8.  Kismet was originally identified 
as an extragenic suppressor of Polycomb and therefore assigned as a member of the trxG 
of activators (291).  Further studies revealed that Kismet assists in an early step in 
transcriptional elongation (61, 89).  This reported data is consistent with CHD8 
regulating the cyclin E2 gene via interactions with the elongating polymerase (100).  AR 
not only plays a role in transcriptional initiation but also transcriptional elongation.  AR 
has been reported to interact with COBRA1 (NELF-B), a subunit of negative elongation 
factor (NELF), and depletion of endogenous NELF-B enhances DHT-mediated 
transcriptional activation (292).  AR also interacts with the positive elongation factor P-
TEFb, and this interaction serves to enhance transcriptional elongation (293).  In 
addition, AR has been shown to regulate transcriptional initiation as well as elongation 
via interactions with the general transcription factors TFIIF and TFIIH (294, 295).  Taken 
together with our current studies, these reports suggest CHD8 could possibly be 
regulating AR mediated transcription by modulating transcriptional elongation.   
In this study, we have identified the binding of CHD8 to the TMPRSS2 enhancer 
region located approximately 13.5 kb upstream from the start site.  This data initially 
seems to be at odds with the model proposed above.  However, the investigation of 
various nuclear receptors binding to DNA at both proximal and distal sites accompanied 
with reports of RNA polymerase II localization to these sites suggests that 
enhancer/promoter looping may play an important role in the regulation of nuclear 
hormone regulated transcription (296).  Indeed, a direct interaction is reported between 
the TMPRSS2 -13.5 kb enhancer and the promoter region (131).  Therefore, the 
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recruitment of CHD8 to the TMPRSS2 distal enhancer does not preclude CHD8 
functioning in transcriptional elongation.  More experiments need to be performed to 
determine the precise point of action for CHD8 in the transcriptional cycle.  
In summary, the activity of AR is critical for normal prostate development and 
function, but also plays a major role in the development and progression of prostate 
cancer.  Understanding the mechanisms of transcriptional regulation by AR and AR-
associated cofactors is critical to the development of new therapies for prostate cancer.  
Here we report the characterization of a novel AR-associated cofactor required for the 
proper regulation of the androgen responsive gene TMPRSS2.  These results highlight 
the potential of CHD8 as a novel diagnostic, preventative, or therapeutic target in prostate 
cancer. 
Mechanistic Studies of Substrate Specificity of CHD8 Chromatin Remodeling 
To better understand the functional implications of chromatin remodeling by 
CHD8, the substrate specificity of its catalytic activity was determined.  This would 
provide further insights into the nature of the chromatin substrates that CHD8 
preferentially remodels and thus allow us to build upon the model of CHD8 function in 
androgen-responsive transcriptional regulation.  We found that CHD8 can remodel 
recombinant, unmodified nucleosomes at a similar rate to core nucleosomes.  This result 
indicates that histone modifications are not necessary for CHD8 remodeling on substrates 
and also that we could further utilize recombinant nucleosomes for experiments to 
determine its substrate preference.  Competitive assays using core and recombinant 
nucleosomes revealed that CHD8 preferentially remodeled core nucleosomes, indicating 
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that while histone modifications were not a requirement per se for CHD8 remodeling 
activity, one or more particular modifications that were present on the core nucleosomes 
and not on the recombinant defines the preferred substrates of CHD8 activity. 
In order to narrow down on the preferred nucleosomal substrate for CHD8 
remodeling, we reconstituted nucleosomes from histones with their H3-H4 tails deleted 
and performed remodeling assays on these.  It was seen that CHD8 can remodel H3-H4 
tailless nucleosomes, indicating that CHD8, similar to CHD3/4 does not require histone 
tails for remodeling, unlike CHD1.  Competitive nucleosome sliding assays using wild-
type and tailless recombinant nucleosomes showed that while CHD8 can remodel both 
substrates, it appears to remodel nucleosomes lacking H3-H4 tails less effectively as 
indicated by the alternate migration of the remodeled species on a gel, indicating 
differential repositioning of these substrates based on the presence or absence of histone 
tails.  This is an interesting result from the perspective of which histone contacts CHD8 
utilizes during catalysis and how these contacts affect the remodeled product as discussed 
in Chapter III.  We determined from these results that while CHD8 can reposition 
nucleosomes by contacts mediated by the globular core of the histone octamer, specific 
contacts with histone tails may be responsible for additional substrate specificity with 
regards to the positioning of the remodeled products by CHD8. 
Finally, we examined the effect of a specific histone modification on the 
chromatin remodeling activity of CHD8.  We chose to examine the H3K4 dimethyl mark 
for its effect on CHD8 remodeling, due to the previously established binding of the 
chromodomains of CHD8 to this mark (100).  We generated synthetic analogs that 
mimicked the K4-dimethylated histone H3 or unmodified H3 by the strategy devised by 
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Simon et al (219).  When the unmodified control and H3K4 dimethylated nucleosomes, 
produced as described in Chapter III, were subjected to competitive sliding assays, we 
found that CHD8 preferentially remodeled the dimethylated species.  This observation, 
along with the results of the competitive assays done using core vs. recombinant 
nucleosomes, led to the conclusion that CHD8 preferentially remodels substrates bearing 
the dimethyl H3K4 mark.  This preference may be due to the enhanced binding to the 
substrate due to the chromodomains which recognize this histone mark and hence would 
improve catalysis by lowering the Km of binding. 
Further experiments need to be performed to verify the substrate preferences of 
CHD8 for nucleosome remodeling.  The same experiments described above could be 
performed upon nucleosomes incorporated into a DNA template encoding the sequence 
of an ARE targeted by CHD8, to examine these remodeling results in an androgen-
responsive context by doing them in the presence of androgens and AR.  Deletion of the 
individual histone tails may elucidate further aspects of the substrate specificity and 
nature of remodeling by CHD8.  We might be able to see differentially remodeled 
products when particular histone tails are eliminated and thus we could infer the specifics 
of particular histone tail contacts in the remodeling activity of CHD8.  Finally, the effect 
of other histone modifications on CHD8 activity could be determined by introducing 
different histone methylation marks as described here or by using enzyme-modified 
histone substrates bearing other candidate modifications like acetylation, sumoylation or 
ubiquitination, and assaying remodeling activity on these nucleosomal substrates. 
Loci such as PSA and TMPRSS2, which are specifically activated in prostate 
cancer have been found to have constitutively elevated levels of H3K4 di- and 
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trimethylation in prostate cancer cell lines like LNCaP, C4-2B and PC-3, independent of 
androgen stimulation (297).  This methylation pattern of H3K4 could be responsible for 
the androgen-independent constitutive localization of CHD8 that we observe at these 
sites, via recruitment mediated by its chromodomains.  In addition, the presence of H3K4 
dimethylated nucleosomes at CHD8 target sites may enhance its remodeling activity at 
these genomic locations.  Indeed a recent study has shown that H3K4 dimethylation is 
required for the binding of AR to target enhancers, as the overexpression of the H3K4 
demethylase KDM1, also known as LSD1, completely abolished AR binding to these 
enhancers (225).  We can thus speculate that the deposition of H3K4 dimethyl marks is 
important for CHD8 recruitment to target sites via its chromodomains, whereupon AR is 
the recruited to these sites by the enhanced nucleosome remodeling by CHD8 at these 
H3K4-methylated loci. 
Interaction Studies of CHD8 with the MLL1-WAR Complex 
 The association between CHD8 and H3K4 methylation is further supported by 
previous findings from our group that indicate CHD8 interacts with components of the 
WDR5/Ash2L/Rbbp5 (WAR) complex which is common to the MLL family of histone 
methyltransferases.  MLL1 in association with the WAR complex is known to 
specifically methylate H3K4 (250, 251).  It has also been recently shown that H3K4 
methylation is required for AR recruitment to its target promoters (225).  This raises the 
possibility that if CHD8 interacts with the MLL1-WAR complex, it would establish the 
missing link between H3K4 methylation and the remodeling by CHD8 in androgen-
responsive transcriptional regulation. 
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 The studies outlined in Chapter IV were therefore designed to characterize the 
interactions of CHD8 with the MLL1-WAR complex, and determine how these 
interactions may affect its chromatin remodeling activity.  We showed that CHD8 
interacts with MLL1-WAR through extensive contacts.  Elimination of any one 
component does not preclude complex formation and CHD8 also interacts individually 
with each component of this complex.  The precise interactions could be mapped further 
to specific interacting domains or epitopes by using smaller recombinant fragments of the 
complex component proteins and doing pull-down experiments.  Size exclusion 
chromatography of purified complexes showed that CHD8 had more extensive contacts 
with MLL1-WAR than with WAR alone.  This could be verified by doing competitive 
binding studies to derive binding constants between the exact fragment of CHD8 
involved in these interactions and either the MLL1-WAR complex or the WAR 
subcomplex alone.  We also showed that association of CHD8 with either of these 
complexes did not affect its remodeling activity.  This analysis was done using the 
restriction enzyme assay which allows us to quantitate the remodeling activity of CHD8 
by itself or in each of these complexes.  While these activities were not distinguishable by 
this assay, we could compare the remodeled products by nucleosome sliding assays to 
detect changes in the remodeling activity of CHD8 due to association with either 
complex as compared to its monomeric form.  Alternatively, the converse hypothesis that 
nucleosome remodeling by CHD8 affects histone methylation by MLL1-WAR complex 
could also be tested by doing HMTase assays of either the complex alone or the complex 
in association with CHD8.  These additional assays will help to determine the 
mechanistic details of the interplay between CHD8 and MLL1-WAR and consequently 
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provide a more complete picture of how these enzymes participate in androgen-
responsive gene activation by AR.  In fact, a recent report has established global details 
of this kind of interplay between histone modifying and nucleosome remodeling enzymes 
on a genome-wide scale (298).  Similar genome-wide studies of loci where MLL1-WAR 
and CHD8 interact will yield further opportunities to study their cooperative effect on 
transcriptional regulation. 
 Taken together, these studies delineate a novel pathway for AR-mediated 
transcriptional activation of androgen-responsive genes.  We propose a model where 
MLL1-WAR is recruited to AR target genes and methylates H3K4 marks at the AREs on 
their promoters.  This mark is recognized by the chromodomains of CHD8 which 
facilitates its binding to target AREs and also enhances its remodeling activity on 
nucleosomes bearing this modification at these sites.  Nucleosome remodeling by CHD8 
then facilitates the recruitment of AR to the AREs of target promoters upon induction by 
androgens which subsequently leads to the optimal androgen-responsive transcriptional 
activation of these genes.  This model is somewhat complicated by reports that H3K4 
methylation is drastically increased at AR target promoters upon androgen induction 
(299).  Thus if MLL1-WAR is involved in maintenance of constitutive H3K4 
methylation of target promoters allowing for the constant recruitment of CHD8 to these 
sites, this androgen-responsive increase in H3K4 methylation may be due to another 
HMTase.  In fact, this spike in H3K4 methylation upon induction was found to be highly 
coincident with the recruitment pattern of AR (299), unlike the androgen-independent 
basal level of methylation which was found to be necessary to be already established for 
AR recruitment (225).  Thus this later, androgen-responsive methylation may be due to a 
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different HMTase which is recruited by AR as part of its coactivation complex to activate 
transcription, while the constitutive, basal levels of H3K4 methylation may be maintained 
by MLL1-WAR to establish proper recruitment of CHD8.  Thus basal H3K4 methylation 
levels may maintain constitutive CHD8 localization to target genes which is required for 
the proper recruitment of AR upon reception of androgen signaling.  This may then 
trigger higher levels of methylation of the promoter in the course of transcriptional 
activation by AR.  This novel pathway of AR regulation is an important subject for future 
studies which could then help us understand its potential as a target for the prevention 
and therapy of prostate cancer. 
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